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palavras-chave 
 
Beta-lactamases, mecanismos de resistência a antibióticos, antibióticos β-
lactâmicos, carbapenemos, metalo-β-lactamases, carbapenemases. 
resumo 
 
 
As carbapenemases, serínicas e metalo-β-lactamases (MBLs), formam um 
grupo cada vez mais importante de β-lactamases capazes de tornar as 
bactérias resistentes a antibióticos β-lactâmicos, incluindo carbapenemos 
utilizados como antibióticos de último recurso no tratamento de infecções 
causadas por bactérias multirresistentes. De modo a compreender melhor a 
relação estrutura-função deste grupo de enzimas, prosseguimos com a 
caracterização bioquímica e estrutural das carbapenemases SFC-1 e Sfh-I 
específicas de Serratia fonticola UTAD54, uma estirpe ambiental isolada 
previamente de águas de consumo não tratadas no Nordeste de Portugal. 
Ambas as β-lactamases foram sobre-expressas em Escherichia coli e 
purificadas por cromatografia líquida. A SFC-1 recombinante, uma 
carbapenemase serínica, hidrolisa eficientemente antibióticos β-lactâmicos de 
todas as classes e exibe, comparativamente a enzimas relacionadas (ex. 
KPC), uma maior eficiência contra a ceftazidima e uma menor susceptibilidade 
aos inibidores convencionais das β-lactamases. As estruturas do cristal da 
SFC-1 nativa e de complexos de mutantes, obtidos por mutagénese dirigida, 
com o meropenemo não hidrolisado e na forma de acetilenzima foram 
determinados por substituição molecular utilizando cristalografia de raios-X. A 
estrutura da SFC-1 contém todas as características conservadas do centro 
activo das carbapenemases de classe A. Nas estruturas dos mutantes o 
meropenemo aparece orientado no centro activo por Thr236 e Thr238, 
posicionando-o próximo da Ser130 para a transferência do protão. Nas 
enzimas de classe A inibidas por carbapenemos, a interacção com a Arg244 
impõe uma orientação diferente do meropenemo ligado, prejudicando a 
transferência do protão. Estas constituem as primeiras estruturas de uma 
carbapenemase de classe A com um carbapenemo no centro activo e revelam 
que estas enzimas alteram a orientação do meropenemo ligado para promover 
a catálise, sem alteração significativa da estrutura geral. A Sfh-I, tal como as 
outras MBLs da subclasse B2, apresenta um perfil de substratos reduzido, que 
inclui maioritariamente os carbapenemos. A Sfh-I hidrolisa imipenemo e 
meropenemo com um kcat de 51 e 109 s-1 e um KM de 79 e 215 μM, 
respectivamente. A Sfh-I liga um equivalente de zinco, como demonstrado por 
espectrometria de massa. Contrariamente a enzimas da subclasse B2 
previamente caracterizadas, a Sfh-I hidrolisa a cefepima, mostrando que a Sfh-
I é uma MBL da subclasse B2 com propriedades únicas. Por espectroscopia 
de fluorescência mostrou-se que a Sfh-I é capaz de ligar até 3 equivalentes de 
zinco (Kd2 = 95 µM; Kd3 = 2.3 mM). A estrutura do cristal da Sfh-I, determinada 
por substituição molecular utilizando a CphA como modelo, é a primeira para 
uma MBL da subclasse B2 não ligada. Esta estrutura revela a disposição das 
moléculas de água no centro activo corroborando um mecanismo catalítico 
para as MBLs da subclasse B2 no qual a His118, em vez do Asp120 proposto 
anteriormente, activa a molécula de água nucleofílica. 
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abstract 
 
Carbapenemases, both serine and metallo-β-lactamases (MBLs) constitute an 
increasingly important group of β-lactamases that render bacteria resistant to β-
lactam-containing antibiotics, including carbapenems used as last resort 
antibiotics in treatment of multidrug resistant bacteria. In order to better 
understand the structure-function relationship among this group of enzymes we 
pursued the biochemical and structural characterization of SFC-1 and Sfh-I 
both carbapenemases specific to Serratia fonticola UTAD54, an environmental 
strain previously isolated from untreated drinking waters in Northeast Portugal. 
Both β-lactamases were over-expressed in Escherichia coli and purified by 
liquid chromatography.  
Recombinant SFC-1, a serine carbapenemase, efficiently hydrolyses β-lactams 
of all classes and exhibits, as compared to related enzymes (e.g. KPC), an 
increased activity towards ceftazidime but a decreased sensitivity to 
conventional β-lactamase inhibitors. Crystal structures of wild-type SFC-1 and 
of complexes of site-directed mutants with the meropenem in unhydrolysed and 
acylenzyme intermediate forms were solved by molecular replacement using X-
ray crystallography. Wild-type SFC-1 has all the conserved features of the 
class A carbapenemases active site. In the mutants structures meropenem is 
shown to be oriented in the active site by Thr236 and Thr238, placing it close to 
Ser130 for proton transfer. In the carbapenem-inhibited class A enzymes 
interaction with Arg244 imposes a different orientation on bound meropenem, 
impairing proton transfer. These first structures of a class A carbapenemase 
with bound carbapenem reveal that these enzymes change the orientation of 
bound meropenem to promote catalysis, without gross distortion of overall 
structure. 
Sfh-I, like other subclass B2 MBLs, has a narrow substrate profile which mostly 
include carbapenems. Sfh-I hydrolyses imipenem and meropenem with a kcat of 
51 and 109 s-1 and KM of 79 and 215 μM, respectively. Purified Sfh-I binds one 
equivalent of zinc, as shown by mass spectrometry. Unlike previously 
characterised subclass B2 enzymes, Sfh-I hydrolyzes cefepime showing that 
Sfh-I is a subclass B2 MBL with unique properties. Fluorescence spectroscopy 
shows that Sfh-I is able to bind up to 3 zinc equivalents (Kd2 = 95 µM; Kd3 = 2.3 
mM). The Sfh-I crystal structure, solved by molecular replacement using CphA 
as search model, is the first of an unliganded B2 MBL. This structure reveals 
the disposition of water molecules in the active site supporting a catalytic 
mechanism for subclass B2 MBLs in which His118, rather than the previously 
proposed Asp120, activates the nucleophilic water molecule.  
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SDS   Sodium dodecyl sulfate 
SDS-PAGE  Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
TEM   Temoniera β-lactamase 
TEMED  n’, n’, n’, n’- Tetramethylethylenediamine 
Tris   tris(hydroxymethyl)aminomethane 
WT   Wild-type 
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1.1 Antimicrobial agents and bacterial resistance 
“Antibiotics, compounds that are literally “against life”, are typically 
antibacterial drugs that interfere with some structure or process that is essential to 
bacterial growth or survival without harming the eukaryotic host that harbour’s the 
bacterial infection” (WALSH, 2000). Introduced in human therapy for more than 60 
years, antibiotics constitute one of the most important medical inventions, reducing 
human morbidity and mortality. 
Antibiotics display differing modes of action. They are considered to be 
bactericides if they effectively kill bacteria or bacteriostatic if the ability of the 
bacterium to grow is impaired. There are several classes of antimicrobials available to 
clinicians. These compounds can target vital microbial processes such as cell wall 
biosynthesis (e.g. β-lactam antibiotics and glycopeptides such as vancomycin), 
protein synthesis (e.g. aminoglycosides, tetracyclines, macrolides) and bacterial DNA 
replication and repair (e.g. fluoroquinolones, rifampicin) (LEVY and MARSHALL, 
2004; WALSH, 2000). 
Antimicrobials have been successfully employed for therapy of bacterial 
infections for more than six decades, leading to a rise in average life expectancy in 
the last century. However their use is now threatened by the emergence of resistant 
pathogenic strains. Antibiotic resistance is now well recognized as a major problem 
in the treatment of infections in hospitals and, with increasing and alarming 
frequency, in the community (LEVY and MARSHALL, 2004; LIVERMORE, 2007).  
Antibiotic resistance confers an advantage for bacterial survival. Resistant 
bacteria are selected by exposure to antibiotics as a product of Darwinian selection: 
resistant strains are selected while susceptible strains are inhibited or eliminated 
(SYKES, 2010). In order to survive an organism has to be intrinsically resistant or 
acquire resistance after the introduction of drugs in the bacterial environment (LEVY 
and MARSHALL, 2004; MAZEL and DAVIES, 1999). Intrinsic resistance means that 
each member of an entire bacterial group (genus or species) is resistant without any 
additional genetic alteration. For example, in Gram-negative bacteria the presence of 
a relatively impermeable outer membrane is a barrier to antibiotics such as 
glycopeptides and macrolides, making these bacteria intrinsically resistant to these 
drugs (WRIGHT and BEGLEY, 2007). Also mycoplasma bacteria, lacking a cell wall, 
are intrinsically resistant to β-lactam antibiotics as well as other antibiotics targeting 
the cell wall components (BEBEAR and PEREYRE, 2005). On the other hand, 
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resistance to antibiotics can result from selection of spontaneous mutations that lead 
to activation or modification of chromosomal determinants or from acquisition of 
resistance genes localized on mobile genetic elements (FROST et al., 2005) such as 
transposons, plasmids (BENNETT, 2008), and ISCR elements (TOLEMAN et al., 
2006), which can be exchanged among bacteria of a wide range of genera. Although 
they are not considered to be mobile genetic elements, integrons (HALL and COLLIS, 
1998) also play an important role in the transfer and dissemination of resistance 
genes and are most often associated with mobile genetic elements (MOURA et al., 
2010). The rapid generation time of bacteria allows them to evolve quickly, becoming 
resistant to antimicrobials within a short time of their introduction (SYKES, 2010; 
WRIGHT and BEGLEY, 2007). 
Although used in human therapy, antimicrobial drugs are also used 
inappropriately in animal husbandry for prophylaxis, chemotherapy and growth 
promotion (COLLIGNON, 2004; WEGENER, 2003; WITTE, 1998). The ultimate fate of 
these drugs is the soil and aquatic environments (ALLEN et al., 2010; XI et al., 2009) 
where bacteria can exchange their genetic material through horizontal gene transfer 
(FROST et al., 2005). Selective pressure can promote the transmission of resistant 
traits to pathogenic bacteria and ultimately to humans via the food chain (QIN et al., 
2006; RHODES et al., 2000). 
Antibiotic use by humans plays an important role in selection and evolution of 
resistance in pathogenic bacteria. However antibiotic resistance genes are likely to 
have originated in natural microbial communities (DAVIES, 1994). Indeed, many 
antibiotics are produced by environmental strains (NAGARAJAN et al., 1971; SYKES 
et al., 1981) so it is possible that these organisms could be the origin of antibiotic 
resistance genes, used to protect themselves from the antimicrobials they produce 
(PANG et al., 1994; TAHLAN et al., 2007).  
Recent studies by D’Costa and collaborators (2006) and Dantas and 
colleagues (2008) have demonstrated that soil bacteria are both antibiotic producers 
that are resistant to antimicrobials, and sources of resistance determinants. 
Moreover the antibiotics tested included not only “older” compounds but also some 
that have been just recently approved and resistance was observed to all antibiotics 
in these strains of soil bacteria (D'COSTA et al., 2006). 
Also evidence shows that bacterial multidrug efflux pumps are common in 
environmental bacteria, where their primary functions are not associated with 
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antibiotic resistance but rather detoxification of the cell, virulence, cell homeostasis 
and intercellular signal trafficking (LIN et al., 2006; MARTINEZ et al., 2009).  
Relatively few studies are available concerning the role(s) of antibiotic resistance 
genes in the environment. However, it is clear that natural environments constitute 
important reservoirs of antibiotic resistance microorganisms and resistance genetic 
determinants (ALLEN et al., 2010; D'COSTA et al., 2006; SAAVEDRA et al., 2003). 
Once available, resistance genes are picked up from these reservoirs and propagated 
into pathogenic microbes upon use of antimicrobial agents either in medicine or 
agriculture posing a serious problem in human therapy (MARTINEZ, 2009). For 
example, the genes encoding CTX-M β-lactamases, enzymes that compromise the 
activity of clinically important antibiotics and constitute a major clinical problem 
(CANTON and COQUE, 2006), have been shown to originate from environmental 
Kluyvera species that are not recognized as antibiotic producers (POIREL et al., 
2002).  
 
1.2 β-lactam antibiotics 
The first antibiotic was penicillin, discovered accidentally from a mould 
culture of Penicillium by Alexander Fleming in 1928 (FLEMING, 1929). This discovery 
revolutionized the treatment of infectious diseases and marks the start of modern 
medicine. Florey and Chain developed the purification method (CHAIN et al., 1940) 
and used it to treat bacterial infections during the Second World War, regarded as a 
“magic bullet”. Penicillin was first used in patients in 1942. Alexander Fleming, 
Howard Florey and Boris Chain were awarded the Nobel Prize of Medicine and 
Physiology in 1945 for the discovery and application of penicillin. Further studies on 
this important molecule by Dorothy Hodgkin led to the determination of the 
structure of penicillin using X-ray crystallography (HODGKIN, 1949) and identified 
the β-lactam ring as the key functional group. The β-lactams remain a cornerstone of 
antimicrobial chemotherapy. 
β-lactam antibiotics comprise natural or semi synthetic compounds that can 
be divided into four main groups based on their structure: penicillins, 
cephalosporins, monobactams and carbapenems (Figure 1.1). These antibiotics 
possess, as a common feature, a highly reactive β-lactam ring constituted by three 
carbon atoms and one nitrogen, but differ in the presence of additional rings to 
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which the β-lactam ring may be fused (DEMAIN and ELANDER, 1999). For example, 
β-lactam ring is fused to a five-membered thiazolidine ring in the penicillins but to a 
six-membered dihydrothiazine ring in the cephalosporins. Monobactams have no 
additional ring. Carbapenems have a β-lactam ring fused to a ring that is similar to 
that of penicillins but is unsaturated and the sulphur atom is substituted by a 
carbon. Different antibiotics within the same group are distinguished by the nature 
of one or more side chains (DEMAIN and ELANDER, 1999).  
Carbapenem antibiotics were originally developed from thienamycin, a natural 
product identified in culture filtrates of Streptomyces cattleya (BIRNBAUM et al., 
1985). The thienamycin molecule was chemically unstable and was never used for 
therapy. However, its structural scaffold was used to produce similar drugs with 
adequate properties for chemotherapy. Imipenem, meropenem, ertapenem, and 
doripenem are the carbapenems approved for human use so far (BAUGHMAN, 2009). 
The carbapenems exhibit the broadest spectrum of activity among the β-lactam 
antimicrobials, providing safe and efficacious therapies in the treatment of serious 
infections, caused by multidrug-resistant Gram-positive, Gram-negative, and 
anaerobic pathogens (BAUGHMAN, 2009; MANDELL, 2009). 
 
 
Figure 1.1 The core structures of β-lactam antibiotics with the numbering scheme shown. 
 
 
The discovery and subsequent development of β-lactam antibiotics was very 
important both for drug development and medicine. Today several hundred β-lactam 
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molecules structurally different from the four subclasses are available and most of 
them are prescribed for medical use. The antibacterial effect of all β-lactam 
antibiotics is dependent on their ability to cross the cellular membrane, the affinity of 
the antibiotic to target proteins and the stability to bacterial degradation (KOTRA and 
MOBASHERY, 1999). 
The β-lactams are among the most safe and efficient of all antibiotics. These 
drugs are also characterised by an absence of secondary effects in eukaryotes. Due 
to these characteristics and their relatively low cost and ease of delivery, β-lactam 
antibiotics are the most important antimicrobial agents in the treatment of bacterial 
infections, accounting for over 50% of antibiotic prescriptions in many countries 
(MOLSTAD et al., 2002; THERRIEN and LEVESQUE, 2000). 
Antimicrobial agents from the β-lactam class are still the first choice for 
treatment of infections in critically ill patients caused by multidrug resistant Gram-
negative bacteria where other options may be limited. Among these organisms are 
Pseudomonas aeruginosa, Acinetobacter baumannii, and the Enterobacteriacea, all of 
which may be responsible for a wide range of infections, particularly hospital 
acquired infections of immunocompromised patients (LIVERMORE, D., 2009; PELEG 
and HOOPER, 2010). In particular, the spread of resistance to other antibiotic 
classes, including cephalosporins, means that carbapenems are increasingly used 
routinely for these infections, rather than being in held in reserve in case of failure of 
other treatments (MASTERTON, 2009).  
 
1.2.1 Mechanism of action 
β-lactam antibiotics exert their bactericidal activity primarily by inactivation 
of bacterial cell wall synthesis. The cell wall is a protective layer located externally to 
the cytoplasmic membrane and composed of an inner layer of peptidoglycan that is 
surrounded by an outer membrane in Gram-negative bacteria.  
Peptidoglycan is the main component of the bacterial cell wall. It is a complex  
polymer composed of peptide chains and sugars that are linked by covalent bonds 
and is responsible for bacterial cell wall strength and resistance to osmotic pressure 
from cytoplasm (SCHLEIFER and KANDLER, 1972; WALSH, 2000). 
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The basic repeating unit is a disaccharide consisting of alternating residues of 
N-acetylglucosamine (NAG) and N-acetylmuramic acid (NAM) (Figure 1.2). A five 
amino-acid stem peptide chain of variable sequence, according to bacterial species, is 
terminated by a D-alanine, D-alanine moiety and attached to each NAM unit. It 
normally contains L-alanine, D-glutamic acid, mesodiaminopimelic acid (which may 
be substituted by other amino acids including L-lysine in Gram positive bacteria), 
and two residues of D-alanine (VOLLMER et al., 2008). The peptidoglycan polymer is 
constructed using two kinds of covalent bonds: β 1-4 glycosidic bonds link the sugar 
rings while the amino acid side chains are joined by peptide bonds. These peptide 
bonds are formed in the final transpeptidation step of cell wall synthesis which 
results in the cross-linking of the peptide chains of two neighbouring sugar strands 
by peptide bridges to form a three-dimensional network. This reaction is catalyzed by 
a series of transpeptidase enzymes that are also known as penicillin binding proteins 
(PBPs) due to their ability to bind to penicillin molecules (JEAN-MARIE, 1997; 
MACHEBOEUF et al., 2006).  
 
 
Figure 1.2 Schematic representation of peptidoglycan cross-linking in Gram-negative 
bacteria. 
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Tipper and Strominger (1965) suggested that the nucleus of β-lactam 
antibiotics mimics the terminal of D-alanyl-D-alanine of the linear stem peptide 
(Figure 1.3) and inhibits transpeptidation by reacting with the substrate binding site 
of PBPs. PBPs are active-site serine enzymes that catalyse the transpeptidation 
reaction via a covalent acylenzyme intermediate. In the initial step an acylenzyme 
complex is formed by reaction of the active site serine hydroxyl with the terminal D-
Ala-D-Ala, leading to cleavage of the last D-Ala residue. This is followed by a second 
reaction, involving the transfer of the acylenzyme to an amino group of a 
neighbouring chain, cross-linking individual peptidoglycan strands to establish a 
unifying network (TIPPER and STROMINGER, 1965). Cross-linking of the glycan 
strands generally occurs between the carboxyl group of D-Ala at position 4 and the 
amino group of the diamino acid at position 3, either directly in Gram-negative 
bacteria (Figure 1.2) or through a short peptide bridge (Gram-positive bacteria) 
(VOLLMER et al., 2008).  
 
 
Figure 1.3 Structural similarities between penicillin G (A) and D-alanyl-D-alanine (B). 
 
β-lactam antibiotics bind to PBPs, promoting the formation of an acylenzyme 
complex with the PBP by acylating the essential serine residue of the active site 
(Figure 1.4) (LEE et al., 2001). Once acylated by a β-lactam, the PBP deacylates very 
slowly, leading to irreversible inhibition of PBP catalysis and rendering them unable 
to catalyse the transpeptidation reaction (FISHER and MOBASHERY, 2009). This 
causes an incomplete biosynthesis of bacterial cell wall that triggers peptidoglycan 
autolysin action, resulting in osmotic lysis and ultimately cell death (BAYLES, 2000). 
However, the specific details of how this occurs are not yet known. The high 
specificity and absence of secondary effects is thus explained as molecules similar to 
peptidoglycan precursors do not exist in eukaryotic cells (MACHEBOEUF et al., 
2006). 
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Figure 1.4 A. Stereoview of the active site of Streptomyces R61 DD-
carboxypeptidase/transpeptidase acylated by a cephalosporin. The ligand is rendered as ball and 
stick with CPK atom colours. Hydrogen bonds between the enzyme and the ligand are shown as 
dotted white lines. Residues labeled in red are conserved among PBPs and β-lactamases. B. A 
schematic of interactions shown in A; the cephalosporin backbone (red) mimics the terminal acyl-
D-Ala-D-Ala portion of the peptide branch of the first strand of the peptidoglycan. The 
cephalosporin acylates the active site serine of the transpeptidase, as would the peptide from the 
first strand of peptidoglycan, concomitant with the departure of the terminal D-Ala. The β-lactam 
nitrogen and its adjacent carbon and carboxylate collectively serve as a substitute for the departing 
D-Ala. The acyl-enzyme species depicts the first enzyme-bound “peptidoglycan” strand (shown in 
red) poised to receive the amine of DAP from the second strand of peptidoglycan (shown in green). 
Figure and legend were adapted from Lee et al., (2001). 
 
1.2.2 Resistance mechanisms 
In order to exert their antimicrobial action, antimicrobial compounds must 
enter the cell, accumulate to inhibitory concentrations, and interact with their 
targets. Antibiotic resistance can arise from alterations to any of these processes, 
through a number of changes in the cell. Bacteria have developed escape strategies 
against all antimicrobials drugs and β-lactams are no exception. Resistance to these 
agents is common to Gram-positive and Gram-negative bacteria and is mediated by 
four mechanisms: alteration of the target (i.e. PBPs) (LAMBERT, 2005), reduction of 
the entry of the antibiotic to the cell by decreased permeability and/or efflux 
mechanisms (KUMAR and SCHWEIZER, 2005; POOLE, 2007) and inactivation of the 
antibiotic by hydrolytic enzymes before it can reach the target (FISHER et al., 2005). 
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In Gram-negative bacteria a synergy between resistance mechanisms is 
frequently used not only to increase but also to broaden resistance profile. The most 
commonly observed combinations are a reduction in outer membrane permeability 
together with active efflux and β-lactamase expression (BONOMO and SZABO, 2006; 
QUALE et al., 2006).  
 
The subject of this dissertation is the study of β-lactamases; therefore just a 
brief overview of other resistance mechanisms to β-lactams will be presented, while 
β-lactamases will be covered in more detail.  
 
1.2.2.1 Target alteration 
Resistance to β-lactam antibiotics due to PBP alteration occurs either by 
mutations in the chromosomal genes that code for PBPs or acquisition of 
supplementary genes that code for new PBPs with reduced affinity for the antibiotics 
(GEORGOPAPADAKOU, 1993). In Streptococcus pneumoniae resistance to β-lactams 
occurs almost entirely from modified versions of their own PBPs, mainly 2X, 2B, and 
1A, that are poorly acylated by β-lactams (GREBE and HAKENBECK, 1996; SMITH et 
al., 2005). The altered proteins from penicillin-resistant isolates are encoded by 
mosaic genes that have arisen by interspecies recombination events (HAKENBECK et 
al., 2001; LAIBLE et al., 1991).  
Resistance to penicillin and methicillin in Staphylococcus aureus has been 
known for a long time. Resistance to penicillin, reported soon after its introduction as 
a therapeutic agent, is due to expression of the “penicillinase” PC1 (RICHMOND, 
1963). More importantly, shortly after the clinical use of methicillin, a semi-synthetic 
penicillin introduced to restore β-lactam activity, methicillin-resistant S. aureus 
(MRSA) strains were identified (Barber, 1961). Methicillin-resistance is mediated by 
the acquisition of an altered PBP, encoded by the mecA gene that is designated as 
PBP2a or PBP2’ (DE LENCASTRE et al., 1994; HARTMAN and TOMASZ, 1984), and 
shows reduced affinity for all β-lactams (FUDA et al., 2005). 
PBP alteration is an important resistance mechanism to β-lactam antibiotics in 
Gram-positive cocci such as S. aureus and S. pneumoniae but is observed less 
frequently in Gram-negative bacteria (GEORGOPAPADAKOU, 1993). However, in 
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Neisseria gonorrhoeae, the causative agent of gonorrhoea, the production of modified 
PBP2 plays a major role in resistance to these agents, including extended-spectrum 
cephalosporins (OCHIAI et al., 2007; OHNISHI et al., 2010). Recently, it has been 
reported that modification of native PBPs also accounts for β-lactam resistance in 
other Gram-negative multi-resistant species such as A. baumannii (RUSSO et al., 
2009) and P. aeruginosa (ZAMORANO et al., 2010).  
 
1.2.2.2 Decreased permeability  
As stated above, Gram-negative bacteria have an impermeable outer membrane 
surrounding the peptidoglycan layer. This membrane functions as a barrier, 
preventing the access of several toxic compounds to the cell interior. Therefore, the 
transport of nutrients and other substances, including β-lactam antibiotics, across 
the outer membrane is achieved by water-filled channel-forming proteins known as 
porins (NIKAIDO, 2003). Resistance to β-lactams among Gram-negative bacteria can 
be attained by altered (reduced) permeability through change in porin copy number 
or selectivity. This mechanism is often combined with active efflux to enable bacteria 
acquire high level resistance to many antibiotics (KUMAR and SCHWEIZER, 2005). 
One of the mechanisms responsible for carbapenem resistance in important 
human oportunistic pathogens such as Klebsiella pneumoniae, P. aeruginosa and A. 
baumannii is the loss of specific porins which generally occurs in combination with 
other resistance mechanisms. In K. pneumoniae for example, it has been reported 
that resistance to carbapenems can arise via combination of AmpC or ESBLs 
enzymes that display very low carbapenemase activity, together with loss of the 
porins OmpK35 and/or OmpK36 (CHIA et al., 2010; SONG et al., 2009). Recently 
García-Fernández and co-workers (2010) described an ertapenem-resistant K. 
pneumoniae isolate that did not produce the OmpK35 porin due to a nonsense 
mutation, but expressed an altered OmpK36 along with the ESBLs SHV-12 and CTX-
M-15. Although this clone remained susceptible to meropenem and imipenem, the 
loss of OmpK36 expression in two isolates of the same clone converted these to an 
imipenem and meropenem-resistant phenotype (GARCIA-FERNANDEZ et al., 2010).  
P. aeruginosa also contains specific porins involved in antibiotic resistance. 
Apart from the expression of carbapenemases (LIVERMORE and WOODFORD, 2006), 
carbapenem resistance in P. aeruginosa is attributed to an interplay between low 
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permeability, activity of the efflux pump MexAB-OprM and an inducible or 
derepressed chromosomal AmpC β-lactamase (QUALE et al., 2006). In these bacteria 
derepressed expression of the OprD porin is important to achieve resistance to 
carbapenems (RODRIGUEZ-MARTINEZ et al., 2009; WANG et al., 2010). In a recent 
study, the loss of OprD proved to be the main mechanism of resistance to 
carbapenems (RODRIGUEZ-MARTINEZ et al., 2009). 
The decreased expression of some OMPs (outer membrane proteins) has also 
been reported to be associated with antimicrobial resistance in A. baumannii (MUSSI 
et al., 2005; TOMAS et al., 2005). Although there is not much data available on 
decreased permeability in A. baumannii, carbapenem resistance has been specifically 
correlated with loss of porins including CarO (LIMANSKY et al., 2002; MUSSI et al., 
2005), and additional OprD-like (DUPONT et al., 2005) and 33- to -36 kDa proteins 
(TOMAS et al., 2005). In these studies no other mechanism is associated with 
carbapenem resistance, in contrast to the K. pneumonia and P. aeruginosa described 
above. 
 
1.2.2.3 Active efflux  
β-lactam antibiotics must pass through the cell membrane to reach their 
targets in order to exert their bactericidal action on bacterial cells. Bacteria can 
become resistant to β-lactam antibiotics by reducing the effective intracellular 
antibiotic concentration by means of increased energy-dependent (or active) efflux, 
expelling the antimicrobials out of the cell interior (KUMAR and SCHWEIZER, 2005; 
POOLE, 2007).  
Efflux pumps are membrane-bound proteins working as transporters of 
antibiotics (and other toxic substrates) to the outside of the cell. Efflux pumps can be 
single- or multi-component. Gram-positive bacteria, which have only a cytoplasmic 
membrane, use single component pumps to transport their substrates, while Gram-
negative bacteria use these pumps to export drugs across their inner membranes. By 
way of contrast, multi-component pumps found in Gram-negative organisms 
transport molecules across both the inner and the outer membranes and comprise 
an inner membrane transporter associated with a periplasmic membrane fusion 
protein component and an outer membrane protein component, thus effluxing 
substrates across the entire cell envelope (KUMAR and SCHWEIZER, 2005). 
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Efflux systems are divided into five classes according to their number of pump 
components, energy source used and type of substrate (POOLE, 2007). The RND 
(resistance-nodulation-division) family of efflux systems accommodates a variety of 
clinically significant antibiotics, including β-lactams, and is therefore one of the most 
relevant efflux mechanisms of multidrug resistance in Gram-negative bacteria. RND 
systems are multi-component pumps constituted by the transporter protein in the 
inner membrane, a periplasmic membrane fusion protein and an outer membrane 
protein (POOLE, 2007). Such a pump can expel antibiotics from both the cytoplasm 
and the periplasmic space. 
 
The RND efflux pumps that have been studied in most detail are the MexAB-
OprM from P. aeruginosa and AcrAB-TolC from Escherichia coli. MexAB-OprM from P. 
aeruginosa is constitutively expressed, accounting for intrinsic resistance of these 
bacteria, and often confer multidrug resistance due to a broad substrate specificity 
(LLANES et al., 2004; MASUDA et al., 2000). MexAB-OprM is able to acomodate a 
wide range of β-lactam antibiotics including penems (faropenem), carbapenems 
(meropenem and panipenem), penicillins (carbenicillin and azlocillin), moxalactam 
and extended-spectrum cephalosporins (cefepime, cefotaxime, cefoxitin) (LI et al., 
1995; MASUDA et al., 2000; OKAMOTO et al., 2001). Additionally this pump also 
recognizes other clinically relevant antibiotics such as quinolones, macrolides, 
tetracyclines, and chloramphenicol (MASUDA et al., 2000). Quale and colleagues 
reported that carbapenem resistance in clinical isolates of P. aeruginosa is achieved 
by interplay between increased expression of chromosomal AmpC and of efflux 
systems, and reduced expression of OprD (QUALE et al., 2006). 
Recent studies also show that the efflux system AcrAB-TolC plays a key role in 
the β-lactam uptake and susceptibility in clinical isolates of K. pneumoniae (PADILLA 
et al., 2010; PAGES et al., 2009).  
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1.3 β-lactamases 
The most common resistance mechanism to β-lactam antibiotics, particularly 
among Gram-negative bacteria, is the production of β-lactamases (β-lactam 
hydrolases EC.3.5.2.6). β-lactamases are efficient enzymes that cleave the amide 
bond of the four-membered β-lactam ring rendering these drugs microbiologically 
inactive (LIVERMORE, D. M., 2009) (Figure 1.5).  
 
 
Figure 1.5 β-lactamase attack on penicillin with formation of inactive penicilloic acid. 
 
Once expressed β-lactamases produced by Gram-positive bacteria are bound 
to the cytoplasmic membrane or secreted into the extracellular milieu while those 
produced by Gram-negative organisms are concentrated in the periplasmic space. 
Many β-lactamases are structurally related to PBPs and probably evolved from these 
enzymes (MASSOVA and MOBASHERY, 1998). 
The production of penicillinase by E. coli, described even before the 
widespread clinical use of penicillin, represents the first reported resistance 
mechanism to β-lactam antibiotics (ABRAHAM and CHAIN, 1940). Since then, these 
enzymes, now known as β-lactamases, have been described in Gram-negative, Gram-
positive and mycobacteria (LIVERMORE, D. M., 2009).  
 
β-lactamases are found encoded on the chromosome or on plasmids and are 
frequently associated with other mobile genetic elements such as transposons and 
more recently ISCRs (FROST et al., 2005; TOLEMAN et al., 2006). More than 890 β-
lactamases have been described so far and this number continues to grow ((BUSH 
and JACOBY, 2010), http://www.lahey.org/studies/). The production of β-
lactamases constitutes the most important and widespread antimicrobial resistance 
mechanism among important human pathogens. The ability of bacteria to acquire β-
lactamases with a broad range of substrate specificities is a major concern, making 
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bacteria resistant to almost all β-lactams (QUEENAN and BUSH, 2007). The 
situation gets even more dramatic with the rapid spread of β-lactamase-encoding 
genes by the transmission by mobile genetic elements (BENNETT, 2008; SYKES, 
2010). 
 
Bacteria resistant to new β-lactam antibiotics are being selected in a relatively 
short time after their introduction for chemotherapy. In order to overcome β-lactam 
resistance and restore the antibacterial activity of these antibiotics, several strategies 
have been employed: the search of new antibiotics from microbial sources, chemical 
alteration of ‘old’ or first generation antibiotic structures to obtain new compounds 
with decreased sensitivity to resistance mechanisms and/or improved pharmacology 
(e.g. cephalosporins), and the use of β-lactamase inhibitors, such as clavulanic acid 
or sulbactam, in combination with an older antibiotic (e.g amoxicillin, piperacillin) 
(ABBANAT et al., 2008; CLARDY et al., 2006; DONADIO et al., 2010; DRAWZ and 
BONOMO, 2010). 
 
1.3.1 Classification  
 
Due to the diversity of enzymatic features of the β-lactamases identified so far, 
several attempts have been made to classify this group of enzymes. These 
classifications are based on functional and biochemical characteristics such as 
substrate profile and isoelectric point (RICHMOND and SYKES, 1973; SYKES and 
MATTHEW, 1976) or on the amino acid sequences of the enzymes (AMBLER, 1980).  
The Ambler classification initially separated the serine enzymes, designated as 
class A, from the metallo-β-lactamases or class B. It was completed with the 
subsequent inclusion of class C (JAURIN and GRUNDSTROM, 1981) and class D 
enzymes as their sequences became available (HUOVINEN et al., 1988; OUELLETTE 
et al., 1987). 
With the emergence of new β-lactamases it was possible to develop a 
classification system that relates substrate/inhibitor specificity with molecular 
structure (BUSH, 1989). This classification was later updated (BUSH, 2010; BUSH et 
al., 1995) and nowadays is the most used classification scheme. Table 1.1 shows the 
most used classification schemes with representative enzymes of each group. 
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 Table 1.2 Classification and properties of β-lactamases (adapted from Bush et al., 1995).  
Functional group 
(Bush et al., 1995) 
Molecular 
class 
Substrate 
profile 
Inhibition 
ACa    EDTA 
Representative 
enzymes 
1 C 
Cephalosporins 
penicillins 
cephamycins 
monobactams 
_          _ 
AmpC, CMY variants, 
FOX, ACT-1, LAT-1, 
MIR-1, DHA-  
2a A Penicillins +          _ 
PC1 (Gram-positive 
bacteria) 
2b A Penicillins cephalosporins +          
_ TEM-1, TEM-2, SHV-1 
2be A 
Penicillins 
cephalosporins 
monobactams 
+         _ 
TEM, SHV, CTX-M 
and GES/IBC 
variants, PER-1 –2, 
VEB-1 
2br A Penicillins _          _ 
TEM-30 –41, TEM-44 
–45, TEM-51, 54 
2c A Penicillins carbenicillins +          
_ PSE-1, PSE-3, PSE-4 
2d D Penicillins cloxacillins ±           
_ OXA variants  
2e A Cephalosporins +          _  
Cephalosporinase from 
Proteus vulgaris 
2f A 
Penicillins 
cephalosporins 
carbapenems 
+          _ 
NMC-A, Sme-1-3, 
IMI-1, KPCs 
3 B 
All β-lactams 
except 
monobactams 
_           + 
BcII, L1, CphA, ImiS, 
IMP, VIM, SPM-1 
4 Unknown Penicillins  
Penicillinase from 
Burkholderia 
(formerly 
Pseudomonas) cepacia 
 
a Clavulanic acid 
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1.3.2 Serine β-lactamases 
The serine β-lactamase group includes enzymes belonging to molecular 
classes A, C and D. This is a rather heterogeneous group that requires an active-site 
serine residue to catalyse the opening of the β-lactam ring. They are mostly 
penicillinases and cephalosporinases, including TEM, SHV and CTX-M-type enzymes 
that do not hydrolyse carbapenems (JACOBY and MUNOZ-PRICE, 2005), although 
increasing numbers of such enzymes with carbapenemase activity have now been 
reported (WALTHER-RASMUSSEN and HOIBY, 2007). 
The interaction between serine β-lactamases (and related serine penicillin-
recognizing enzymes) and β-lactams comprises three steps: non-covalent binding to 
form a Michaelis complex (k−1/k1), acylation (k2), and deacylation (k3) (Scheme 1.1) 
(HERZBERG and MOULT, 1987).  
 
 Scheme 1.1 
 
In scheme 1.1 E represents a β-lactamase, S the β-lactam substrate, ES is the 
noncovalent Michaelis complex, ES* is the covalent acylenzyme complex, where the 
antibiotic is covalently bound to the active-site serine residue, and P is the released 
hydrolysed β-lactam. In general, β-lactamases efficiently catalyze the deacylation 
step (high k3 value) which regenerates the active enzyme (E) and releases a 
biologically inactive product (P). By contrast, in the PBPs the hydrolysis of the 
acylenzyme ester bond is slow. Compared with the deacylation rate constant 
displayed by the β-lactamases, the same rate in PBPs is up to six orders of 
magnitude slower (KNOX et al., 1996).  
 
The reaction mechanism of serine β-lactamases consists of two main steps: 
acylation of an active site serine by the β-lactam antibiotic, followed by deacylation 
and release of the inactive compound (Figure 1.6). 
The first step involves activation of the serine residue in the active site, the 
nucleophile, by a general base. Upon activation this serine performs a nucleophilic 
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attack on the carbonyl of the β-lactam ring creating a tetrahedral intermediate that is 
stabilized by hydrogen bonding between the carbonyl oxygen and an oxyanion hole 
formed by the enzyme active site. Protonation of the β-lactam nitrogen and cleavage 
of the C-N bond in the β-lactam ring leads to the formation of a covalent acylenzyme 
intermediate. In the second step, a base-activated water molecule attacks the 
covalent complex with formation of a tetrahedral deacylation intermediate. Cleavage 
of this intermediate by hydrolysis of the bond between the serine oxygen and the 
carbonyl of the β-lactam, releases the inactive (hydrolysed) β-lactam and the active 
enzyme. 
 
 
Figure 1.6 Schematic reaction mechanism for a β-lactam substrate and a serine β-
lactamase. The acylation and deacylation transition states of the reaction pathway are shown, 
where B represents the general base and it is not necessarily the same residue for both acylation 
and deacylation.  
 
The differences between the catalytic mechanisms of serine β-lactamases from 
molecular classes A, C and D are largely focussed on the identity of the residues 
used as general base for acylation and deacylation (DRAWZ and BONOMO, 2010; 
FISHER et al., 2005). In enzymes from molecular class A it is well accepted that 
Glu166 acts as the general base for the deacylation reaction, while the precise 
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mechanism by which the catalytic Ser70 is activated remains the subject of long-
term debate (see discussion in section 1.3.3).  
Studies of the crystal structure of the C. freundii class C enzyme have 
suggested that the conserved residue Tyr150 activates the active site Ser64 for 
nucleophilic attack on the β-lactam ring (OEFNER et al., 1990), and is involved in the 
deacylation step by accepting a proton from the deacylation water (OEFNER et al., 
1990). However, recent data indicate that Tyr150 is protonated throughout the 
reaction coordinate, disfavouring mechanisms that involve a stable tyrosinate as the 
general base for deacylation (CHEN et al., 2006). These authors propose a role for 
Tyr150 in coordinate activation of the deacylating water in cooperation with the 
lactam nitrogen of the substrate itself (substrate-assisted catalysis), although it does 
not rule out, in itself, the alternative Lys67-Tyr150 coordinate base mechanism.  
Class D enzymes display the unique feature of activation of their β-lactamase 
activity by CO2. In these enzymes Lys70 (the structural equivalent of Lys73 and 
Lys67 of class A and class C β-lactamases, respectively) is N-carboxylated by addition 
of the lysine side chain amine to CO2 (GOLEMI et al., 2001; MAVEYRAUD et al., 
2000). Structural analysis shows that the resulting carbamate anion forms a 
hydrogen bond with the nucleophilic Ser67, suggesting that this carboxy-lysine may 
be the agent that activates the attacking groups, Ser67 and the hydrolytic water, in 
both the acylation and deacylation reactions, respectively (GOLEMI et al., 2001; 
MAVEYRAUD et al., 2002; MAVEYRAUD et al., 2000). 
 
From this point, the discussion in this dissertation will focus on the class A 
and class B β-lactamases as these are the most relevant to the work here presented. 
 
1.3.3 Structure and mechanism of class A β-lactamases 
Among the four Ambler classes of β-lactamases, class A enzymes are largely 
plasmid encoded, the most numerous and widespread among Gram-positive and 
Gram-negative bacteria. 
The study of three dimensional structures of several β-lactamases from 
molecular class A showed remarkable similarities with the penicillin-binding proteins 
(PBPs). The first class A β-lactamase crystal structure to be determined was that of 
PC1 from S. aureus (HERZBERG and MOULT, 1987) followed by the class A β-
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lactamases of Streptomyces albus G (DIDEBERG et al., 1987), Bacillus licheniformis 
749/C (MOEWS et al., 1990) and E. coli (TEM-1) (JELSCH et al., 1992; JELSCH et al., 
1993). By the same time Strynadka and collaborators solved the crystal structure of 
the TEM-1 mutant Glu166Asn as an acylenzyme complex with benzylpenicillin 
(STRYNADKA et al., 1992). Since then numerous structures of wild-type, mutants 
and substrate and inhibitor complexes have been determined for class A β-
lactamases (FISHER et al., 2005). 
Comparison of these structures revealed that molecular class A β-lactamases 
consist of two structural domains: an all α domain consisting of eight α helices and 
an α/β domain formed by three α helices and five β sheets. The active site pocket is 
located at the interface of the two domains (HERZBERG and MOULT, 1987). Along 
with the similarity in the three dimensional structures, a high degree of similarity is 
also found in the relative positions of four highly conserved motifs (Figure 1.7).  
 
 
 Figure 1.7 Overall structure of the class A β-lactamase TEM-1 (PDB accession 1ZG4) with 
the two domains labelled. The conserved motifs of class A β-lactamases are shown in different 
colours. The first motif (S70-K73) in the active site is in green; the second motif (S130-N132) is in 
orange; the third motif (K234-G236) and the omega loop (residues 163 to 178) are shown in blue 
and magenta, respectively. The catalytic S70, and S130, E166 and N170, some of the residues 
involved in the catalytic mechanism, are shown as a stick model with grey carbon atoms, red 
oxygen atoms, and blue nitrogen atoms.  
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The first motif extends from Ser70 to Lys73 (SXXK) (residue numbering 
according to Ambler et al., (AMBLER et al., 1991)) and includes the critical serine 
that is activated to undergo acylation. This residue is located near the N-terminus of 
a helix (Figure 1.7) thus facilitating its activation as a nucleophile (HERZBERG and 
MOULT, 1987; MOEWS et al., 1990). Replacement of the active-site serine with other 
residues abolishes enzyme activity, providing evidence that Ser70 is involved in the 
β-lactam hydrolysis (CHEN et al., 1996; DALBADIE-MCFARLAND et al., 1986). Lys73 
is located in the same helix and points into the active site, however its role in the 
catalytic mechanism is still under discussion. Mutagenesis studies have shown 
experimentally that Lys73 is involved in the acylation reaction (CHEN et al., 1996), 
probably through stabilization of Ser70 during its deprotonation (CHEN et al., 1996). 
The second element, situated on a short loop, contains Ser130 to Asn132 
(SXN) and forms one side of the active site groove (Figure 1.7). Ser130 is an 
important residue in the catalytic mechanism and is thought to be required to 
transfer a proton from its hydroxyl group to the nitrogen atom of the β-lactam 
substrate after formation of the tetrahedral intermediate (LAMOTTE-BRASSEUR et 
al., 1991).  
A triad composed of residues Lys234-Thr(Ser)235-Gly236 composes the third 
motif and forms the opposite wall of the active site cavity (Figure 1.7). Lys234 is 
considered to be involved in stabilization of Ser130 (in the SXN motif) through 
hydrogen bonding (MATAGNE et al., 1998). 
A fourth element, found in class A β-lactamases, extends from Glu163 to 
Asn178 and forms the bottom of the active site cavity (HERZBERG and MOULT, 
1987; JELSCH et al., 1993) (Figure 1.7). This element is known as the Ω loop and 
contains the essential Glu166, involved in deacylation. Involved in a dense hydrogen-
bonding network, the conserved residues Glu166 and Asn170 are essential to 
position the conserved deacylating water molecule close to Ser70 (LAMOTTE-
BRASSEUR et al., 1991). During deacylation Glu166 activates this water molecule 
that then attacks the carbonyl carbon of the acylenzyme intermediate. Transfer of a 
proton to the catalytic Ser70 regenerates the enzyme (HERZBERG and MOULT, 
1987). The study of Glu166 mutants confirmed the involvement of this residue in 
substrate hydrolysis (ADACHI et al., 1991; DELAIRE et al., 1991) while the decrease 
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in the deacylation rate with the E166A mutant is consistent with Glu166 acting as a 
general base to activate water in the deacylation step (ESCOBAR et al., 1991). 
Although the mechanism for deacylation is well established, the identity of the 
residue involved in the activation of the active serine (Ser70) in the acylation step has 
been subject of controversy. Two residues, Glu166 and Lys73 have been proposed as 
candidates to act as the general base in the acylation mechanism, i.e. abstracting the 
hydroxyl proton of the active serine and increasing its nucleophilicity. Strynadka and 
co-workers proposed that Lys73 acts as a general base, abstracting a proton from 
Ser70 and transferring it to the nitrogen atom of the β-lactam amide of the substrate 
via Ser130, assuming that the lysine is unprotonated (STRYNADKA et al., 1992). 
However, a NMR study suggested that Lys73 is positively charged in the free enzyme, 
with a pKa value above 10 (Damblon et al. 1996). Also, Lietz and collaborators 
studied the role of Lys73 in the acylation reaction using the mutant K73A from B. 
licheniformis β-lactamase (LIETZ et al., 2000). According to these authors, a 
decreased turnover rate and catalytic efficiency was observed, but also a significant 
shift in pKa to higher pH, consistent with the removal of the positive ammonium 
group of the lysine from the proximity of Glu166. These data provide indication that 
Lys73 does not act as the general base in the activation of the serine hydroxyl group 
but is most likely involved in both acylation and deacylation through electrostatic 
effects on neighbouring residues (LIETZ et al., 2000). 
 
In an alternative mechanism, Glu166 is proposed to act as the general base in 
both acylation and deacylation (Figure 1.8), activating Ser70 by way of a water 
molecule that is situated between the two residues (LAMOTTE-BRASSEUR et al., 
1991). Several mutagenesis studies support this hypothesis: with the El66C mutant 
both acylation and deacylation are decreased by several orders of magnitude 
(Escobar, 1994); mutants E166N in TEM-1 and E166H in the S. albus G β-
lactamases were shown to form stable acylenzymes with β-lactam antibiotics but 
with a reduced acylation rate when compared to the wild-type enzymes (GUILLAUME 
et al., 1997). In addition, ultra-high resolution crystal structures of TEM-1 in 
complex with an acylation transition-state analogue (MINASOV et al., 2002) and of 
CTX-M-9 (CHEN et al., 2007) together with theoretical simulations of the reaction 
coordinates (HERMANN et al., 2009) suggest that Glu166 acts through a water 
molecule to activate Ser70 for nucleophilic attack on the β-lactam ring of the 
substrate. 
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Taken together these studies strongly support the conclusion that Glu166 
functions as a general base catalyst in both formation and hydrolysis of the 
acylenzyme intermediate as originally proposed by Lamotte-Brasseur and 
collaborators (1991).  
 
Over the course of the reaction pathway, tetrahedral transition-state 
intermediates are formed in which the β-lactam carbonyl oxygen is negatively 
charged (B and D in Figure 1.8). In order to stabilize this charge, hydrogen-bonding 
interactions are made with an “oxyanion hole” formed by the main chain amino 
groups of Ser70 and Ala237 (HERZBERG and MOULT, 1987; STRYNADKA et al., 
1992). 
 
 
 Figure 1.8 Proposed reaction mechanism for a penicillin β-lactam substrate and a class A 
serine β-lactamase in which Glu166 participates in activating a water molecule for both acylation 
and deacylation. Dashed lines represent hydrogen bonds. Following activation of the hydroxyl 
group, Ser70 performs a nucleophilic attack on the carbonyl group of the β-lactam antibiotic (A), 
resulting in a high-energy acylation intermediate (B). Protonation of the β-lactam nitrogen leads to 
cleavage of the C-N bond and formation of the covalent acyl-enzyme (C), which adopts a lower 
energy state. Attack by a catalytic water leads to a high-energy deacylation intermediate (D), with 
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subsequent hydrolysis of the bond between the β-lactam carbonyl and the oxygen of Ser70 (E). 
Deacylation regenerates the active enzyme and releases the inactive β-lactam. Adapted from Drawz 
and Bonomo (2010). 
1.3.4 Evolution of class A β-lactamases 
Penicillin-resistant staphylococci were observed shortly after the introduction 
of penicillin, threatening the treatment of infectious diseases (BARBER, 1947). In 
order to restore penicillin activity, pharmaceutical companies developed new 
generations of penicillins, including methicillin and oxacillin. Methicillin was 
introduced to the clinic in 1959, but by 1961 strains of methicillin resistant S. 
aureus (MRSA) had emerged (JEVONS, 1961) due to the production of altered PBPs 
as described earlier (see section 1.2.2.1 ).  
To fight pathogenic bacteria able to produce penicillinases, particularly Gram-
negative organisms, new β-lactams, aimed at resisting the hydrolytic action of β-
lactamases and further increasing their spectrum of activity, were developed 
(ABBANAT et al., 2008). Among these “β-lactamase-stable” antibiotics are modified 
penicillins (e.g. ampicillin), third (e.g. cefotaxime and ceftazidime) and fourth 
generation cephalosporins (cefepime), cephamycins (cefoxitin), oxacephamycins 
(moxalactam), monobactams (aztreonam) and carbapenems (e.g. imipenem). Another 
strategy employed to retain the effectiveness of β-lactam antibiotics is the discovery 
and use of compounds that inactivate the β-lactamases (DRAWZ and BONOMO, 
2010; FISHER et al., 2005). Clavulanate, a natural product of Streptomyces 
clavuligerus, was the first inhibitor to be identified (BROWN et al., 1976). Subsequent 
modifications to its structure lead to the development of two other inhibitors, 
sulbactam and tazobactam (CARTWRIGHT and COULSON, 1979; ENGLISH et al., 
1978). Although they share structural similarity with β-lactam antibiotics, generally 
these inhibitors do not have antimicrobial activity on their own, and are formulated 
with a β-lactam antibiotic (e.g. amoxicillin-clavulanate and ampicillin-sulbactam) to 
act as shields against β-lactamases (DRAWZ and BONOMO, 2010). The three 
commercially available β-lactamase inhibitors described above are directed mainly to 
class A β-lactamases and are usually less effective against other β-lactam resistant 
enzymes (BUYNAK, 2006). Still, bacteria have always evolved to counteract the action 
of new β-lactam drugs and β-lactam inhibitor combinations as these are introduced 
into clinical use (LIVERMORE, D. M., 2009). 
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The plasmid-encoded β-lactamases TEM-1, TEM-2 and SHV-1 are the most 
frequently found β-lactamases in clinical isolates of E. coli and Klebsiellae, 
respectively, and confer resistance to penicillins and first generation cephalosporins. 
The introduction of third and fourth generation cephalosporins in the early 1980s 
has driven the evolution of extended-spectrum TEM and SHV β-lactamases (ESBLs) 
that are characterised by the ability to hydrolyse second and third generation 
cephalosporins and aztreonam, but not cefoxitin or carbapenems (PATERSON and 
BONOMO, 2005; PEREZ et al., 2007). These ESBLs result from one to four 
aminoacid substitutions compared with their parent enzymes, usually at positions 
located close to the active site cavity. The mutations associated with the ESBL 
activity occur at positions Glu104 (TEM), Ala146 (SHV), Gly156 (SHV), Arg164 (TEM), 
Leu169 (SHV), Asp179 (SHV and TEM), Arg205 (SHV), Ala237 (TEM), Gly238 (TEM 
and SHV), and Glu240 (TEM and SHV) (KNOX, 1995; MATAGNE et al., 1998).  
The most frequent substitutions occurring in both TEM and SHV-derived 
ESBLS are those of Gly238 for serine and Glu240 for lysine 
(http://www.lahey.org/studies). Mutagenesis studies on TEM and SHV ESBLs 
determined that the G238S and E240K mutations were the primary cause for 
ceftazidime resistance and that an increased catalytic efficiency towards cefotaxime 
was observed only with G238S mutants (HULETSKY et al., 1993; VENKATACHALAM 
et al., 1994). Cantu and Palzkill (1998) proposed that a steric conflict with the S238 
side chain affects the displacement of the Ω loop and that an intramolecular 
hydrogen bond between S238 side chain and N170 main chain carbonyl group in the 
Ω loop is required to stabilize the Ω loop in a new location. This would allow 
extended-spectrum cephalosporins greater access to the active site cavity and 
consequently improves the catalytic efficiency of the enzyme for these substrates 
(CANTU and PALZKILL, 1998). The crystal structure of SHV-2, a naturally occurring 
G238S mutant of SHV-1, has shown a significant displacement of part of the β-sheet 
strand S3 (residues 234-237), and of the short loop connecting S3 and S4 (residues 
238-243), as well as a conformational rotation in the 240–241 region in this loop 
(NUKAGA et al., 2003b). The structure of TEM-52 (E104/M182T/G238S) reports the 
movement of loop 238-243 with respect to its position in TEM-1, widening the 
opening of the active site and causing a reorganization of adjacent loops (ORENCIA et 
al., 2001). Consequently, the carboxylate group of E240 is shown to be removed from 
the active site and oriented over the strand S3, decreasing the possibility of any 
interference with substrate side chain (ORENCIA et al., 2001). These structural 
changes at the β-sheet are caused by the insertion of the larger S238 side-chain 
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between the strand S3 and the Ω loop. The displacement of strand S3 away from the 
Ω loop results in an expansion of the β-lactam binding site so that it is better able to 
accommodate the bulky, rigid R1 substituents of the oxyimino cephalosporins, as 
previously suggested by Huletsky and collaborators (HULETSKY et al., 1993).  
More recently (since 1995) a new family of plasmid-mediated ESBLs has 
emerged that preferentially hydrolyse cefotaxime, the CTX-M-type enzymes. CTX-M 
enzymes are more active against cefotaxime and ceftriaxone than against ceftazidime 
and are now the most frequently observed ESBLs (BONNET, 2004). These enzymes 
are not related to TEM or SHV β-lactamases but probably originate from 
chromosome-encoded class A β-lactamases from environmental Kluyvera species 
with an inherited intrinsic ESBL activity (POIREL et al., 2002). In contrast to the 
enlarged active site observed in the TEM and SHV mutant ESBLs, thought to be 
responsible for their specificity (NUKAGA et al., 2003b; ORENCIA et al., 2001), CTX-
M enzymes have small active sites (CHEN et al., 2005). 
Crystallographic data for CTX-M ESBLs provided insight for understanding 
the structure-activity relationship in these β-lactamases (CHEN et al., 2005; 
DELMAS et al., 2008). According to these studies, the increased activity against the 
bulky third-generation cephalosporins, especially ceftazidime, results from an 
enhanced flexibility of the β-sheet strand S3 of the active site. This increased 
flexibility is correlated with higher ceftazidimase activity, but costs a reduction in 
enzyme stability. The improved activity towards ceftazidime is related with the 
substitution Asp240Gly. In CTX-M-16 (Val231Ala/Asp240Gly), an enzyme that is 
significantly more active against both cefotaxime and ceftazidime compared to the 
CTX-M-9 (Val231Ala), the substitutions that occur at strand S3 create structural 
defects, apparently loosening the strand in a coordinated way that is linked to a 
decreased internal stability (CHEN et al., 2005). This relation between activity and 
stability is also common in TEM and SHV-ESBLs and IRTs (inhibitor resistant TEMs) 
(KNOX, 1995). Recently, it was reported that the substrate binding site in CTX-M-16 
is not enlarged and that the residue at position 240 is unable to interact with 
ceftazidime (DELMAS et al., 2008), in clear contrast to the situation observed with 
TEM and SHV ESBLs (NUKAGA et al., 2003b). Molecular dynamics simulations 
showed that in CTX-M-16 G240 promotes the coordinated vibration of strand S3 
along with the catalytic S70 and residues 167 to 170 located in the Ω loop. These 
coordinated vibrations improve interactions between residues 237 and 235 and the 
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side chain of ceftazidime, favouring the accommodation of the bulky antibiotic 
(DELMAS et al., 2008).  
The ESBLs are mostly plasmid-encoded and thus easily spread through 
horizontal gene transfer. They are now found worldwide, not only in the hospitals but 
also in the community. These enzymes are able to hydrolyse β-lactam antibiotics 
from several classes resulting in resistance to penicillins, cephalosporins and 
aztreonam. Since the 1980s, they have been known to cause nosocomial outbreaks 
and have been on the increase in recent years (CANTON and COQUE, 2006; PEREZ 
et al., 2007). 
 
1.3.5 Metallo-β-lactamases 
Not all β-lactamases use a serine residue for catalytic activity. The metallo-β-
lactamases (MBLs) or molecular classe B β-lactamases are classified in functional 
group 3 (BUSH and JACOBY, 2010) and constitute a subset of zinc hydrolases with 
the ability to hydrolyse the amide bond of the β-lactam ring of a number of β-lactam 
antibiotics. The metallo-β-lactamase group includes a small number of enzymes 
when compared to serine β-lactamases, but their numbers are still increasing.  
The first metallo-β-lactamase to be described was the BcII enzyme isolated 
from Bacillus cereus in 1966 (SABATH and ABRAHAM, 1966). For two decades it was 
the only example of an MBL and was regarded as a biochemical curiosity as B. cereus 
was not considered to be a serious clinical pathogen. Later these enzymes were 
described in several species of bacteria that occur naturally, such as Bacteroides 
fragilis, Chryseobacterium spp., Legionella gormanii, Stenotrophomonas spp., and 
several species of Aeromonas. In these environmental bacteria MBLs are encoded in 
the chromosome (QUEENAN and BUSH, 2007). The zinc-dependent enzymes were 
only regarded as potential threats when found to be transferable (WATANABE et al., 
1991). Since 1991 a dramatic increase in acquired and transferable MBLs has been 
observed among major Gram-negative pathogens, including various Acinetobacter, P. 
aeruginosa and the Enterobacteriaceae (WALSH et al., 2005). The majority of 
transferable metallo-β-lactamases are included in common families: IMP, VIM, GIM, 
SPM and SIM, members of which are associated with several genetic platforms such 
as integrons, plasmids, transposons and ISCRs. Some of these are mobile, facilitating 
the transfer of MBLs among bacteria (WALSH et al., 2005). 
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1.4 Carbapenemases 
The treatment of infectious diseases by penicillins and cephalosporins is 
increasingly challenged by the emergence and dissemination of numerous CTX-M, 
TEM and SHV mutants with a broad spectrum of activity (PEREZ et al., 2007). Of all 
β-lactams, carbapenems are the least prone to β-lactamase activity, being stable 
against ESBLs and AmpC β-lactamases. This β-lactamase stability, together with the 
rapid penetration to the target site and strong PBP affinity, gives carbapenems the 
broadest spectrum of activity of any β-lactams (BONFIGLIO et al., 2002). Unlike most 
other antibiotics, most carbapenems are effective against clinically-significant, Gram-
negative non-fermenters (e.g., P. aeruginosa, Burkholderia cepacia and Acinetobacter 
spp.) (BETRIU et al., 2010; CASTANHEIRA et al., 2009) and anaerobes (GOLDSTEIN 
and CITRON, 2009). Moreover, these β-lactam compounds also behave as irreversible 
inhibitors of most serine-β-lactamases (BEADLE and SHOICHET, 2002; NUKAGA et 
al., 2003a). As is the case of the other β-lactamase inhibitors, carbapenems can give 
rise to a tetrahedral acylenzyme intermediate that resists deacylation and 
permanently inactivates the β-lactamase (BEADLE and SHOICHET, 2002). 
Therefore, carbapenems have traditionally been reserved to treat the most 
serious infections, being considered last resource antibiotics in the hospital, used 
against bacterial strains that exhibit resistance to other β-lactams. However, their 
clinical use has increased over the last 20 years as the prevalence of resistance to 
penicillins, cephalosporins, fluoroquinolones and aminoglycosides has increased 
(BAUGHMAN, 2009). Although carbapenems are susceptible to serine 
carbapenemases and metallo-β-lactamases, so far these resistance mechanisms are 
less common; nevertheless they are increasing worldwide, selected by the treatment 
of infections caused by ESBL-producing pathogens. Their dissemination severely 
limits the options for treatment of producing organisms (QUEENAN and BUSH, 
2007; WALTHER-RASMUSSEN and HOIBY, 2007).  
According to Poirel and Nordmann, carbapenemases can be defined as β-
lactamases that significantly hydrolyse at least imipenem and/or meropenem; 
additionally most of these enzymes are also active against other β-lactams such as 
penicillins, oxyimino-cephalosporins and cephamycins (POIREL and NORDMANN, 
2002). Carbapenemases are a diverse group including enzymes from molecular 
classes A, B and D (QUEENAN and BUSH, 2007). 
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Occasionally overproduction of AmpC enzymes can confer clinically relevant 
resistance to carbapenems, if this is associated with other resistance mechanisms 
such as porin loss (MAMMERI et al., 2008). 
 
1.4.1 Oxacillinases 
The class D β-lactamases are also referred as oxacillinases because they 
hydrolyse oxacillin and cloxacillin much faster than classical penicillins. A limited 
number of oxacillinases with weak carbapenemase activity have been described, 
mainly in A. baumannii (BERTINI et al., 2006; CARRER et al., 2010), but also occur 
in P. aeruginosa (GIRLICH et al., 2004) and Enterobacteriaceae (GÜLMEZ et al., 2008; 
POIREL et al., 2004b). The OXA carbapenemases are very diverse enzymes that can 
be divided into subgroups such as OXA-23-like, OXA-24-like, OXA-48, OXA-51-like, 
and OXA-58-like. OXA carbapenemase genes are located on both chromosomes and 
plasmids (WALTHER-RASMUSSEN and HØIBY, 2006). 
The substrate specificities of the OXA-type carbapenemases are diverse, but 
generally the enzymes have measurable hydrolytic activity against the penicillins 
(benzylpenicillin, ampicillin, piperacillin and ticarcillin), some cephalosporins 
(cefalotin and cefaloridine) and imipenem while the extended-spectrum β-lactams, 
ceftazidime, cefotaxime and aztreonam, are not or only very poorly hydrolysed 
(WALTHER-RASMUSSEN and HOIBY, 2007). In general, imipenem hydrolysis, which 
is faster than meropenem hydrolysis, is slow, with the highest kcat values for the 
OXA-54 and OXA-48 enzymes at 1 s–1 and 2 s–1, respectively (POIREL et al., 2004a; 
POIREL et al., 2004b). The Km values for imipenem are also low, ranging from 2 to 20 
µM, indicating that the OXA enzymes have very high affinity for these substrates 
(QUEENAN and BUSH, 2007).  
Class D β-lactamases are usually not inhibited by clavulanic acid, 
tazobactam, and sulbactam, whereas their activities may be inhibited in vitro by 
sodium chloride (NaCl) (WALTHER-RASMUSSEN and HOIBY, 2007). Inhibition by 
NaCl is attributed to the presence of a Tyr residue in the Tyr144-Gly-Asn motif 
(HERITIER et al., 2003). 
Most of the OXA-type carbapenemases exhibit low catalytic efficiency for the 
carbapenems in vitro; however the association with other resistance mechanisms 
such as reduced permeability (MUSSI et al., 2005; POIREL et al., 2004b) or 
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expression of efflux pumps (HERITIER et al., 2005; LEE et al., 2010) usually results 
in high-level resistance to carbapenems in the resistant strains. 
 
1.4.2 Class A carbapenemases 
Class A β-lactamases with activity against carbapenems were considered 
uncommon. These were first described in the 1980s in some Enterobacteriaceae 
(NORDMANN et al., 1993; YANG et al., 1990). However, they are now widespread as 
result of the transmission of plasmid-mediated carbapenemases (LIVERMORE, D. 
M., 2009). The class A carbapenemases belong to functional group 2f, are inhibited, 
to varying degrees, by β-lactamase inhibitors (but not EDTA), and still represent a 
relatively small group of β-lactamases. However, they are increasing in number, due 
primarily to the increasing identification of the plasmid-mediated enzymes KPC 
(Klebsiella pneumoniae carbapenemase) and GES (Guiana extended spectrum) (BUSH 
and JACOBY, 2010). These enzymes have been described in isolates that also have 
AmpC-type cephalosporinases, thereby broadening their substrate profile to a wide 
variety of β-lactam compounds (RASMUSSEN and BUSH, 1997). 
As mentioned earlier, carbapenems are able to irreversibly inhibit most class 
A β-lactamases including ESBLs (BEADLE and SHOICHET, 2002; NUKAGA et al., 
2003a). However, so far, the mechanism by which class A carbapenemases escape 
inhibition and hydrolyse these antibiotics remains unclear. 
The group of class A carbapenem-hydrolysing β-lactamases consists of a small 
number of chromosomal enzymes including NMC-A and IMI-1 from E. cloacae 
(NORDMANN et al., 1993; RASMUSSEN et al., 1996), Sme-1 to -3 from S. marcescens 
(enzymes differing by one to two amino acid substitutions) (QUEENAN et al., 2006; 
QUEENAN et al., 2000; YANG et al., 1990), SFC-1 from S. fonticola (HENRIQUES et 
al., 2004) and the recently described BIC-1 from P. fluorescens (GIRLICH et al., 
2010). In addition, class A carbapenemases also include plasmid-mediated enzymes, 
the most important being the carbapenemases from K. pneumoniae (KPCs), and some 
GES β-lactamases (POIREL et al., 2001; YIGIT et al., 2001). 
The chromosomal enzymes NMC-A, Sme and IMI-1 share a similar spectrum 
of hydrolysis that includes penicillins, early cephalosporins, carbapenems and 
aztreonam. Imipenem is hydrolysed faster than meropenem and they display, if 
detected, a very low activity against extended-spectrum cephalosporins. These 
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enzymes are inhibited by the β-lactamase inhibitors clavulanic acid, tazobactam and 
sulbactam (MARIOTTE-BOYER et al., 1996; QUEENAN et al., 2000; RASMUSSEN et 
al., 1996). The expression of these β-lactamases is inducible and regulated by a 
LysR-type regulator (NAAS et al., 1995; NAAS and NORDMANN, 1994). In two reports 
IMI-2 has been identified in plasmids associated with transposable elements 
(AUBRON et al., 2005; YU et al., 2006).  
The plasmid-mediated class A carbapenemases KPC were first described in 
Klebsiellae (KPC-1 to KPC-3 differing by one to two point mutations), and were later 
reported in other members of the Enterobacteriaceae family (QUEENAN and BUSH, 
2007; YIGIT et al., 2001). KPC enzymes display a similar hydrolytic profile, exhibiting 
resistance to carbapenems, penicillins, cephalosporins and aztreonam and inhibition 
by the β-lactamase inhibitors clavulanic acid and tazobactam. Cephamycins and 
ceftazidime are weakly hydrolysed (WOODFORD et al., 2004; YIGIT et al., 2001; 
YIGIT et al., 2003). In contrast to most chromosomal carbapenemases, expression of 
KPC enzymes is not inducible (YIGIT et al., 2001). The KPC family has a great 
potential for spread due to its location on plasmids. KPC enzymes were recently 
reported in non-fermenters such as P. aeruginosa (VILLEGAS et al., 2007) and 
Acinetobacter spp. (ROBLEDO et al., 2010). To date, nine different KPC variants 
(KPC-2 to -10) have been identified that differ by one or two amino acid substitutions 
(ROBLEDO et al., 2010). Of great concern is the concomitant occurrence of KPC 
enzymes with multiple plasmid-mediated enzymes, most often TEM-1 and SHV-11 
(GIANI et al., 2009; YANG et al., 2010). More worrisome is the co-expression of KPCs 
and metallo-carbapenemases (YANG et al., 2010) and additionally common ESBLs 
such as CTX-M-15 (POURNARAS et al., 2010). This fact, together with their current 
spread worldwide, makes KPCs a potential threat to the antibiotic-based treatments 
currently available.  
The GES family is the most recently reported group of class A 
carbapenemases. The first enzyme to be described with carbapenemase activity was 
GES-2, a point mutant derivative (G170N) of the extended-spectrum β-lactamase 
GES-1 (POIREL et al., 2001). GES-2 is an ESBL with the substrate profile extended 
to imipenem but with hydrolysis rates lower than those of other carbapenem-
hydrolyzing class A β-lactamases (POIREL et al., 2001). Subsequently, three other 
variants with similar carbapenemase activity have been described (GES-4, GES-5, 
and GES-6), displaying the amino acid substitution G170S in the Ω-loop of the 
catalytic site (VOURLI et al., 2004; WACHINO et al., 2004). The genes encoding GES 
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β-lactamases were found in the variable region of class 1 integrons carried on self-
transferable plasmids from different geographical locations (POIREL et al., 2001; 
WACHINO et al., 2004).  
 
1.4.2.1  Tertiary structure 
Class A carbapenemases comprise a peculiar group of enzymes as they are 
very broad spectrum β-lactamases able to efficiently hydrolyse not only classical 
penicillins and cephalosporins but also β-lactam substrates that are usually 
considered resistant to the activity of class A enzymes (QUEENAN and BUSH, 2007; 
WALTHER-RASMUSSEN and HOIBY, 2007).  
To date crystal structures of class A carbapenemases have been determined 
for NMC-A, Sme-1, KPC-2 and GES-2 showing that all share an overall structural 
organization and catalytic residues similar to those of other class A β-lactamases 
(FRASE et al., 2011; KE et al., 2007; SOUGAKOFF et al., 2002; SWARÉN et al., 1998) 
(Figure 1.9A and B). 
 
Figure 1.9 Superposition of a class A carbapenemase (KPC-2, green; PDB accession 2OV5) 
and a non-carbapenemase (TEM-1, magenta; PDB accession 1ZG4). A) Overall structure with some 
conserved residues depicted to position the active site. B) Active site of carbapenemase KPC-2 with 
β-lactamase TEM-1 as reference. Hydrogen bonds are shown as dashed lines and the deacylation 
water as a red sphere (W). C) Change in structure between β-sheets strands S3 and S4 (black 
arrows). 
 
At the structural level, one of the most striking features of class A 
carbapenemases is the unique disulfide bond between Cys69 and Cys238, located 
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near the active site (Figure 1.9B), and absent in the other class A β-lactamases (KE et 
al., 2007; RAQUET et al., 1997; SOUGAKOFF et al., 2002; SWARÉN et al., 1998). 
Homology modelling studies with NMC-A and Sme-1 suggested that this disulfide 
bridge connects and constrains the two structural domains, significantly modifying 
the position of the S3 β-strand and consequently, the active site geometry (RAQUET 
et al., 1997). According to these authors, the altered active site geometry allows a 
better interaction of the β-lactam carbonyl of imipenem with the oxyanion hole of 
Sme-1 than is possible with that of TEM-1 (RAQUET et al., 1997). However, site-
directed mutagenesis experiments have shown that the disulfide bond is required for 
hydrolysis of all β-lactams by Sme-1 and therefore, although important, it does not 
uniquely provide carbapenemase activity. These data suggest that the disulfide bond 
is necessary for the structural organization, or to stabilize, the enzyme (MAJIDUDDIN 
and PALZKILL, 2003; SOUGAKOFF et al., 2002). On the other hand, some GES 
variants, such as GES-1, have cysteine at positions 69 and 238 but have poor 
carbapenemase activity while hydrolysing extended-spectrum cephalosporins 
(WALTHER-RASMUSSEN and HOIBY, 2007). This is evidence that other features are 
necessary for carbapenem hydrolysis. 
The structure of NMC-A revealed a number of structural differences in the 
proximity of the active site in comparison to other class A β-lactamases (SWARÉN et 
al., 1998). Apart from the disulfide bond discussed above, the conformation adopted 
by C238 induces a change in conformation of β-sheet strand S3 between residues 
237 and 240 (Figure 1.9C), potentially increasing the access of substrate to the active 
site. In addition, positional differences were observed at N132 (Figure 1.9B); this 
residue is shifted away from strand S3 by 1.0 Å in NMC-A compared to the 
acylenzyme complex TEM-1-6-hydroxymethyl penicillanic acid, and provides 
additional space in the substrate-binding cavity. This modification was proposed to 
allow the accommodation of the 6α-1R-hydroxyethyl substituent of carbapenems 
(SWARÉN et al., 1998).  
In the crystal structure of Sme-1 however, N132 occupies a position that is 
almost identical to that observed in TEM-1 (SOUGAKOFF et al., 2002). In Sme-1 the 
most remarkable structural feature is the short distance (1.4 Å) separating the side 
chains of residues S70 and E166 in the active site cleft, compared with NMC-A and 
TEM-1. This leads to a lack of space to accommodate the catalytic water molecule 
found in that position in the other class A β-lactamases (SOUGAKOFF et al., 2002). 
The authors hypothesized that a water molecule situated in the oxyanion hole of 
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Sme-1 can serve as the deacylating agent of the acylated enzyme (SOUGAKOFF et al., 
2002). 
A Ser237Ala mutation in Sme-1 resulted in a marked decrease in catalytic 
activity against imipenem and cephalosporin substrates, showing that S237 
contributes to the carbapenemase activity (SOUGAKOFF et al., 1999). In another 
site-directed mutagenesis study of Sme-1, it was possible to recognize that several 
positions are important for hydrolysis of β-lactam antibiotics, but no single position 
was found to uniquely contribute to carbapenem hydrolysis (MAJIDUDDIN and 
PALZKILL, 2005). Taken together, these data support the idea that the 
carbapenemase activity of the group 2f carbapenemases is due to the important 
conserved residues that contribute together to form an active site that can 
accommodate and hydrolyse the carbapenems (MAJIDUDDIN and PALZKILL, 2005). 
The structure of KPC-2 shows several active site alterations that are unique 
among carbapenemases. A shift of the catalytic S70 residue (Figure 1.9B) renders the 
active sites of the carbapenemases shallower, likely allowing easier access of the 
bulkier substrates. Further multiple active site adjustments including shifts in N132 
and N170 (Figure 1.9B) are likely to collectively provide additional room to 
accommodate the α-substituents present in carbapenems and cephamycins (KE et 
al., 2007).  
Apart from the disulfide bridge, no major structural differences have been 
observed between class A carbapenemases and non-carbapenemases. Moreover, the 
structures of the class A carbapenemases solved so far did not provide a precise 
mechanism for the carbapenem hydrolysis in these enzymes. The structure of a class 
A carbapenemase complexed with a β-lactam molecule would provide useful 
information to definitely establish the catalytic mechanism of these threatening 
enzymes. 
 
1.4.3 Metallo- β-lactamases 
Most of the carbapenemases described so far belong to the metallo-β-
lactamase (MBL) group. These are part of a superfamily of metallo-hydrolases with 
wide catalytic diversity (including oxydoreductases, glyoxylases, phosphoryl 
cholinesterase, etc.) (BEBRONE, 2007). The MBLs are unique among β-lactamases in 
requiring divalent cations (usually Zn (II)) in the active site for activity and constitute 
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the only family of β-lactamases whose carbapenemase activity is prevalent 
(QUEENAN and BUSH, 2007). A major characteristic of most MBLs is that they 
catalyse the hydrolysis of nearly all β-lactams used for therapeutic purposes. These 
enzymes have a very broad spectrum of activity exhibiting high activity towards 
carbapenems, cephamycins, third-generation cephalosporins and penicillins. 
Monobactams are the sole β-lactam antibiotics to be poorly recognized (FELICI et al., 
1993), however MBLs are often identified in isolates that also produce an ESBL able 
to hydrolyse aztreonam (POURNARAS et al., 2010). Metallo-β-lactamases are 
resistant to the clinically available class A β-lactamase inhibitors such as clavulanic 
acid, but are susceptible to chelating agents such as EDTA, dipicolinic acid or 1,10-
phenanthroline (QUEENAN and BUSH, 2007). 
 
1.4.3.1  Classification 
Based on DNA sequence alignments, protein structure, activity profile and 
metal ion requirements, MBLs are classified into three subclasses: B1, B2, and B3 
(GALLENI et al., 2001; GARAU et al., 2004). 
Subclass B1 includes several chromosomally encoded enzymes such as BcII 
from B. cereus (HUSSAIN et al., 1985), CcrA from B. fragilis (RASMUSSEN et al., 
1990), BlaB from Elizabethkingia meningoseptica (ROSSOLINI et al., 1998), as well as 
the plasmid-encoded IMP (WATANABE et al., 1991), VIM (LAURETTI et al., 1999), 
SPM (TOLEMAN et al., 2002), and GIM (CASTANHEIRA et al., 2004)-type enzymes. 
The acquired MBL genes located on plasmids are usually embedded in class 1 
integrons, which can contain additional gene cassettes, and are easily disseminated 
among clinical isolates (HU and ZHAO, 2009; TATO et al., 2010). The most recent 
examples of transferable B1 enzymes are DIM-1 from P. stutzeri (POIREL et al., 
2010b) and NDM-1, originally described in a K. pneumoniae isolate (YONG et al., 
2009) but rapidly spreading in India, Pakistan, the UK (KUMARASAMY et al., 2010), 
Australia (POIREL et al., 2010a) and a rapidly growing number of other countries 
(NORDMANN et al., 2011). 
The subclass B2 includes the enzymes produced by different Aeromonas 
species (CphA (MASSIDDA et al., 1991), ImiS (WALSH et al., 1998) and AsbM1 (YANG 
and BUSH, 1996)) and the Sfh-I β-lactamase from S. fonticola (SAAVEDRA et al., 
2003). These MBLs are considered as “true” carbapenemases due to their high 
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specificity for hydrolyzing carbapenems, and cannot effectively be detected with the 
use of nitrocefin (QUEENAN and BUSH, 2007).  
Subclass B3 includes the MBLs L1 from S. maltophilia (WALSH et al., 1994), 
GOB from E. meningoseptica (BELLAIS et al., 2000), FEZ-1 from L. gormanii (BOSCHI 
et al., 2000), THIN-B produced by Janthinobacterium lividum (ROSSOLINI et al., 
2001), Mbl1b (SIMM et al., 2001) and CAU-1 (DOCQUIER et al., 2002) from 
Caulobacter crescentus, and BJP-1 from Bradyrhizobium japonicum (STOCZKO et al., 
2006). Most of the organisms cited above are environmental species, of which some 
can cause opportunistic infections (such as S. maltophilia and L. gormanii) whereas 
others are not pathogenic. Apart from L1 enzyme from S. maltophilia, reported to 
exist as a tetramer (CROWDER et al., 1998), all the MBLs are monomeric enzymes.  
MBLs included in both subclasses B1 and B3 have a broad substrate profile 
exhibiting high hydrolytic activity for all β-lactams except aztreonam (FELICI et al., 
1993) and require two bound zinc atoms for full activity; however, these enzymes 
differ in the amino acids involved in zinc binding in the active site (GALLENI et al., 
2001; GARAU et al., 2004). In contrast, the enzymes belonging to subclass B2 
behave as strict carbapenemases, efficiently hydrolyzing only carbapenems, and 
display weak hydrolytic activity towards penicillins and cephalosporins (FELICI et al., 
1993; WALSH et al., 1996). Another distinctive feature of this subclass is that these 
MBLs require only one Zn (II) for its maximal enzymatic activity and are considered 
to be inactivated by a second Zn (II) (COSTELLO et al., 2006; VALLADARES et al., 
1997) 
 
1.4.3.2  Structure of MBLs 
The three-dimensional structures of several B1 enzymes (BcII (CARFI et al., 
1995; FABIANE et al., 1998), CcrA (CONCHA et al., 1996), IMP-1 (CONCHA et al., 
2000), SPM-1 (MURPHY et al., 2006), VIM-2 (GARCIA-SAEZ et al., 2008) and IND-7 
(YAMAGUCHI et al., 2010)), one B2 enzyme (CphA (GARAU et al., 2005)) and a few B3 
enzymes (L1 (ULLAH et al., 1998), FEZ-1 (GARCIA-SAEZ et al., 2003) and BJP-1 
(DOCQUIER et al., 2010)) have been solved by X-ray crystallography. Despite the 
generally low degree of sequence similarity between the different subclasses, the 
MBLs share a similar folding pattern (Figure 1.10).  
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Metallo-β-lactamases exhibit a common αββα fold, known as the metallo-β-
lactamase fold, which includes a compact core of two β sheets sandwiched by five α 
helices on the external faces (CARFI et al., 1995) (Figure 1.10). The active site, 
containing one or two Zn (II) ions, is located within a shallow groove formed by the 
interface of the two β domains (CARFI et al., 1995). The MBLs have a conserved 
structural metal-binding sequence, the amino acid sequence 
H116XH118XD120…H196…C221…H263 and are able to bind up to two metal ions in their 
active site (CROWDER et al., 2006). 
 
 
Figure 1.10 Metallo-β-lactamase overall fold, showing a representative of each subclass: 
IMP-1 from P. aeruginosa (B1; PDB accession 1DDK), CphA from A. hydrophila (B2; PDB accession 
1X8G) and L1 from S. maltophilia (B3; PDB accession 1SML). The helices are coloured red, the β-
sheets are green and loops are yellow. Zinc ions are represented as grey spheres. Non-conserved 
secondary structural elements among subclasses are labelled and/or shown in cyan. 
 
Although the first structure determined for BcII revealed one zinc ion bound 
(CARFI et al., 1995), subsequent structures of enzymes from the B1 and B3 
subclasses, including BcII, show a dinuclear metal center (FABIANE et al., 1998). In 
these enzymes, one Zn (II) ion (Zn1) is tetrahedrally coordinated to three histidine 
ligands, His116, His118, and His196 and a bridging water/hydroxide (Figure 1.11), 
while the second Zn (II) ion (Zn2) displays a trigonal bipyramidal coordination 
geometry (CONCHA et al., 1996; FABIANE et al., 1998; ULLAH et al., 1998). In B1 
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enzymes the second metal ion-binding site consists of Asp120, Cys221, His263, the 
bridging water/hydroxide and an additional solvent molecule. In B2 enzymes this 
site represents the active site species in the mono-zinc form (CRAWFORD et al., 
2005; GARAU et al., 2005). The B1 Zn2 ligand Cys221 is substituted by His121 in B3 
enzymes affecting the geometry of this site; thus the metal ion is bound to Asp120, 
His121 and His263, and one or two water molecules. The serine residue present at 
position 221 in B3 MBLs does not act as a metal ligand (ULLAH et al., 1998) (Figure 
1.11). The other exception to the consensus metal-binding site is the single mutation 
of His116 to Asn116 in the Zn1 binding site among B2 enzymes (GALLENI et al., 
2001) (Figure 1.11).  
 
 
Figure 1.11 Metallo-β-lactamase active sites from the three subclasses: IMP-1 (B1), CphA 
(B2) and L1 (B3) (PDB accessions are as in Figure 1.9). Zinc ions (Zn) and water molecules (W) are 
represented as grey and red spheres, respectively. Coordination bonds are shown as dashed lines. 
Act (IMP-1, left) represents an acetate molecule that occupies the place of a water molecule. 
 
The structure of B1 MBLs is characterised by a mobile loop or flap spanning 
residues 61-65 covering the active site (Figure 1.10), believed to be involved in 
substrate recognition and binding (CONCHA et al., 2000; MOALI et al., 2003). 
Mutagenesis studies showed that a large percentage of residues in the flap have a 
limited tolerance for substitutions further supporting the key role of the flap in the 
structure and function of IMP-1 (MATERON and PALZKILL, 2001). The mobile loop is 
disordered in the structure of native enzymes but in the presence of an inhibitor, the 
loop is stabilized (CONCHA et al., 2000; GARCÍA-SÁEZ et al., 2003). Deletion of the 
flap from IMP-1 resulted in a loss of catalytic efficiency dependent on the substrate 
tested, with almost no effect over carbapenems (MOALI et al., 2003). The structure of 
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SPM-1, however, reveals the lack of the mobile flap, suggesting a different 
mechanism of β-lactam recognition by this enzyme compared with related enzymes 
(MURPHY et al., 2006).  
The 61-65 mobile flap is absent in MBLs from subclasses B2 and B3. In 
CphA, a B2 enzyme, an elongated 3 helix is present (Figure 1.10) and shows a kink 
about Trp150 that enables 3 to follow the surface curvature of the protein and 
provide a hydrophobic face that contributes to binding of carbapenem substrates 
(GARAU et al., 2005). Crystal structures of B3 enzymes showed that there is an 
elongated loop between residues 150 and 168 extending over the active site (Figure 
1.10) which is absent in the better characterised subclass B1 enzymes (GARCIA-
SAEZ et al., 2003; ULLAH et al., 1998). Modelling studies have predicted that two 
residues of this flexible loop, Ile164 and Phe158, make significant contacts with large 
hydrophobic substituents of penicillins, cephalosporins, or carbapenems (ULLAH et 
al., 1998). However, mutagenesis studies revealed that these residues are not 
essential for tight substrate binding (CARENBAUER et al., 2002). 
A unique feature is observed in the structure of B3 enzymes: a single 
intramolecular disulphide bridge links two cysteines, Cys256 and Cys290 in L1 and 
FEZ-1 (GARCIA-SAEZ et al., 2003; ULLAH et al., 1998) while in the recently solved 
structure of BJP-1 a single disulphide bridge is also present but in a different region 
of the structure (between Cys200 and Cys220) (DOCQUIER et al., 2010). 
 
1.4.3.3  Catalytic mechanism 
As for serine β-lactamases, β-lactam hydrolysis in metallo-β-lactamases 
occurs by a nucleophilic attack on the carbonyl group of the β-lactam ring, followed 
by the cleavage of the amide bond and protonation of the bridging nitrogen atom 
(CROWDER et al., 2006). However, in contrast to serine enzymes, in the MBL 
mechanism no covalent intermediate is formed. Although the number of metal ions 
required for hydrolysis, and the role of each metal site in the hydrolysis of β-lactams 
by MBLs, are still under debate, there is a general consensus that the Zn1-bound 
water molecule, or hydroxide, is the nucleophile for the reaction of mono- and 
dinuclear B1 and B3 MBLs (CROWDER et al., 2006).  
The structures of enzyme-product complexes of hydrolysed moxalactam with 
the subclass B3 MBL L1 (SPENCER et al., 2005) and hydrolysed and rearranged 
biapenem with the subclass B2 MBL CphA (GARAU et al., 2005) have suggested a 
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common role for Zn2 in MBLs. In both cases, the Zn2 site displays strong 
interactions with the bridging nitrogen of the hydrolysed β-lactam ring and the 
carboxylate moiety of the antibiotic. These studies indicate that Zn2 may be involved 
in C–N bond cleavage by stabilization of the development of negative charge in the β-
lactam nitrogen atom, and may also play a role in substrate binding (LLARRULL et 
al., 2007; SPENCER et al., 2005). A quantum mechanical−molecular mechanical 
(QM−MM) reaction modelling report postulates that Zn2 orients a water molecule to 
act as a proton donor in the rate-determining step (DAL PERARO et al., 2007). 
Based on the crystal structures and models of β-lactams bound to the active 
site, a catalytic mechanism has been proposed for dinuclear MBLs, such as B1 and 
B3 enzymes (CONCHA et al., 2000; SPENCER et al., 2005; ULLAH et al., 1998). 
Following substrate binding, one of the Zn ions, together with enzyme residues, 
polarizes the β-lactam carbonyl for attack by the metal-bridging hydroxyl group that 
is additionally positioned and oriented by hydrogen bonding to Asp120. This creates 
an unstable tetrahedral species that undergoes C-N bond cleavage to generate an 
intermediate in which the β-lactam nitrogen is anionic. This species is resolved by 
proton transfer to the nitrogen followed by product dissociation from the enzyme 
active site. The source of the proton may be Asp120 or a water molecule (DAL 
PERARO et al., 2007). The unprotonated anionic intermediate is not necessarily 
highly populated- while in some cases (such as hydrolysis of the chromogenic 
cephalosporin nitrocefin by the CcrA or L1 enzymes (MCMANUS-MUNOZ and 
CROWDER, 1999; SPENCER et al., 2001; WANG, ZHIGANG et al., 1999)) this species 
accumulates to high levels, in others (e.g. hydrolysis of cephalosporins by BcII 
(RASIA and VILA, 2004)) it does not and hydrolysis effectively occurs in a single step. 
A different mechanism, however, has been proposed for the B2 MBL CphA 
based on the crystal structures of the native enzyme and of a product complex with 
hydrolysed biapenem (GARAU et al., 2005). Nucleophilic attack is performed by a 
water molecule that is activated by a general base, His118 or Asp120, and is not 
coordinated to zinc (GARAU et al., 2005; XU et al., 2006). This water molecule 
attacks the β-lactam carbonyl to generate a tetrahedral intermediate. The single Zn 
ion (Zn2) is thought to promote C-N bond cleavage by coordination to the β-lactam 
nitrogen as described above for the binuclear enzymes (XU et al., 2006). An incoming 
solvent molecule that replaces the water used in the nucleophilic attack protonates 
the amide nitrogen, followed by release of the final product. However, a recently 
published computational study of the complete reaction mechanism of CphA 
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proposes a single-step mechanism involving two water molecules in the active site 
(SIMONA et al., 2009). One water molecule (Wat1) performs the nucleophilic attack to 
the β-lactam carbonyl carbon, and another Zn-bound water (Wat2) simultaneously 
protonates the β-lactam nitrogen (Figure 1.12). This work also highlights a role for 
His118 in the orientation of the catalytic water as well as acting as the general base. 
Despite significant effort aimed at identifying the general base in the catalytic 
mechanism of the B2 MBLs, this remains controversial with studies pointing to 
either Asp120 (XU et al., 2006) or His118 (SIMONA et al., 2009) as the likely 
candidates.  
 
 
Figure 1.12 Schematic representation of the proposed reaction mechanism of B2 MBL 
CphA involving two water molecules (Wat). In the Henry-Michaelis complex, the interaction of the 
substrate with the zinc ion is mediated by Wat1 and Wat2. Wat1 is activated by a general base 
(His118 in the scheme) to perform the nucleophilic attack. The zinc-bound Wat2 acts as a proton 
donor to the lactam nitrogen. Figure and legend were modified from Simona et al., (2009). 
 
Until recently, the identification of the second, inhibitory zinc binding site in 
B2 enzymes was a matter of debate. Spectroscopic studies of cobalt-substituted ImiS 
from A. veronii suggested that the inhibitory zinc binds in a site distinct from the 
active site, involving both His118 and Met146 as ligands (COSTELLO et al., 2006; 
CRAWFORD et al., 2005). However, a mutagenesis study that aimed to investigate 
the potential zinc binding sites in CphA indicated that the position of the second zinc 
is similar to the tri-histidine site (see above) of subclasses B1 and B3 MBLs, with 
His118 and His196 as potential ligands (BEBRONE et al., 2008). This hypothesis was 
confirmed by determination of the structure of the dizinc form of CphA (BEBRONE et 
al., 2009). The structure shows that the first zinc binds in the cysteine site, as 
previously determined, and that the second zinc occupies a modified histidine site. In 
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CphA the second zinc ion is coordinated by His118 and His196 where a sulfate ion 
and a water molecule complete the metal coordination, with the sulfate ion acting as 
a bridging species between the two zinc ions (BEBRONE et al., 2009). 
 
 
 

  
 
 
 
 
 
 
 
 
 
 
2. Scope of this dissertation  
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2.1 Serratia fonticola UTAD54 
 
Currently bacterial resistance to β-lactam antibiotics constitutes a very 
serious threat to the clinical community. Resistance to this class of antibiotics is 
primarily due to the expression of several serine and metal-containing β-lactamases 
that hydrolyse the amide bond of the β-lactam rings, resulting in antibiotic 
inactivation. Of utmost importance are the carbapenemases, β-lactamases that are 
able to hydrolyse the carbapenems (i.e. imipenem and meropenem), drugs considered 
to be the last resort agents to treat infections caused by multiresistant pathogens. 
The study here presented consists of a biochemical characterisation of SFC-1 
and Sfh-I, both carbapenemases of Serratia fonticola UTAD54. In this work the three-
dimensional structures of the two β-lactamases were also determined. 
The strain S. fonticola UTAD54 is an environmental strain that was isolated in 
2002 during a study in Northeastern Portugal investigating the susceptibility of 
bacterial populations of untreated drinking waters to antimicrobial agents, including 
carbapenems. This new strain was resistant to penicillins, cephalothin, cefuroxime 
and carbapenems, antibiotics to which other strains of the same species were 
susceptible (SAAVEDRA et al., 2003). Research upon carbapenem resistance 
mechanisms in S. fonticola UTAD54 led to the characterisation of a new gene coding 
for a metallo-β-lactamase, Sfh-I, that was assigned to subclass B2.  
However, this β-lactamase alone could not explain the complete resistance 
profile of S. fonticola UTAD54. Further investigation lead to the identification of a new 
gene coding for a class A β-lactamase designated SFC-1 (HENRIQUES et al., 2004). 
At the primary structure level, SFC-1 has high homology with the class A 
carbapenemases, the closest relative being KPC-1 (62% identical), a clinically 
important carbapenemase described in K. pneumoniae and other nosocomial 
pathogens. As reported for KPC-1, no transcriptional regulator controlling the 
expression of blaSFC-1 was found. SFC-1 is active against penicillins, cephalothin and 
aztreonam but has reduced susceptibility to meropenem and imipenem. The activity 
of SFC-1 is inhibited by β-lactamase inhibitors (e.g. clavulanic acid, tazobactam). The 
hydrolytic profile of SFC-1 is thus typical of the class A carbapenemases already 
described (HENRIQUES et al., 2004). 
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2.2. Goals  
 
Compared to other β-lactamases, a relatively low number of class A 
carbapenemases have been identified and characterised. Thus, the first goal of the 
work here presented was the kinetic characterisation of SFC-1. 
A further aim was then to investigate the molecular basis of carbapenemase 
activity in SFC-1, in particular, and by implication of class A carbapenemases in 
general, by determining the three-dimensional structure of this enzyme. 
There was considered to be both a lack of structural data on the interactions 
between β-lactamases and β-lactams while the mechanism of hydrolysis of 
carbapenems by class A carbapenemases remains unclear. A further objective of this 
project was thus to use structures of β-lactam complexes to establish a basis for the 
mechanism and specificity of SFC-1, especially with respect to carbapenem 
hydrolysis.  
Given the divergent amino acid sequence of Sfh-I relatively to those of other 
B2 enzymes (50%), and the generally lower level of characterisation of these enzymes 
when compared to B1 and B3 MBLs, an initial aim for studies on this Sfh-I was to 
overexpress the blaSfh-I gene in E. coli to facilitate purification and kinetic 
characterisation of the recombinant β-lactamase. 
Considering that there is little consensus about the catalytic mechanism of 
the metallo-β-lactamases, in particular for subclass B2 enzymes, the final goal of this 
work was to determine the crystal structure of Sfh-I in order to establish a basis for 
the mechanism and specificity of this group of enzymes.  
 
  
 
 
 
 
 
 
 
 
 
 
 
3. Biochemical characterisation of recombinant SFC-1 from Serratia 
fonticola UTAD54 
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3.1 Introduction 
 
β-lactam antibiotics are among the safest, most efficient and most frequently 
prescribed antibacterial agents available (BUSH, 2002; MOLSTAD et al., 2002). The 
intensive use of stable β-lactams in activities such as animal farming and medicine 
has resulted in the large spread of resistant bacterial strains (WEGENER, 2003; 
WITTE, 1998). The most efficient and prevalent mechanism of resistance to β-
lactams is the production of β-lactamases, which inactivate the antibiotics by 
hydrolysis of the β-lactam ring (FISHER et al., 2005; THOMSON and BONOMO, 
2005).  
Considering that carbapenems are broad spectrum β-lactams and are less 
prone to the hydrolytic action of most of the β-lactamases, a serious threat is posed 
by carbapenem-hydrolysing enzymes (QUEENAN and BUSH, 2007). Although 
comparatively rare, the frequency of carbapenemase containing-bacterial species has 
been increasing (QUEENAN and BUSH, 2007; WALTHER-RASMUSSEN and HOIBY, 
2007). Previously characterised carbapenem-hydrolysing enzymes were included into 
Ambler molecular classes A, B and D (POIREL and NORDMANN, 2002; RASMUSSEN 
and BUSH, 1997). Class A carbapenemases belonging to functional group 2f 
(WALTHER-RASMUSSEN and HOIBY, 2007) are uncommon and comprise the 
chromosomally encoded β-lactamases NMC-A and IMI-1 from E. cloacae 
(NORDMANN et al., 1993; RASMUSSEN et al., 1996), Sme-1 to -3 from S. marcescens 
(QUEENAN et al., 2006; QUEENAN et al., 2000; YANG et al., 1990), SFC-1 from S. 
fonticola (HENRIQUES et al., 2004) and BIC-1 from P. fluorescens (GIRLICH et al., 
2010); and the plasmid mediated enzymes KPC-2 to -3 initially found in K. 
pneumoniae (SMITH MOLAND et al., 2003; WOODFORD et al., 2004; YIGIT et al., 
2001) but later described in other Enterobacteriaceae (BUSH, 2010) and non-
fermenters (ROBLEDO et al., 2010; VILLEGAS et al., 2007) performing a total of 9 
different variants (KPC-2 to -10). 
Most of the strains included in the species Serratia fonticola express both a 
chromosomally encoded extended-spectrum class A β-lactamase and a species-
specific AmpC β-lactamase (PEDUZZI et al., 1997; STOCK et al., 2003). Previous 
studies have shown that S. fonticola UTAD54 additionally expresses a metallo-
enzyme (Sfh-I) (SAAVEDRA et al., 2003) and a class A carbapenem-hydrolyzing β-
lactamase (SFC-1) (HENRIQUES et al., 2004). Both enzymes are chromosomally 
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encoded and are absent from other S. fonticola strains. The deduced amino acid 
sequence of SFC-1 displays considerable similarity to those of class A 
carbapenemases already described and the expression of the blaSFC-1 gene in E. coli 
confers on the host an antibiotic resistance profile typical of class A carbapenemases 
(HENRIQUES et al., 2004). 
In order to further characterise this class A carbapenemase, the gene 
encoding SFC-1 from S. fonticola UTAD54 was cloned and the protein was over-
expressed in E. coli. After purification, the recombinant protein was characterised by 
kinetic and biochemical techniques. 
 
3.2 Materials and methods 
 
3.2.1 Bacterial strains and plasmid 
 
E. coli XL-2 Blue (Stratagene Inc., La Jolla, CA, USA) and E. coli BL21 (DE3) 
(Novagen Inc., Madison, WI, USA) were respectively used as hosts for blaSFC-1 cloning 
and expression experiments. Plasmid pET-26b (Novagen, Inc.) was used as the 
cloning and expression vector.  
E. coli bacterial cultures were routinely grown aerobically in LB medium at 
37ºC, unless otherwise specified. Transformed cells were selected for the presence of 
plasmids using 50 μg/ml kanamycin. S. fonticola UTAD54 was grown aerobically in 
LB medium at 30ºC. 
 
 3.2.2 Antimicrobial agents 
 
Antibiotics were provided as powders by GlaxoSmithKline (ceftazidime), Atral 
Laboratories (piperacillin), Hoeport Pharmaceutical Products (cefotaxime), Eurobio 
(ampicillin), Sigma (aztreonam, cephalothin, clavulanic acid, tazobactam), Sequoia 
Research Products (meropenem) and Merck Sharp & Dohme Co (cefoxitin). 
Sulbactam and imipenem were kindly provided by Pfizer Inc. and Merck Sharp & 
Dohme Co, respectively. 
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 3.2.3 Plasmid construction 
 
Genomic DNA was extracted from S. fonticola UTAD54 with the Genomic DNA 
Purification kit (MBI Fermentas, Vilnius, Lithuania) following the manufacturer’s 
recommendations. All restriction enzymes were from Roche (Roche Diagnostics, 
Meylan, France).  
 
The open reading frame encoding the mature SFC-1 polypeptide without the 
leader sequence was amplified by PCR using the following primers containing 
restriction sites (underlined) for BspLu11I and XhoI: 
SFCexp2_for: 5'-GGA TCC ACA TGT CAC GCA CCG GTC GAC TG-3’ 
SFCexp2_rev: 5'-GTG CTC GAG TTA GAA GCCGAT AGA CTT TCC-3’ 
 
PCR was carried out in an iCycler Thermal Cycler (Bio-Rad Laboratories, 
Richmond, CA, USA) using Taq polymerase, nucleotides and buffers purchased from 
MBI Fermentas (Vilnius, Lithuania). PCR was performed in 50 μl mixtures containing 
0.5x PCR buffer with (NH4)2SO4, 0.5x PCR buffer without MgCl2, 3 mM MgCl2, 200 
μM deoxynucleoside triphosphates, 15 pmol of each primer, 1 U of Taq polymerase, 
and 50-100 ng of purified DNA from S. fonticola UTAD54. The temperature profile 
was as follows: initial denaturation at 94ºC for 7 min; 30 cycles of denaturation at 
94ºC for 1 min, annealing at 60ºC for 1 min, and extension at 72ºC for 1 min; and a 
final extension at 72ºC for 10 min. PCR products (5 µl) were analysed by 
electrophoresis on a 1% agarose gel to confirm the 900 bp blaSFC-1 amplification. The 
remaining PCR product was purified using the Concert Rapid PCR Purification 
System (Gibco BRL, Eggenstein, Germany).  
The amplified fragment was digested with BspLu11I and XhoI and ligated with 
T4 ligase into the NcoI site of the pET-26b vector to produce the recombinant 
plasmid pMF13. This plasmid expressed SFC-1 as a fusion with the pelB leader 
sequence from the pET-26b vector. E. coli XL-2 Blue competent cells were 
transformed and recombinant clones were selected on LB agar plates supplemented 
with 50 μg/ml kanamycin and 5 μg/ml aztreonam. 
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Five colonies were picked into 10 ml LB medium supplemented with 50 μg/ml 
kanamycin and grown overnight at 37°C. Plasmid DNA was purified using the 
Concert High Purity Plasmid Miniprep System (Life Technologies Inc., Gaithersburg, 
MD, USA). The presence of inserts was confirmed by double digestion with BspLu11I 
and XhoI. The gene was sequenced in the forward direction to verify that blaSFC-1 was 
inserted in frame. Plasmid pMF13 was then transformed into the expression host E. 
coli BL21 (DE3). 
 
3.2.4 Detection of β-Lactamase activity by SDS-PAGE 
 
Crude cell extracts of the E. coli clone expressing the recombinant enzyme 
were prepared. Expression of the SFC-1 enzyme was confirmed by SDS-PAGE. β-
lactamase activity was detected by incubation of SDS-PAGE gels with nitrocefin, 
according to Stock and collaborators (STOCK et al., 2003). After the identification of 
the β-lactamase band, the gel was stained with Coomassie Brilliant Blue (Sigma). 
The Low Molecular Weight SDS Calibration Kit (GE Healthcare UK Limited, 
Buckinghamshire, UK) was used to estimate the molecular weight of the protein. 
 
3.2.5 Optimization of the expression of recombinant SFC-1 
 
SFC-1 production was tested in induced and non-induced cultures. Overnight 
cultures of E. coli BL21 (DE3) transformed with pMF13 were used to inoculate 100 
ml LB medium supplemented with kanamycin, and grown at 37ºC to reach an 
OD600nm of 0.6. At that point, the culture was split into 2 x 50 ml cultures: one was 
induced by addition of 1 mM IPTG and the other served as uninduced control. 
Different temperatures were tested: 25ºC, 30ºC and 37ºC. Aliquots (1 ml) were 
sampled at different times (2, 3, 5, 12, 18 and 24 h) and centrifuged (23,000 x g for 
122 min at 4ºC). Cell pellets were suspended in 0.25 ml of 50 mM sodium phosphate 
(pH 7.0) and frozen overnight at -20ºC. Cells were disrupted by sonication and the 
debris was removed by centrifugation (23,000 x g, 15 min, 4ºC). The crude protein 
solution was stored at -20ºC until use. β-lactamase activities in cell extracts were 
determined spectrophotometrically using 100 μM aztreonam as substrate (Δε318nm = –
640 M–1cm–1; (POIREL et al., 2000)) in 50 mM sodium phosphate (pH 7.0). 
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3.2.6 Over-expression and purification of SFC-1 
 
Recombinant SFC-1 was purified from an uninduced culture of E. coli BL21 
(DE3) (pMF13) grown in 0.5 L of LB medium supplemented with kanamycin at 37ºC 
to an OD600nm of 0.6. The incubation was continued for 12 h at 25ºC. Cells were 
harvested by centrifugation (23,000 x g, 5 min, 4ºC) and resuspended in 5 ml of 10 
mM sodium phosphate buffer (pH 7.0). Crude lysates were obtained as described 
above (section 2.2.5).  
Clear supernatant containing β-lactamase activity was filtered through a 0.2-
μm-pore-size filter and loaded onto a pre-equilibrated S-Sepharose column 
(Amersham Pharmacia Biotech) with 10 mM sodium phosphate buffer (pH 6.0). The 
proteins were eluted with a linear gradient of NaCl (0 to 1 M) in the same buffer, at a 
flow rate of 3 ml/min.  
The fractions presenting β-lactamase activity, measured as initial rate of 
hydrolysis of 100 μM ampicillin (∆ε232nm = - 1070 M-1 cm-1),  were loaded onto a pre-
equilibrated Superdex 75 column (Amersham Pharmacia Biotech) with 10 mM 
sodium phosphate buffer, pH 7.0. Elution was performed with the same buffer at a 
flow rate of 1 ml/min, and active fractions were collected.  
The protein content of each sample was determined with the Pierce BCA 
protein assay using BSA as standard. The purification yield and the relative 
molecular mass of SFC-1 were estimated by SDS-PAGE on 12% gels (LAEMMLI, 
1970). 
 
3.2.7 IEF analysis 
 
Isoelectric focusing (IEF) of crude β-lactamase extracts of S. fonticola UTAD54 
and E. coli BL21 (DE3) (pMF13), as well as of purified SFC-1 was performed with 
commercially prepared polyacrylamide gel plates (pH 3 to 9; Amersham Pharmacia 
Biotech), on a Phast System apparatus (Amersham Pharmacia Biotech). Focused β-
lactamases were detected by a 1 mM nitrocefin solution (Oxoid, Basingstoke, UK). 
The pI of SFC-1 was determined by comparison to those of β-lactamases TEM-2 (pI 
5.6) and SHV-5 (pI 8.2). 
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3.2.8 N-terminal sequencing  
 
Purified enzyme was subjected to electrophoresis in a 15% acrylamide gel (200 
V, 1 h). Proteins were electroblotted onto a polyvinylidene difluoride (PVDF) 
membrane (Bio-Rad) for 4h at 100 mA. After transfer the membrane was stained with 
0.1% Coomassie Brilliant Blue. SFC-1 bands were excised and N-terminal sequence 
analysis was performed in the gas-pulsed liquid phase using a model 476A protein 
sequencer with a micro reaction chamber and an on-line HPLC system for 
phenylthiohydantoin (PTH) analysis (Applied Biosystems, Foster City, California, 
USA). Absorbance was monitored at 269 nm. The first 7 residues were determined 
and compared with the deduced sequence. 
 
 3.2.9 Mass spectrometry 
 
The exact mass of the SFC-1 enzyme was determined by electrospray 
ionization-mass spectrometry (ESI-MS) on a Q-TOF 2 mass spectrometer (Micromass, 
Manchester, UK). An aliquot (400 μg) of the purified enzyme was desalted by 
overnight dialysis against water and lyophilized. Before injection into the mass 
spectrometer, the sample was solubilised in 200 μl of 0.005% (v/v) trifluoroacetic 
acid (TFA) in methanol. Data acquisition was carried out with a Micromass 
MassLynkx 3.4 data system.  
 
3.2.10 Determination of kinetic parameters  
 
Initial hydrolysis rates were measured at 25ºC in 50 mM sodium phosphate 
(pH 7.0) on an ULTROSPEC 2000 spectrophotometer (Amersham Pharmacia 
Biotech). The following antibiotics and inhibitors were used: ampicillin, piperacillin, 
cephalothin, cefoxitin, cefotaxime, ceftazidime, aztreonam, imipenem, meropenem, 
tazobactam, sulbactam, clavulanic acid and EDTA. The wavelengths and extinction 
coefficients of β-lactams have been described previously (POIREL et al., 2000). 
Substrates were assayed at different days, with ampicillin included as a reference 
each day. Kinetic parameters were determined by recording the initial rates at 
different substrate concentrations and by fitting the experimental data to the 
Michaelis-Menten equation, using GraphPad Prism (GraphPad Software Inc., La 
Jolla, USA). 
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Inhibition was measured after a 10-min pre-incubation of enzyme with 
inhibitor in phosphate buffer (pH 7.0), using cephalothin (100 μM) as the reporter 
substrate. Fifty percent inhibitory concentrations (IC50) were determined from 
inhibition graphs of percent control activity versus concentration of inhibitor. 
 
3.3 Results and discussion 
 
3.3.1 Over-expression of SFC-1 in E. coli 
 
Over-expression of the S. fonticola blaSFC-1 gene in E. coli was carried out using 
the T7 promoter-based expression vector, pET-26b. SFC-1 is expressed without the 
leader sequence as a fusion with the pelB leader sequence from the pET-26b vector. 
The construct was transformed into E. coli BL21 (DE3), expressing T7 RNA 
polymerase.  
In order to confirm the expression of the enzyme, separation of proteins by 
SDS-PAGE was performed. The crude cell extract of E. coli BL21 (DE3) (pMF13) 
revealed a unique β-lactamase band with an apparent molecular weight of around 
30.5 kDa after staining with nitrocefin. This result was in agreement with the value 
of 30.7 kDa predicted for the mature SFC-1 protein (HENRIQUES et al., 2004).  
Conditions for large-scale production of recombinant SFC-1 were optimised by 
testing IPTG-induced and non-induced cultures at three different temperatures (37, 
30 and 25ºC). Production of the SFC-1 enzyme is shown to be temperature-
dependent (Figure 3.1).  
Cultures grown at 37ºC yielded a β-lactamase activity of 43 μM.min-1.ml-1 
when induced with 1 mM of IPTG. Lowering the temperature to 30ºC and 25ºC 
significantly increased the enzyme yield (to 55 and 234 μM.min-1.ml-1, respectively). 
It was also verified that the SFC-1 production was remarkably influenced by IPTG 
induction. In non-induced cultures the yield was significantly higher with β-
lactamase activities of 333, 420 and 542 μM.min-1.ml-1 for the cultures grown at 37, 
30 and 25ºC, respectively. After 24h SFC-1 activity was drastically reduced in the 
cell fraction. Since highest yields were obtained in uninduced cultures, grown at 
25ºC, these conditions were adopted for larger-scale SFC-1 production and 
purification. 
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Figure 3.1 Influence of temperature and IPTG induction on the production of the SFC-1 β-
lactamase. Production temperatures include 25ºC (□), 30ºC (∆) and 37ºC (○). In each case, time is 
post cell density equal to OD600nm of 0.6. Cultures to which IPTG (1 mM) was added as inducer 
(__■__) and cultures not induced (--□--) are represented. 
 
3.3.2 Purification and biochemical properties of SFC-1 
 
Recombinant SFC-1 enzyme was purified from a 500 ml culture grown at 
25ºC for 12 h, by means of two chromatographic steps, as described in the Material 
and methods section 2.2.6. A summary of a typical purification experiment is shown 
in Table 3.1.  
The initial SP-Sepharose chromatography step removed the majority of the 
contaminating proteins. Approximately 25 mg of purified enzyme was obtained per 
liter of culture using the described methodology. Protein was estimated to be >95% 
pure by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
(Figure 3.2) and the overall yield of the purification protocol was 82% (Table 3.1).  
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Table 3.1 Purification of the carbapenem-hydrolyzing β-lactamase SFC-1 produced by E. 
coli BL21 (DE3) (pMF13). 
Purification Volume Total Specific Total Yield Purification 
step (ml) protein activity
a activity (%) (fold) 
  (mg) (mM min-1mg-1) (mM min-1)   
Crude extract 7.0 119.7 2.0 244 100 1 
SP-Sepharose 15.5 16.4 12.7 208 85 6 
Superdex 75 27.0 12.7 15.8 201 82 8 
 
a β-lactamase activity of the different fractions was determined with 100 µM ampicillin as 
substrate. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 SDS-polyacrylamide gel of crude extract and of purified SFC-1 β-lactamase 
from E. coli BL21 (DE3)(pMF13). Lane M, molecular weight marker; lane 1, crude extract from E. 
coli BL21 (DE3)(pMF13); lane 2, crude extract 10 fold diluted; lane 3, cation exchange fraction with 
β-lactamase activity; lane 4, purified SFC-1. The gel was stained with Coomassie Brilliant Blue. 
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SDS-PAGE analysis showed that the purified SFC-1 migrates as a single band 
of approximately 30.5 kDa (Figure 3.2). However, isoelectric focusing revealed two 
forms of the purified SFC-1, with pIs of 7.6 and 8.2 (Figure 3.3).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 IEF patterns of crude extracts and purified SFC-1. Lanes 1 and 5, crude 
extracts from reference strains producing TEM-2 (pI 5.6) and SHV-5 (pI 8.2), respectively; lane 2, 
purified SFC-1; lane 3, crude extract from S. fonticola UTAD54; lane 4, crude extract from S. 
fonticola 7882T; lane 6, crude extract from E. coli BL21 (DE3).  
 
Mass spectrometry confirmed the presence of two molecular forms of the SFC-
1 enzyme, with 30773 and 31083 Da (Figure 3.4). The value of 30773 Da is 
consistent with the predicted molecular mass of the mature protein (HENRIQUES et 
al., 2004) and this form seems to be relatively more abundant in the purified 
product. Truncated forms of β-lactamases have been encountered in other bacteria, 
but those forms share similar hydrolytic properties and inhibitor activities 
(WALTHER-RASMUSSEN et al., 1999).  
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Figure 3.4 Q-TOF mass spectrogram of purified SFC-1, showing two forms of the 
carbapenem-hydrolysing β-lactamase.  
 
The N-terminal sequence of the SFC-1 β-lactamase produced by E. coli was 
found to be ASQPPQV, showing that a 26-amino acid leader sequence is removed 
from the primary translation product during processing to generate the mature SFC-
1 (HENRIQUES et al., 2004). The mass difference of 310 Da between both forms of 
the purified protein may indicate the presence of an uncharacterised post-
translational modification.  
 
3.3.3 Kinetic properties of SFC-1  
 
SFC-1 recognizes a variety of β-lactams (penicillin, cephalosporin, 
monobactam and carbapenem groups) as substrates, as summarized in Table 3.2. 
The activity against penicillins (ampicillin and piperacillin), narrow spectrum-
cephalosporins (cephalothin) and aztreonam is very high, while the hydrolytic 
activities against extended-spectrum cephalosporins (cefotaxime, ceftazidime and 
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cefoxitin) are much lower, a feature shared by other class A carbapenem hydrolyzing 
β-lactamases (MARIOTTE-BOYER et al., 1996; RASMUSSEN et al., 1996; YANG et al., 
1990; YIGIT et al., 2001).  
The highest turnover rates were obtained for cephalothin (kcat, 280 s-1) 
followed by aztreonam (162 s-1) and ampicillin (155 s-1). Although SFC-1 showed a 
strong hydrolytic activity against aztreonam revealed by the value of kcat, the enzyme 
has a relatively low affinity towards this substrate (Km of 484 μM) and therefore a low 
catalytic efficiency was observed when compared to those obtained using penicillins, 
cephalothin and imipenem as substrates (Table 3.2). 
The highest catalytic efficiency was observed with cephalothin and penicillins, 
while extended-spectrum cephalosporins appeared to be poor substrates. SFC-1 had 
the highest apparent affinity for meropenem and piperacillin (Km, 26 μM and 38 μM, 
respectively). Among carbapenems, SFC-1 hydrolysed imipenem with a rate 8 times 
higher than that of meropenem (kcat, 54 s-1 and 6.5 s-1, respectively).  
Analysis of the kinetic parameters for SFC-1 shows that this enzyme has a 
broad substrate profile, similar to that of other carbapenamases of group 2f 
(MARIOTTE-BOYER et al., 1996; RASMUSSEN et al., 1996; WOODFORD et al., 2004; 
YANG et al., 1990). However, SFC-1 exhibits catalytic efficiencies and turnover rates 
for ceftazidime and cefoxitin that are somewhat higher than those reported for IMI 
and KPC-1 (Table 3.2), the closest enzymes at the amino acid sequence level. The 
turnover rate for ceftazidime (kcat, 2 s-1) was approximately 300 and 20 times higher 
than those reported for IMI-1 and KPC-1 (0.0068 s-1 and 0.1 s-1, respectively), 
resulting in much higher catalytic efficiencies (1730 and 40 times higher, 
respectively). SFC-1 hydrolysed cefoxitin more efficiently than IMI-1 and KPC-1 (8 
and 27 times, respectively). 
In the SFC-1 (and KPC) sequence(s) the serine residue at position 237 (as 
found in to Sme-1, NMC-A and IMI-1) is substituted by a threonine. This residue is 
known to be directly involved in imipenem hydrolysis and was also associated with 
higher hydrolytic efficiency against cephalosporins (SOUGAKOFF et al., 1999). Yigit 
and co-workers reported that KPC-1 hydrolysed cefotaxime better than Sme-1, 
suggesting that Thr237 extends the activity of the enzyme to a broader array of 
cephalosporins (YIGIT et al., 2001). Also, a site-directed mutagenesis study 
demonstrated that when random mutations of Sme-1 were selected for cefotaxime 
resistance only threonine was observed at position 237 (MAJIDUDDIN and 
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PALZKILL, 2005). A recent study of KPC-2 showed that T237 plays a role in the 
hydrolysis of carbapenems and selected cephalosporins (PAPP-WALLACE et al., 
2010b). In this report, of 19 aminoacid variants at position 237, only the T237S 
mutation maintains carbapenem resistance in KPC-2. Therefore, in agreement with 
previous reports, it is possible that threonine at position 237 contributes to the 
oxyimino-cephalosporinase activity observed in SFC-1. However, site-directed 
mutagenesis is required to confirm this hypothesis. 
In addition, a valine found at position 240 may be involved in the increased 
hydrolytic activity against extended-spectrum cephalosporins displayed by SFC-1. 
KPC-1 also exhibits a valine at position 240 (YIGIT et al., 2001) that is substituted by 
an alanine in the other carbapenem-hydrolysing β-lactamases. In the ESBLs, lysine 
or serine have usually been described at this position, suggesting that they are 
involved in the extension of the substrate profile (HULETSKY et al., 1993; ORENCIA 
et al., 2001). Interestingly, TEM-149 a β-lactamase with ESBL activity which 
displays, among other substitutions, a valine at position 240 has been recently 
characterised (PERILLI et al., 2008). TEM-149 hydrolyses cefazolin, cefotaxime, 
ceftazidime, cefepime, aztreonam, and penicillins. Ceftazidime proved to be a better 
substrate than cefotaxime that behaved as an overall poor substrate. The authors 
suggested that the presence of a nonpolar residue, such as valine, at position 240 
can facilitate the accommodation of the bulky oximino substituent of ceftazidime 
(PERILLI et al., 2008). However, to our knowledge, the effect of a valine at this 
position has never been demonstrated and site-directed mutagenesis would be 
necessary to determine its precise effect in the specificity of β-lactamases. 
The activity of SFC-1 was inhibited by the class A β-lactamase inhibitors 
clavulanic acid (IC50, 73 μM), sulbactam (IC50, 23 μM) and tazobactam (IC50, 7 μM). 
In contrast to previously published data for IMI-1 and KPC-1, which are well 
inhibited by tazobactam (IC50, 0.03 μM and 0.374 μM, respectively; (RASMUSSEN et 
al., 1996; YIGIT et al., 2001)), SFC-1 was not efficiently inhibited by any of the 
compounds tested, with IC50 > 1 μM. The weak inhibition displayed by SFC-1 could 
be hypothetically linked to the Asn276Asp substitution. This is one of the point 
mutations in TEM enzymes that lead to the inhibitor-resistant phenotype, occurring 
either alone, as in TEM-84 (LEFLON-GUIBOUT et al., 2000), or in combination with 
other substitutions (usually at Met69) as in TEM-35 (IRT-4) and TEM-36 (IRT-7) 
(HENQUELL et al., 1995; ZHOU et al., 1994) (www.lahey.org/studies). 
Characterisation of an Asn276Asp TEM mutant showed that an asparte at position 
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276 plays a significant role in the resistance to clavulanic acid inhibition (SAVES et 
al., 1995). According to Saves and co-workers this resistance would be explained by 
electrostatic interaction of the aspartate with arginine 244, together with the possible 
displacement of the water molecule involved in the inactivation process. However, a 
comparison of the amino acid sequence of SFC-1 with those of other class A 
carbapenemases revealed that these enzymes also have an aspartate at position 276. 
A recent study by Papp-Wallace et al., (2010a) have shown that, in addition to its role 
in the hydrolysis of carbapenems and cephalosporins, T237 in the KPC-2 
carbapenemase is implicated in the resistance to β-lactamase inhibitors. As proved 
for the class A carbapenemase KPC-2, the weak activity of the inhibitors tested 
against SFC-1 is most likely associated with threonine found at position 237.  
As expected, no inhibition was observed when the enzyme was assayed with 
10 mM EDTA. 
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 Table 3.2 Kinetic parameters of purified SFC-1 and comparison to other class A carbapenem-hydrolysing β-lactamases. a 
Substrate or 
inhibitor 
kcat (s
-1)   Km (µM)   kcat/Km (mM
-1 s-1) 
SFC-1 IMI-1 KPC-1b   SFC-1 IMI-1 KPC-1   SFC-1 IMI-1 KPC-1 
Substrates            
Ampicillin 155 ± 2 190 110  176 ± 17 780 130  881 240 850 
Piperacillin 44.7 ± 1 6.1 24  38 ± 4 13 18  1190 470 1333 
            
Cephalothin 280 ± 2 120 75  129 ± 14 130 53  2171 920 1400 
Cefotaxime 8.3 ± 0.5 3.4 14  89 ± 16 190 160  93.3 18 90 
Ceftazidime 2.1 ± 0.1 0.0068 0.1  52 ± 10 270 94  40.4 0.024 1 
Cefoxitin 4.2 ± 0.2 0.3 0.26  77 ± 14.46 45 120  54.5 6.7 2 
            
Aztreonam 162 ± 7 51 20  484 ± 78 93 310  334.7 550 70 
            
Imipenem 54 ± 1 89 12  82 ± 5 170 81  659 520 150 
Meropenem 6.5 ± 0.1 10 3  26 ± 2 26 12  250 380 250 
            a Kinetic values used for IMI-1 and KPC-1 were reported by Rasmussen et al., (1996) and Yigit et al., (2001), respectively. kcats and Kms for SFC-1 are 
means ± standard deviations. 
b KPC-1 is now KPC-2; KPC-1 designation is not used. 
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3.4 Concluding remarks  
 
The over-expression of blaSFC-1 allowed us to obtain a large quantity of SFC-1 
enzyme, enabling effective protein purification. Kinetic studies showed that purified 
SFC-1 exhibits a remarkably broad substrate range including β-lactams of all 
classes, and exhibits an increased efficiency against ceftazidime when compared to 
other class A (group 2f) carbapenemases. Moreover, SFC-1 is less inhibited by class 
A β-lactamase inhibitors than other characterised group 2f carbapenemases. These 
results confirm that SFC-1 is a member of β-lactamase group 2f, according to the 
Bush β-lactamase classification (BUSH et al., 1995), with some unusual properties. 
Tertiary structures for KPC-2, Sme-1 and NMC-A are already available (KE et 
al., 2007; SOUGAKOFF et al., 2002; SWARÉN et al., 1998). It would be interesting to 
generate a crystal structure of the carbapenem-hydrolyzing β-lactamase SFC-1 and 
investigate biochemical/structural relationships of SFC-1 in comparison with these 
enzymes. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
4. Crystallographic structure of SFC-1: insights into carbapenemase activity 
in class A β-lactamases 
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4.1 Introduction 
 
The evolution of narrow spectrum β-lactamases (e.g. TEM-1, SHV-1) into so-
called extended-spectrum β-lactamases (ESBLs) with the ability to hydrolyse 
oxyimino cephalosporins (e.g. cefotaxime and ceftazidime) in addition to penicillins 
and previous generations of cephalosporins (PATERSON and BONOMO, 2005; 
PEREZ et al., 2007), has resulted in an increased use of carbapenems. Carbapenems 
were formerly reserved for treatment of severe infections by Gram-negative pathogens 
(BAUGHMAN, 2009), but are now increasingly viewed as front-line therapy for 
treatment of nosocomial infections by both Enterobacteriaceae and non-fermenting 
pathogens (MASTERTON, 2009). This growth in carbapenem use has led to an 
increase in the incidence of carbapenem-hydrolysing β-lactamases of classes A, B 
and D (QUEENAN and BUSH, 2007; WALTHER-RASMUSSEN and HOIBY, 2007). 
In the case of the class A serine β-lactamases, several such enzymes (e.g. IMI, 
NMC, KPC and SFC-1) have been identified from environmental and pathogenic 
organisms. In particular, members of the KPC group are now endemic in 
Enterobacteriaceae in a number of locations (NORDMANN et al., 2009) where their 
production results in organisms with reduced or abolished susceptibility to 
carbapenems and for which there are few other effective treatment options (BUSH, 
2010). The situation is further complicated by the ability of many class A 
carbapenemases to resist the effect of mechanism based inhibitors such as 
clavulanic acid that are successful against the majority of class A β-lactamases 
(PAPP-WALLACE et al., 2010a). 
Carbapenems are able to inhibit the majority of class A β-lactamases through 
formation of a stable acylenzyme species that deacylates slowly. Carbapenems 
readily acylate enzymes such as TEM-1 and SHV-1 via nucleophilic attack of the 
active site serine, Ser70, upon the scissile β-lactam amide bond. However, kinetic 
(EASTON and KNOWLES, 1982), crystallographic (MAVEYRAUD et al., 1998; 
NUKAGA et al., 2008)  and spectroscopic (KALP and CAREY, 2008) experiments 
demonstrate that the acylenzyme so formed can partition between two states, a 
deacylation-competent form in which the acylenzyme carbonyl oxygen occupies the 
oxyanion hole, and a deacylation-incompetent state in which this oxygen is displaced 
from the oxyanion hole. Thus two distinct acylenzyme species are observed in crystal 
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structures of complexes of TEM-1 with imipenem (MAVEYRAUD et al., 1998) or SHV-
1 with meropenem (NUKAGA et al., 2008).  
In order for class A β-lactamases to act as effective carbapenemases it is 
therefore likely that their interactions with carbapenems will differ substantially from 
those made by their carbapenem-inhibited counterparts. However, despite the 
determination of numerous crystal structures (KE et al., 2007; SOUGAKOFF et al., 
2002; SWARÉN et al., 1998) those properties that are responsible for carbapenemase 
activity in class A enzymes remain relatively obscure. Whilst it is clear that certain 
features (substitution of Arg244; possession of a disulfide bond between Cys69 and 
Cys238) are important, the close structural resemblance between the active sites of 
carbapenem-hydrolysing and carbapenem-inhibited enzymes has led to speculation 
that multiple subtle alterations are responsible for activity against carbapenem 
substrates. Moreover, to date there remains little information regarding the 
interactions between class A carbapenemases and their carbapenem substrates. 
Therefore, in order to pursue this lack of structural information on 
carbapenem binding and hydrolysis in class A carbapenemases we investigated SFC-
1, a close relative of KPC-type enzymes. Here we present crystal structures of wild-
type SFC-1 and of complexes of site-directed mutants with the carbapenem 
meropenem in unhydrolysed and acylenzyme intermediate forms. 
 
4.2 Materials and methods 
 
4.2.1 Mutagenesis of SFC-1 
 
The SFC-1 β-lactamase gene from S. fonticola UTAD54 (HENRIQUES et al., 
2004) was cloned into pET-26(b) and transformed into E. coli BL21(DE3) as described 
in Chapter 3. The recombinant plasmid harbouring SFC-1 (pMF13) was used as the 
DNA template for site-directed mutagenesis. The mutagenic oligonucleotide primers 
used in the PCR reactions are shown in Table 4.1.  
SFC-1 mutants were generated using QuikchangeTM Site-Directed 
Mutagenesis Kit (Agilent) according to the manufacturer’s instructions, except for the 
PCR cycling parameters.  
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Briefly, the double stranded plasmid template pMF13 was initially denatured 
at 95ºC for 1 min and oligonucleotide primers containing the desired mutations were 
extended during 25 cycles of denaturation at 95ºC for 1 min, annealing at 55ºC for 2 
min, and extension at 68ºC for 8 min by PfuTurbo DNA polymerase. Amplification 
products were digested by Dpn I (1h at 37ºC) to remove the parent strands and 
transformed into E. coli XL1-Blue. The transformation reaction was plated on LB agar 
plates supplemented with 50 μg/ml kanamycin and incubated at 37ºC overnight. 
Plasmid DNA containing the putative mutation was subsequently isolated from 
transformed XL1-Blue cells using the QIAprep Spin Miniprep Kit (Qiagen) and 
sequenced in order to ensure the introduction of the desired mutation. DNA 
sequencing was performed by The Sequencing Service (School of Life Sciences, 
University of Dundee, Scotland). 
 
Table 4.1 Primers used to generate SFC-1 mutants. 
Primer Sequence 5’ --- 3’ 
  
 
S70A_F CGAGCGTTTTCCTCTCTGTGCTTCATTTAAAGGCTTCCTTG  
S70A_R CAAGGAAGCCTTTAAATGAAGCACAGAGAGGAAAACGCTCGT  
E166A_F CGTCTGGACCGATGGGCACTGGAGTTGAATTCC  
E166A_R GGA ATTCAACTCCAGTGCCCATCGGTCCAGACG  
 
 
4.2.2 Protein expression and purification  
 
In order to obtain a yield suitable for crystallisation trials, wild-type SFC-1 
was purified from cells growing in 4 L LB supplemented with kanamycin and purified 
as described in Chapter 3 (section 3.3.6). 
For protein expression mutant proteins were transformed into E. coli strain 
BL21 (DE3) and selected on LB agar plates containing 50 μg/ml kanamycin. Over-
expression and purification of the mutant proteins were performed as described for 
the wild-type SFC-1 (Chapter 3). After purification proteins were stored at 4ºC until 
use. 
Protein concentrations were determined by UV absorbance at 280 nm with 
molar extinction coefficients ε280 = 31840 M-1 cm-1, estimated from the amino-acid 
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composition by the method of Gill and von Hippel (GILL and VON HIPPEL, 1989) 
using the Protean application of Lasergene (DNAStar Inc.)  
 
 4.2.3 β-Lactamase crystallisation  
 
Wild-type or mutant SFC-1 in 10 mM phosphate buffer (pH 7.0) were 
concentrated by centrifugal filtration in Amicon Ultra-15 spin concentrators with a 
molecular weight cut off (MWCO) of 10 kD. For wild-type SFC-1, an initial screen of 
crystallisation parameters was performed by the sitting drop vapour diffusion 
method using protein concentrated to 12.3 and 6.15 mg/mL against the sparse-
matrix screens Structure screen I & II HT-96 (JANCARIK and KIM, 1991), JCSG-plus 
HT-96 and PACT premier (NEWMAN et al., 2005) (Molecular Dimensions) using a 
Phoenix crystallisation robot (Art Robbins Instruments) by mixing 0.5 μL protein 
solution with 0.5 μl screen solution. MRC two well crystallisation plates in the 96-
well format (Hampton Research) were used. Plates were sealed with ClearSeal FilmTM 
(Hampton Research) and incubated at 20 °C.  
Within a week, plate-like crystals were observed in conditions F6 from 
Structure screen (no salt, 0.1 M Hepes pH 7.5, 4.3 M sodium chloride) and C10 from 
PACT premier (0.2 M magnesium chloride, 0.1 M Hepes pH 7.0, 20% w/v PEG 6000). 
Needle-like crystals were also obtained in condition F10 from the Structure screen 
(0.1 M MES pH 6.5, 1.6 M magnesium sulphate. These conditions were used to 
optimise crystal quality in 24-well XRL crystallisation plates (Molecular Dimensions) 
by hanging drop vapour diffusion using a wide range of approaches: varying salt and 
precipitant concentrations, pH, and the ratio of protein: crystallisation solution. 
Crystals obtained from these trials were taken to the Diamond synchrotron but no 
diffraction was observed probably due to their small size.  
In subsequent experiments protein concentration was increased to 30 mg/mL 
and the Additive screen (Molecular Dimensions) was tried (additives were mixed 
either in the drops of protein solution or in the reservoir solution, depending on the 
additive, to a final concentration of 10%) but no single crystals were obtained. A new 
inspection of the initial screens lead us to test condition E7 from the PACT screen, 
consisting of 0.2 M sodium acetate and 20% w/v PEG 3350 with 15 and 30 mg/mL 
of protein. Crystals were reproducible and diffraction quality single crystals of wild-
type SFC-1 were grown by mixing 1.5 μL of protein (30 mg/mL) with 1.5 μL of 
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reservoir solution and equilibrating the samples against 500 μL of reservoir solution. 
The reservoir solution contained 18-22% w/v PEG 3350 and 0.2 M sodium acetate.  
 
Crystallisation of SFC-1 mutants was first attempted using the same 
condition as previously employed for the wild-type protein (17-22% w/v PEG 3350 
and 0.2 M sodium acetate), using proteins concentrated to 15 and 30 mg/mL. The 
drops contained 1μL of protein and 1μL of reservoir solution and were equilibrated 
against 500 μL of reservoir solution. However this condition did not yield crystals. 
The proteins were then screened with JCSG-plus HT-96 and PACT premier (Molecular 
Dimensions) using the Phoenix robot with drops containing 0.5 μL of protein (10 and 
20 mg/mL) and 0.5 μL of reagent. After one week the most promising crystallisation 
conditions for the  mutant proteins  were D5 from JCSG-plus HT-96 (0.1 M Hepes pH 
7.5, 70% v/v MPD) for the E166A mutant and F5 from PACT premier (0.2 M sodium 
nitrate, 0.1 M Bis Tris propane pH 6.5, 20% w/v PEG 3350) for the S70A mutant. 
Reproducibility and optimisation (changing precipitant concentration, pH and use of 
the Additive screen) of the crystals using the above conditions failed. In most cases 
clear drops were obtained. Therefore, in order to obtain single crystals of diffraction 
quality, crystals of native SFC-1 were used for streak seeding. In this trial mutant 
proteins were used at a concentration of 30 mg/mL. Drops were prepared by mixing 
1.5 μL of protein with 1.5 μL of well solution (0.2 M sodium acetate, 18-22% w/v 
PEG 3350). A good crystal of native protein was touched with a whisker that 
transferred seeds to the prepared drops containing mutant proteins. Crystals 
emerged after 1 day. 
 
The crystals used for data collection were looped out from the cover slides 
using either nylon or litholoops (Molecular Dimensions) mounted on cryo-pins, 
dipped into the cryoprotectant solution for a few seconds and stored in liquid 
nitrogen until the diffraction experiments. Cryoprotectant solutions for crystals of 
both wild-type SFC-1 and mutant proteins consisted of mother liquor solution plus 
20% ethylene glycol.  
 
Acylenzyme-intermediates and complexes with unhydrolysed meropenem were 
prepared by soaking crystals of the mutant proteins, E166A and S70A respectively, 
in cryoprotectant solution containing 50 mM meropenem for 30 to 50 minutes before 
freezing in liquid nitrogen. 
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 4.2.3 X-ray diffraction data collection and crystallographic refinement 
 
Diffraction data were collected at 100 K on beamlines 10.1 of the SRS 
(Daresbury, UK) for wild-type enzyme, and IO2/IO3 of the Diamond Light Source 
(Didcot, UK) for mutant proteins.  
The crystals diffracted to maximum resolutions of 1.35 Å (WT), 1.08 Å (S70A 
substrate complex) and 1.3 Å (E166A acylenzyme complex). Data were processed and 
scaled using the programs HKL2000 (OTWINOWSKI and MINOR, 1997) or MOSFLM 
(LESLIE, 2006) and SCALA (EVANS, 2006) as shown in Table 4.2. The crystals of 
wild-type SFC-1 belong to the monoclinic space group P21 with two SFC-1 molecules 
in the asymmetric unit, while the space group of crystals from mutant proteins was 
P212121 with one molecule in the asymmetric unit. 
Structures were determined by molecular replacement with PHASER (MCCOY 
et al., 2007) using chain A of the KPC-2 β-lactamase (PDB ID 2OV5) (KE et al., 2007) 
(wild-type enzyme) or the wild-type structure (mutant enzymes) as the initial search 
model. Model building and refinement were performed with the programs COOT and 
REFMAC, respectively (EMSLEY et al., 2010), (MURSHUDOV et al., 1997). Ligand 
restraints were generated using the CCP4i monomer sketcher (POTTERTON et al., 
2003) and the PRODRG server (SCHUTTELKOPF and VAN AALTEN, 2004).  
The models were further refined using conjugate gradient minimization in 
SHELXL (SHELDRICK, 2008). The program mtz2hkl (GRUNE, 2008) was used in the 
transition from REFMAC refinement to SHELXL. The refinement with SHELXL 
started with the lowest resolution data (to 2.5 Å resolution) and remaining data was 
added in steps to the highest resolution (Table 4.2). Anisotropic B-factors were 
introduced with the highest resolution data and produced a 1−3% drop in the R free 
values, depending on the dataset’s resolution. In all the structures it was possible to 
model alternative side chains in numerous residues. The progress of crystallographic 
refinement was monitored using the MOLPROBITY server (CHEN et al., 2010) and the 
quality of the final structures was verified with PROCHECK (LASKOWSKI et al., 
1993). 
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4.3 Results and discussion 
 
4.3.1 Structure of the SFC-1 carbapenemase 
 
Crystals of the wild-type SFC-1 were obtained by the hanging drop vapour 
diffusion technique using 30 mg/ml protein and 18-22% w/v polyethylene glycol 
3350, 0.2M sodium acetate. Crystals of SFC-1 mutants were obtained by the same 
technique using streak seeding with crystals of the wild-type protein and the same 
protein concentration (Figure 4.1). 
 
 
Figure 4.1 A, SFC-1 crystals growing in 0.2 M sodium acetate with different concentrations 
of PEG 3350 (w/v); B and C, SFC-1 S70A and E166A mutant crystals after seeding, respectively. 
 
The crystal structure of SFC-1 was determined to 1.35 Å resolution by 
molecular replacement using the coordinates of the structure of the β-lactamase 
KPC-2 from K. oxytoca as a search model (KE et al., 2007). The SFC-1 crystal reveals 
two molecules per asymmetric unit, which were refined in space group P21 to a final 
crystallographic R-factor and Rfree values of 11.6 and 16.0 %, respectively.  
The crystallographic and model statistics for the native and SFC-1 mutant-
complexes structures are reported in Table 4.2.  
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Table 4.2 Data collection and refinement statistics for native and SFC-1 mutant-complexes 
structures.  
Dataset Native E166A  S70A  
  
 
Processing HKL2000 MOSFLM/SCALA MOSFLM/SCALA   
Beamline SRS 10.1 DLS I03 DLS I02   
Space Group P 21 P 21 21 21 P 21 21 21   
Cell Dimensions (Å) 
a = 42.33  
b = 85.46  
c= 70.29  
β = 103.26o 
a = 59.17 
b = 61.95 
c= 79.11 
a = 59.06  
b = 61.91 
c= 79.01 
  
Wavelength (Å) 1.117 0.9763 0.9702   
Resolution (Å) 
50 – 1.35 
(1.40 – 1.35)a 
37.64 – 1.49 
(1.57 – 1.49)a 
22.52 – (1.08) 
(1.14 - 1.08)a 
  
Total reflections 355 336 678 589 840 706   
Unique reflections 102 989 (8 012)a 48 468 (7 000)a 123 610 (17 824)a   
Completeness (%) 96.6 (75.5)a 100 (100)a 99.5 (99.5)a   
Redundancy 3.5 (2.0)a 14 (13.4)a 6.8 (6.6)a   
I / (sig. I) 18.6 (1.69)a 28.9 (14.0)a 16.9 (5.1)a   
Rmerge (%) 6.1 (50.7)
a 9.0 (17.4)a 7.0 (28.5)a   
Refinement (SHELXL)      
Resolution range (Å) ∞-1.35 ∞-1.30 ∞-1.08   
No. of reflections used 97807 64944 116903   
R-factor/Rfree (%) 11.6/ 16.0 11.1/ 14.8 11.0/ 13.2   
Rtotal (%)      
Ramachandran plot (%)      
      favored/allowed 98.0/ 2.0 98.9/ 1.1 98.5/ 1.5   
      disallowed 0 0 0   
RMSD values       
      bond lengths (Å) 0.01 0.014 0.015   
      bond distances (Å) 0.04 0.031 0.031   
Mean B-factor (Å2)      
      protein 14.744 12.150 11.205   
      substrate --- 15.348 11.865   
      ethylene carbonate 9.864 --- ---   
      water molecules 27.435 28.743 30.517   
      all atoms 15.733 13.673 13.193   
a The values in parentheses are for the highest-resolution shell used in refinement. One crystal was 
used for the data collection of each dataset. 
Crystallographic structure of SFC-1with bound carbapenem ____________________________________________________________________________________________________________________________________________________ 
 
77 
 
The final model contains two independent molecules: molecule A comprising 
residues Ser23−Ala294 (numbering according to the standard Ambler scheme; 
AMBLER et al., 1991) of the mature polypeptide and molecule B comprising residues 
Ser23−Arg296 with 13 and 10 residues not observed in molecules A and B, 
respectively, due to disorder. 
The Ramanchandran plot shows that 97.8% of the residues have φ and ψ 
angles in the most favoured regions with no residues in the disallowed regions. When 
compared, the two monomers are very similar with an r.m.s. deviation in atomic 
positions of 0.5 Å for 270 aligned Cα atoms, using the secondary structure matching 
(SSM) algorithm (KRISSINEL and HENRICK, 2004) as implemented in COOT. 
 
The SFC-1 active site is located in the cavity generated at the interface of the 
two domains and contains conserved residues that are known to play a role in 
substrate binding and/or catalysis in class A β-lactamases (Figure 4.2). Such 
residues include the catalytic Ser70, Lys73, Ser130, Asn132, Glu166, Asn170, 
Lys234, Thr235 and Thr237, as well as the Cys69-Cys238 disulphide bridge (Figure 
4.3). This disulphide bridge is a feature unique to class A carbapenemases and is 
thought to play a role in the stabilization of the protein fold (RAQUET et al., 1997; 
WALTHER-RASMUSSEN and HOIBY, 2007). The oxyanion hole is formed by the 
backbone nitrogen atoms of Ser70 and Thr237.  
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Figure 4.2 Overall fold of class A carbapenemases. A) Ribbon secondary structure 
representation of the SFC-1 structure; α-helices are shown in magenta and β-strands in limon. B) 
Superposition of SFC-1 structure (magenta) with serine carbapenemases NMC-A (gray; PDB 
accession 1BUE) and KPC-2 (blue, PDB accession 2OV5). The labelled catalytic residues Ser70, 
Ser130 and Glu166 (shown as gray model sticks) and the Ω-loop localize the active site. This and 
all subsequent figures were generated using the program Pymol (DELANO, 2008). 
 
Unexpectedly a cyclic adduct, modelled as ethylene carbonate (EC), was 
shown to be present in the SFC-1 active site (Figure 4.3), and is observed in the 
active sites of both SFC-1 molecules in the asymmetric unit. The electron density 
found close to the catalytic Ser70 during model building did not correspond to any 
compound used in protein purification or crystallisation but resembled a five-
membered ring. In the literature there is a precedent for a similar interaction. 
Indeed, a structure of the recombinant (−) γ-lactamase from an Aureobacterium 
species was determined in complex with a cyclic ethylene carbonate molecule 
covalently bound to the catalytic serine residue (LINE et al., 2004). Therefore an 
ethylene carbonate molecule was built into the positive electron density and refined, 
and a good fit to the electron density maps was achieved. Moreover, in the final 
model, the B-factors of the ligand (mean less than 10 Å2) were comparable to those 
displayed by neighbouring amino acid residues, indicative of a good assignment of 
the ligand modelled into the active site of native SFC-1.  
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Figure 4.3 Stereoview of the SFC-1 active site with labelled conserved residues shown as 
stick models. 2mFo − DFc electron density maps (blue) surrounding catalytic water molecule (Wat1) 
and the cyclic ethylene carbonate (EC; carbon atoms coloured grey) are contoured at 1.5σ. 
Hydrogen bonding interactions (black dashed lines) of the active site water molecule (red sphere) 
and the carbonyl group of ethylene carbonate are displayed. 
 
The ethylene carbonate forms a tetrahedral complex with the catalytic Ser70 
as described for the (−) γ-lactamase (LINE et al., 2004). It is also involved in hydrogen 
bonding with two other active site residues, namely Ser130 and Thr237. 
Interestingly, the carbonyl group of ethylene carbonate sits in the oxyanion hole 
formed by the main chain nitrogen atoms of Ser70 and Thr237, in the position 
usually occupied by a water molecule (Wat2) in class A β-lactamases (CHEN et al., 
2005; STEC et al., 2005; SWARÉN et al., 1998). This water molecule is also missing 
in the structure of carbapenemase KPC-2 due to the positioning of Ser70 side chain, 
partially blocking the oxyanion hole (KE et al., 2007). The carbonyl group of ethylene 
carbonate is hydrogen bonded to the backbone carbonyl (2.74 Å) and nitrogen (2.95 
Å) of Thr237 and to the deacylation/catalytic water (Wat1) (Figure 4.3).  
In contrast to the class A carbapenemase Sme-1 (SOUGAKOFF et al., 2002) 
the putative deacylating water molecule (Wat1) is observed in the structure of SFC-1 
and establishes a hydrogen bonding network with residues Glu166, Asn170 and 
Ser70, as described in other class A β-lactamases (STEC et al., 2005; SWARÉN et al., 
1998), and with the carbonyl group of ethylene carbonate (Figure 4.3). 
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The superposition of the SFC-1 structure on to other available structures of 
class A serine carbapenemases such as NMC-A (SWARÉN et al., 1998) and KPC-2 
(KE et al., 2007) points to the existence of some elements of difference between the 
three carbapenemases as shown in Figure 4.2. These comprise loops near residues 
88 and 98, and two secondary elements in NMC-A and KPC-2 near residues 87 and 
180 which are absent in SFC-1. However, all of these regions are distant from the 
active site and are therefore unlikely to explain the unusual spectrum of activity of 
SFC-1.  
When compared to other class A β-lactamases, the main differences in SFC-1 
are seen at the entrance of the catalytic cavity. Pro104 in SFC-1 and KPC-2 is 
substituted with Tyr and Phe in Sme-1 and NMC-A, respectively, and Glu in TEM-1 
(STEC et al., 2005), indicating that the residue at Ambler position 104 is not 
conserved among class A β-lactamases. In the structure of SHV-1, Asp was found at 
this position and it was observed that the substrate binding cavity was wider when 
compared to TEM-1 β-lactamase (KUZIN et al., 1999). As described for SHV-1, it can 
be proposed that the small nonpolar residue Pro104 that is present in KPC-2 and 
SFC-1 contributes to an enlarged entry to the active site in these enzymes, resulting 
in increased activity against ceftazidime and cefotaxime. A site saturation 
mutagenesis study at position 104 in the SHV-1 and SHV-2 β-lactamases (BETHEL 
et al., 2006) showed that the SHV-1 Asp104Pro variant expressed in E. coli DH10B 
increased resistance to cefotaxime (MIC range, 0.06 to 0.125 µg/ml) while ampicillin 
resistance was fourfold decreased. In the SHV-2 Asp104Pro variant, however, 
resistance to all β-lactams tested (ampicillin, cephalothin, cefotaxime and 
ceftazidime) was twofold increased (BETHEL et al., 2006). 
Adjacent to Pro104 is residue His105 which in SFC-1 (chain A) adopts a 
completely different orientation when compared to other class A β-lactamases. In 
chain A of the SFC-1 structure the side chain of His105 is rotated more than 90º in 
the direction of the entrance of the binding cavity but away from Ser130. In contrast, 
the side chains of residues at position 105 in Sme-1 and NMC-A (His), KPC-2 (Trp) 
and TEM-1 (STEC et al., 2005), SHV-1 (KUZIN et al., 1999) and CTX-M-16 (CHEN et 
al., 2005) (Tyr) are directed towards the active site pocket making hydrogen bonds to 
the main chain carbonyl of the residue at position 129 (Met or Tyr in the enzymes 
referred above). This interaction is absent in SFC-1 whose His105 side chain and the 
backbone carbonyl of Tyr129 are hydrogen bonded to water molecules. This probably 
results in a widened active site cavity in SFC-1, which is able to recognize and 
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accommodate the large oxyimino-cephalosporins, possibly explaining the higher 
hydrolytic activity of SFC-1 against the third generation cephalosporins cefotaxime 
and ceftazidime (FONSECA et al., 2007). Doucet et al., (2004) previously reported a 
site saturation mutagenesis study of Tyr105 in TEM-1 β-lactamase; their results 
suggest that Tyr105 is important in substrate recognition and stabilization rather 
than hydrolysis. Moreover, this study shows that the conformation of the residue at 
Ambler position 105 prevents unfavourable steric interactions with the substrate in 
the active site pocket (DOUCET et al., 2004). 
 
 
 
 
 
 
 
 
 
 
 Figure 4.4 Superposition of the Cα trace of class A carbapenemases (SFC-1, NMC-A, SME-
1, KPC-2) and carbapenem-inhibited enzymes (SHV-1, CTX-M-16, TEM-1). Arrow shows active site 
with key SFC-1 residues (Ser70, Glu166, Ser130 and the Cys69-Cys238 disulphide bridge) 
represented as sticks. 
 
Despite the drastic differences in the ability to hydrolyse carbapenems among 
carbapenemases and non-carbapenemase enzymes, the overall folds of class A β-
lactamases are shown to be closely conserved, as depicted in Figure 4.4. The 
comparison between the crystallographic structures of class A carbapenem-
hydrolysing β-lactamases such as SFC-1, KPC-2, NMC-A and SME-1, and those of 
TEM-1, SHV-1 and CTXM-16, does not provide an unambiguous basis for the 
enhanced catalytic activity of class A carbapenemases against carbapenem 
substrates. The same conclusion was found by Ke and collaborators when analysing 
the structure of KPC-2 (KE et al., 2007). Therefore, the basis for the unusual 
spectrum of activity of SFC-1 and related enzymes is somewhat to be expected in 
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subtle active site rearrangements, together with altered enzyme dynamics, rather 
than in gross structural changes.  
 
To date there is no structural data on the interaction between class A 
carbapenemases and carbapenems, although a number of class A β-lactamase 
structures with bound inhibitors or acyl intermediates are available (DELMAS et al., 
2008; MAVEYRAUD et al., 1998; NUKAGA et al., 2008). To investigate how 
carbapenems achieve hydrolysis by these β-lactamases, mutational techniques were 
used to determine atomic resolution structures of SFC-1 active site bound with the 
carbapenem meropenem, in both the Michaelis complex and the covalent acyl 
intermediate. The results provided relevant structural data on the recognition and 
hydrolysis of carbapenems by SFC-1, that can be extended to other class A 
carbapenemases. 
 
4.3.2 The SFC-1 S70A-meropenem complex structure  
 
In this study two catalytic-deficient mutants of SFC-1 were engineered. 
Mutating conserved active site residues, specifically the acylating nucleophile Ser70 
and Glu166 (responsible for the activation of the catalytic water molecule during 
deacylation), to alanine residues generates class A β-lactamases with impaired ability 
to complete the acylation or deacylation steps of the reaction, respectively. This 
strategy, previously employed by several researchers to maximize the possibility of 
trapping class A β-lactamase acylenzyme intermediates for crystallographic analysis 
(CHEN and HERZBERG, 2001; IBUKA et al., 1999; PADAYATTI et al., 2004; 
SHIMAMURA et al., 2002; TREMBLAY et al., 2010), enabled us to obtain the first 
structures of a class A carbapenemase bound to an intact carbapenem (meropenem) 
(mutant S70A) and of an acylenzyme intermediate (meropenem complex of the E166A 
mutant).  
 
The crystal structure of the SFC-1 S70A mutant in complex with the 
carbapenem meropenem was determined to a resolution of 1.08 Å by molecular 
replacement using chain A of the previously solved wild-type SFC-1 structure as the 
starting model. The complex crystallized in space group P212121 with one molecule 
per asymmetric unit and was refined to final R-factor and Rfree values of 10.9 and 
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13.1%, respectively (Table 4.2). The refined structure of the S70A mutant is 
essentially similar to that of the wild-type, with an r.m.s. deviation of 0.47 Å between 
the Cα atoms of the two structures. Regardless of the better-diffracting crystals, it 
was not possible to model the position of all 283 residues of the mature protein in 
the electron density map, with 13 residues not observed at the C-terminus of the 
current structure due to disorder. The final model also contains a meropenem 
molecule located in the active site, seven sodium ions, four ethylene glycol molecules, 
and 550 water molecules.  
Initial difference electron density maps contoured at 3σ clearly revealed the 
presence of meropenem bound in the active site of the mutant enzyme. Meropenem 
was readily fitted into the 2Fo-Fc maps and electron density for the entire antibiotic 
is complete, indicating that no fragmentation of the molecule occurred during 
soaking procedures. Indeed, the drug refines with an occupancy of 1.0 and 
temperature factors varying from less than 8.0 Å2 (from the hydroxyl to sulphanyl 
moieties) to more than 20.0 Å2 for atoms in the R’ side chain beyond the sulphur, 
where the electron density is less intense and no interaction with protein residues is 
observed. For comparison, the CB atom of the side chain of the mutated residue 
Ala70 has a B factor of 6.13 Å2, confirming a good fit of the bound antibiotic in the 
model. 
 
 
 Figure 4.5 Binding of unhydrolysed meropenem in SFC-1 active site. A) Wild-type SFC-1; 
ethylene carbonate molecule is omitted for clarity. B) SFC-1 S70A mutant showing bound 
meropenem (carbon atoms in gray). Sigma-A weighted electron densities displayed are contoured at 
1.0σ. 
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In the substrate complex, the β-lactam carbonyl oxygen of meropenem is 
hydrogen bonded by the backbone nitrogen and carbonyl group of Thr237 (Figure 
4.5) at 2.84 and 3.08 Å respectively. The hydrogen bonds formed by the carbonyl 
oxygen help to polarise this bond and increase its susceptibility to hydrolytic attack.  
 
The hydroxyl oxygen of the β-lactam interacts, also through hydrogen bonds, 
with the ND2 atom of Asn132 (2.95 Å) and the catalytic water molecule (Wat1, 2.69 
Å). Additionally, hydrogen bonding interactions are observed between the meropenem 
carboxylate and the side chain hydroxyl groups of Thr235 (2.84 Å), Thr237 (2.70 Å) 
and Ser130 (2.84 Å). The carboxylate is also hydrogen bonded to the side chain of 
Lys234 (3.04 Å) and a water molecule (2.89 Å) as shown in Figure 4.5.  
 
4.3.3 The SFC-1 E166A-meropenem acylenzyme structure  
 
The SFC-1 E166A mutant in complex with hydrolysed meropenem 
(acylenzyme) was crystallized and its structure determined by molecular replacement 
as described for the S70A mutant. The acylenzyme complex crystallised in space 
group P212121 with one molecule in the asymmetric unit, and clear electron density 
was observed for residues 32−292 in the initial maps. A total of 269 ordered 
residues, one hydrolysed meropenem molecule, four ethylene glycol molecules, and 
510 water molecules were refined to a resolution of 1.30 Å with a crystallographic R-
factor of 11.1% and an Rfree of 14.8% (Table 4.2). No electron density was found for 
13 residues in the C-terminal of the protein that were assumed to be disordered in 
the crystal structure. Electron density for meropenem, introduced during the soaking 
process, was observed in the active site pocket of the protein, whereas electron 
density for ethylene glycol, the cryoprotectant used for crystal freezing, was found 
mostly on the surface of the protein. 
The overall structure of the SFC-1 E166A acylenzyme is very similar to that of 
native SFC-1. In fact, the two proteins can be superimposed with an r.m.s.d. of 0.48 
Å for 268 structurally aligned Cα positions. Upon alignment of SFC-1 E166A 
acylenzyme and S70A mutant with bound meropenem, an r.m.s.d. of 0.14 Å was 
determined for all Cα atoms, demonstrating the strong similarity throughout the 
entire proteins.  
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In the structure of the E166A acylenzyme, an uninterrupted electron density 
connects the active site catalytic residue Ser70 with the β-lactam ring-opened form of 
meropenem, showing that the enzyme and the antibiotic have been covalently linked. 
This corresponds to the covalent acylenzyme intermediate formed upon attack of the 
conserved serine nucleophile (Ser70 in class A β-lactamases) on the carbonyl carbon 
of the β-lactam ring. The electron density of the covalent acylenzyme intermediate is 
displayed in Figure 4.6B.  
 
 
Figure 4.6 A) Binding of unhydrolysed meropenem (gray carbons) in the active site of SFC-
1 S70A, shown for comparison. B) Binding and interactions of hydrolysed meropenem (yellow 
carbons) and catalytic water molecule (Wat1) in the active site of SFC-1 E166A. The sigma-A 
weighted electron density maps shown are contoured at 1.0σ. 
 
An overlay of the S70A mutant-meropenem complex with the crystal structure 
of the E166A acylenzyme reveals that the β-lactam ring carbonyl oxygen is placed 
deeper into the oxyanion hole in the structure of the E166A acylenzyme. In the 
meropenem complex the β-lactam ring carbonyl oxygen was not hydrogen bonded to 
the Ala70 backbone amide (Figure 4.5B) and the distance to the Thr237 backbone 
amide nitrogen was 2.84 Å. In the acylenzyme, the β-lactam ring carbonyl oxygen 
establishes hydrogen bonding contacts with the backbone amide nitrogen atoms of 
both Ser70 and Thr237 (2.82 Å) (Figure 4.6B). Originally at a distance of 3.15 Å from 
the side chain carbon atom of Ala70 (in the S70A mutant-meropenem complex), the 
β-lactam ring carbonyl carbon shifts position coming closer to Ser70 (2.7 Å to side 
chain carbon atom) to form a covalent bond (1.35 Å) with the hydroxyl group (in the 
structure of the E166A acylenzyme), generating the ester bond and opening the β-
lactam ring. Along with these changes, also the meropenem carboxylate is closer to 
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the side chain hydroxyl of Thr237 and Thr235 (shifts from 2.76 to 2.66 Å and 3.02 to 
2.54 Å, respectively), whereas the existing hydrogen bond with Ser130 hydroxyl 
group is lost, although its position remains unchanged.  
In the crystal structure of the E166A acylenzyme the 6α-hydroxyethyl 
substituent of meropenem is rotated nearly 90° about the C6−C61 axis keeping its 
hydrogen bond with Asn132 while bonding with the deacylating water molecule 
(Wat1) disappeared (Figure 4.6). The deacylating water molecule forms two hydrogen 
bonds, one with backbone oxygen of Ala166 (2.8 Å) and another with the side chain 
oxygen atom of Asn132 (3.0 Å). However, in crystal structures of class A 
carbapenem-inhibited enzymes with carbapenems covalently bound, a hydrogen 
bond is observed between the hydrolytic water molecule and the carbapenem’s 
hydroxyethyl substituent, an interaction considered to weaken the nucleophilicity of 
this important water molecule and thus contribute to the stability of carbapenems in 
the acylenzyme form in TEM-1 and SHV-1 β-lactamases (MAVEYRAUD et al., 1998; 
NUKAGA et al., 2008).  
Superimposing the SFC-1 E166A-meropenem complex on the crystal 
structure of class A carbapenem-inhibited class A β-lactamases complexed with 
carbapenems such as TEM-1 (PDB 1BT5) and SHV-1 (PDB 2ZD8) (Figure 4.7), 
reveals some modifications in active site residues and binding of the carbapenem. 
SFC-1 binds meropenem in a single, well-defined orientation (Figure 4.5B, Figure 
4.6). Two isomers of the carbapenems, Δ1 and Δ2-pyrroline that differ in the position 
of the double bond about the carbapenem nucleus have been observed in the active 
site of the β-lactamase SHV-1 (KALP and CAREY, 2008). According to this work, the 
Δ1 acyl-enzyme is a long-lived, hydrolytically inert species, while the Δ2 acyl-enzyme 
is the reactive species that undergoes deacylation. Although it is not possible to 
visualize the tautomer in the crystal structure, the collinear positioning of the 
thioether sulfur atom in line with the N1, C2, C3, and C4 bonds is indicative of the 
presence of the reactive Δ2-pyrroline ring in SFC-1. This contrasts with the two 
orientations that have been observed for carbapenems bound to SHV-1 (NUKAGA et 
al., 2008) (Figure 4.7A). Moreover, the structure of SHV-1 acylated with meropenem 
showed that the carbonyl oxygen of the acyl group was “flipped outside” the oxyanion 
hole in one of the conformers, whereas in the SFC-1 structure the carbonyl oxygen is 
hydrogen bonded to the amide nitrogens of Ser70 and Thr237 that form the oxyanion 
hole. Also in the TEM-1: imipenem complex the carbonyl group was found outside 
the oxyanion hole (MAVEYRAUD et al., 1998).  
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Nukaga and collaborators reported that Ser130 is reoriented in the complex, 
when compared to the apo structure of SHV-1, with the hydroxyl group directed 
towards the amino group of Lys234 rather than to Lys73 (apo structure). A similar 
conformation is seen in the TEM-1: imipenem structure (Figure 4.7). In the 
structures of SFC-1, both the apo and meropenem complexes, Ser130 is in the same 
orientation and resembles that observed in the apo structure of SHV-1 (PDB 1SHV) 
(KUZIN et al., 1999). In SFC-1 the hydroxyl group of Ser130 interacts, via hydrogen 
bonds, with the amino groups of both Lys73 (2.79 Å) and Lys234 (2.92 Å) and, in the 
structure of the acylenzyme, the amide nitrogen (N4) of meropenem (2.88 Å). This 
nitrogen is also hydrogen bonded to the hydroxyl of catalytic Ser70 (2.84 Å). By 
contrast, no interactions are observed between the carbapenem amide nitrogen and 
protein residues in the TEM-1 and SHV-1 structures. This suggests that Ser130 is 
involved not only in the acylation step by proton transfer to the amide nitrogen (N4), 
but also in the deacylation step by helping to position the carbapenem in an 
orientation favourable to catalysis. 
 
 
Figure 4.7 A) Superposition of SFC-1 E166A: meropenem and SHV-1: meropenem (blue: 
silver; PDB 2ZD8). B) Superposition of SFC-1 E166A: meropenem and TEM-1: imipenem (pink: 
brown; PDB 1BT5). In both schemes, active site residues of SFC-1 E166A and meropenem are 
coloured green and yellow, respectively and water molecules represented as red spheres; active site 
water molecules and their interactions are shown for SHV-1 (A) and TEM-1 (B). Black circles locate 
the side chains of active site Ser130. 
 
Interestingly, the structures of carbapenem-inhibited enzymes complexed with 
carbapenems can be distinguished from that of the SFC-1 acylenzyme by the 
position and interaction of the carbapenem’s 6α-hydroxyethyl substituent. In the 
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acylenzymes of TEM-1 and SHV-1 the hydroxyl group of the substituent is directed 
towards the active site groove, interacting with the hydroxyl group of Ser70, the side 
chain oxygen of Asn132 and the deacylating water molecule. In SFC-1 the hydroxyl 
group of the 6 substituent is oriented in the opposite way, directed away from the 
active site and hydrogen bonded to the amide group of Asn132 and a water molecule. 
In class A carbapenemases the active site residue Asn132 is shifted away from the 
active site, enlarging the substrate binding cavity (SWARÉN et al., 1998). This 
rearrangement in the active site, along with increases in the hydrogen bonding 
distance between the meropenem hydroxyl group and Asn132 side chain (shifts from 
around 2.70 Å in TEM-1 and SHV-1 complexes to 2.86 Å in SFC-1) may possibly 
allow the hydrolytic water to approach the ester carbonyl of the acylenzyme species 
resulting in deacylation of active site bound carbapenems, as occurs in class A 
carbapenemases. In other class A β-lactamases (MAVEYRAUD et al., 1998; NUKAGA 
et al., 2008) the reorientation of the hydroxyethyl substituent in the acylenzyme 
reduces the reactivity of the deacylating water molecule, thus stabilising the 
covalently bound carbapenem intermediate. 
 
An arginine at position 244 is observed in most class A β-lactamases, known 
to interact strongly with the substrate carboxylate in these enzymes (NUKAGA et al., 
2008; STRYNADKA et al., 1992) (Figure 4.7) and has been shown to be important in 
the tautomerization of the Δ2- to Δ1-pyrroline acylenzyme involved in carbapenem 
inhibition by these enzymes (KALP and CAREY, 2008; ZAFARALLA and 
MOBASHERY, 1992). However, in class A carbapenemases an alanine is found 
replacing the arginine. Instead, the side chain of an arginine at position 220 is 
projected into the active site occupying a position similar to that of Arg244 of non-
carbapenemases. Although this doesn’t change the architecture of the active site, the 
anchoring of the substrate’s carboxylate is different in the two groups of enzymes. 
Indeed, in the SFC-1 complex meropenem carboxylate is anchored by Thr237, 
Thr235 and Lys234 while in TEM-1 and SHV-1 acylenzymes, carboxylate is hydrogen 
bonded to Arg244, Ser235 and water molecules. Consequently in TEM-1 and SHV-1 
β-lactamases, bound carbapenem adopts a different orientation due to interaction 
with Arg244, which results in flexible binding at a distance from Ser130 (Figure 4.7). 
It has been proposed that in the deacylation mechanism the leaving group lactam 
nitrogen is activated by accepting a proton from Ser130 (MINASOV et al., 2002). 
However, in the former β-lactamases Ser130 is rotated away from the amide nitrogen 
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(N4), impairing proton transfer. By contrast in the SFC-1 E166A acylenzyme 
structure reported here, the interaction of the amide nitrogen with Ser130 (Figure 
4.7) maintains the hydrolytically active tautomer and allows the proton transfer from 
Ser130, essential for an efficient deacylation. Therefore, the results shown here 
provide evidences to explain the carbapenemase activity exhibited by SFC-1 and 
related enzymes.  
 
4.3.4 Concluding remarks  
 
Here is reported the atomic structures of mutants and native SFC-1, a class A 
carbapenemase that is closely related, at the amino acid sequence level, to the 
clinically relevant KPC enzymes. These data show, for the first time, the interaction 
of carbapenems with class A carbapenemases, both in the unhydrolysed form and 
the acylenzyme intermediate, by X-ray crystallography.  
The overall structure of SFC-1 closely resembles those of other known class A 
β-lactamases. However, these first structures of a class A carbapenemase with 
bound carbapenem and carbapenem acylenzyme suggest that, in SFC-1, and likely 
other class A carbapenemases, tight interaction with Ser130 maintains bound 
meropenem, in a conformation suitable to carbapenem hydrolysis, without gross 
distortion of the overall structure. 
The SFC-1: meropenem complex reveals important differences in the 
interaction with meropenem when compared to carbapenem-inhibited enzymes, 
providing information on the mechanism of carbapenem hydrolysis by class A β-
lactamases.  
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5.1 Introduction 
 
Carbapenems are broad spectrum β-lactams that are insusceptible to the 
hydrolytic action of most β-lactamases, and consequently are growing in importance 
as treatments for infection by opportunist Gram-negative bacterial pathogens 
(MASTERTON, 2009). As other treatment options for such organisms are frequently 
limited, carbapenem-hydrolyzing β-lactamases pose a serious threat to the effective 
resolution of such infections (QUEENAN and BUSH, 2007; WALSH, 2008). Although 
they remain comparatively rare, the frequency of carbapenemase containing-bacterial 
species continues to increase (HAWKEY and JONES, 2009). Carbapenemase activity 
has now been reported for β-lactamases of all four Ambler classes (A-D) (KIM et al., 
2006; QUEENAN and BUSH, 2007).  
Ambler class B or metallo-β-lactamases (MBLs) require zinc as a cofactor and 
are not susceptible to serine β-lactamase inhibitors (e.g. clavulanic acid) in clinical 
use (CROWDER et al., 2006). MBLs are divided, according to their sequence, metal 
requirement and substrate specificity, into three subclasses (GALLENI et al., 2001). 
Subclasses B1 and B3 generally bind two zinc equivalents and exhibit a broad 
spectrum of activity, hydrolyzing all classes of β-lactams except monobactams 
(CROWDER et al., 2006). By contrast, subclass B2 MBLs, such as CphA (SEGATORE 
et al., 1993; VALLADARES et al., 1997), ImiS (CRAWFORD et al., 2004; WALSH et al., 
1996) and AsbM1 (YANG and BUSH, 1996) from Aeromonas spp., are monozinc 
enzymes with a strong preference for carbapenem substrates, and are inhibited upon 
binding of a second zinc ion (VALLADARES et al., 1997; YANG and BUSH, 1996). 
These are the least studied MBLs.  
Serratia fonticola are Enterobacteriaceae found mainly in aquatic and other 
environmental samples (GAVINI et al., 1979; MÜLLER et al., 1995; MÜLLER et al., 
1986) and are generally considered as nonpathogenic, but have also been described 
as occasional human pathogens associated with respiratory tract infections or as 
infectious agents in wounds (BOLLET et al., 1991; FARMER et al., 1985; GORRET et 
al., 2009; PFYFFER, 1992). Previously characterised S. fonticola strains are 
intrinsically resistant to β-lactams due to the expression of both a chromosomally 
encoded extended-spectrum class β-lactamase and a species-specific AmpC β-
lactamase (PEDUZZI et al., 1997; STOCK et al., 2003). 
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However, it was previously established that UTAD54, a S. fonticola strain 
isolated from a natural water source, also expresses a metallo-β-lactamase, Sfh-I 
(SAAVEDRA et al., 2003) and a class A carbapenem-hydrolysing β-lactamase, SFC-1 
(FONSECA et al., 2007; HENRIQUES et al., 2004), that are both absent from other S. 
fonticola strains. The Sfh-I amino acid sequence diverges markedly (approximately 
50% identity) from those of previously described B2 MBLs originating from 
Aeromonas strains (SAAVEDRA et al., 2003).  
In order to further characterise the Sfh-I metallo-enzyme, the gene encoding 
Sfh-I from S. fonticola UTAD54 was cloned and over-expressed in E. coli. This chapter 
describes the purification and biochemical characterisation of the recombinant 
enzyme. 
 
5.2 Materials and methods 
 
5.2.1 Antimicrobial agents and reagents 
 
Antibiotics were obtained as powders from Sigma-Aldrich (ampicillin, 
benzylpenicillin, carbenicillin, cefepime, cefotaxime, cefoxitin, ceftazidime, 
cephalothin, cephaloridine, moxalactam, piperacillin), Merck Sharp & Dohme Co 
(imipenem), Sequoia Research Products (meropenem) and Becton-Dickinson 
(nitrocefin). 
General reagents and buffers were purchased from Sigma-Aldrich or Merck 
Sharp & Dohme Co and were of analytical quality. 
 
5.2.2 Cloning and over-expression of Sfh-I 
 
Molecular biology procedures followed manufacturers’ protocols except where 
stated.  
Initially Sfh-I was expressed as the mature protein, i.e. without its own 
predicted leader peptide, using the pelB sequence leader from the expression vector 
pET-26b (Novagen) that encodes a signal sequence aimed to direct expressed 
recombinant proteins to the periplasmic space. The same procedure was used to 
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obtain a high yield of recombinant SFC-1 (FONSECA et al., 2007) (Chapter 3). For 
that, blaSfh-I was PCR-amplified from the genomic DNA of Serratia fonticola UTAD54 
using the methodology described in Chapter 3 (see section 3.2.3) and primers SfhFv2 
and SfhRv2 (Table 5.1; the NcoI and XhoI recognition sequences are underlined), 
obtained from STAB VIDA (Caparica, Portugal). PCR products were purified with the 
JETQUICK PCR Purification Spin Kit (GENOMED). Purified products and vector were 
digested with NcoI and XhoI (Roche) and cloned into the corresponding site of the 
pET-26b expression vector. The recombinant plasmid (pSfh-Iv2) was transformed 
into E. coli TOP10 (Invitrogen) and the presence of unwanted mutations in the 
expression plasmid was confirmed by sequencing.  
 
Table 5.1 Primers used to clone blaSfh-I. 
Primer Sequence 5’ --- 3’ 
  
 
SfhFv2 GGATCCACCATGGCTTCTGAAAAAAACTTAACG  
SfhRv2 GTGCTCGAGTTACTTAGGCGCCTTCTCAAGC  
SfhFv3 GGATCCCATATGTCTGAAAAAAACTTAACGCTTACC  
SfhFv4 GGATCCCATATGAATATTAAATATTTATTTACGGCTG  
Underlined sequences represent restriction endonuclease sites.  
 
Recombinant protein was expressed from E. coli BL21 (DE3) (Novagen). The 
expression of the recombinant β-lactamase was optimised in a small scale (50 mL) by 
decreasing the post-induction temperature (26ºC, 20ºC, 15ºC) and concentration of 
the inducing agent (IPTG, 1 mM and 0.5 mM), analysing expression under different 
time-course of induction (1h, 3h, 5h, 12h, 24h) and using a range of different culture 
media in a commercially available Media Optimization KitTM (AthenaESTM).  
Several attempts were made to solubilise this material, either using the 
BugBuster® Protein Extraction Reagent (Novagen) or strong denaturants (6M 
Guanidine-HCl, 8M Urea and CAPS pH 11), with refolding of the target protein in 
vitro, by dilution of supernatant (after centrifugation, 15000 g for 15 minutes) into 50 
mM Tris pH 7.5, 100 µM ZnCl2 (4ºC, with gentle swirling). 
With the purpose of obtaining soluble active recombinant Sfh-I two further 
constructs were made lacking the pelB leader sequence of the pET-26b expression 
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vector. Primers SfhFv4 (Sigma-Aldrich) (NdeI restriction site underlined) and SfhRv2 
(Table 5.1) were used to amplify the complete Sfh-I open reading frame (including its 
own predicted leader sequence; Sfh-Iv4). To obtain a construct encoding Sfh-I 
without the predicted periplasmic leader sequence (i.e. nucleotides 55 – 759; Sfh-
Iv3), primers SfhFv3 (Sigma-Aldrich) and SfhRv2 (Table 5.1) were used.  
Sfh-I-containing DNA fragments were amplified from S. fonticola UTAD54 
genomic DNA using Pfu polymerase (Fermentas) and purified from agarose 
electrophoresis gels using the QIAEX II Gel Extraction Kit (QIAGEN). Purified PCR 
products were digested overnight with NdeI and XhoI (New England Biolabs) at 37ºC 
and ligated, using the Quick Ligation KitTM (New England Biolabs) according to the 
manufacturer protocol, into the NdeI − XhoI site of digested pET-26b. The 
recombinant plasmids (pSfh-Iv4 and pSfh-Iv3) were transformed into E. coli TOP10 
and plated into LB agar containing 50 mg/ml kanamycin. Positive clones were 
identified by colony PCR procedures using the following protocol: 5 to 10 colonies 
were picked and resuspended in 5 µl of sterile water, and incubated 10 minutes at 
100ºC; 4 µl of the supernatant solution were used as template DNA in the PCR 
reactions carried out with the T7 primers (Sigma-Aldrich). Plasmid DNA was purified, 
for the clones whose insert was amplified, using the QIAprep Spin Miniprep Kit 
(Qiagen). The cloned inserts were further characterised by restriction enzyme 
analysis of purified plasmid DNA using XhoI followed by agarose gel electrophoresis. 
The integrity of the Sfh-I DNA sequence was ensured by complete sequencing of the 
inserts in both recombinant plasmids. 
 
5.2.3 β-lactamase production and purification 
 
For β-lactamase expression recombinant plasmids (pSfh-Iv4 and pSfh-Iv3) 
were transformed into E. coli BL21 Star (DE3) (Invitrogen). Recombinant Sfh-Iv3 and 
Sfh-Iv4 were produced following procedures previously developed for production of 
recombinant SFC-1 (FONSECA et al., 2007) (Chapter 3) except that expression was 
induced by using 1mM IPTG overnight at 25°C. Protein extracts were loaded onto a 
40ml Q-Sepharose column (GE Healthcare) pre-equilibrated in Tris-HCl buffer (50 
mM, pH 8.5) containing ZnCl2 (100 μM) and bound proteins eluted on a 400ml 0 to 
500 mM NaCl linear gradient.  
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Fractions with β-lactamase activity, identified by hydrolysis of the 
chromogenic β-lactam antibiotic nitrocefin, were concentrated by centrifugal 
filtration (Amicon Ultra, Millipore) and further purified on a 300ml Superdex 75 
column (GE Healthcare) running in HEPES buffer (50 mM, pH 7.0). Active fractions 
were collected and concentrated. The presence and purity of protein at each stage of 
the purification process was confirmed by SDS-PAGE (LAEMMLI, 1970).  
 
5.2.4 Determination of kinetic parameters  
 
Kinetic parameters, kcat and KM, for the hydrolysis of a range of β-lactam 
antibiotics were calculated from initial hydrolysis rates measured at 25ºC in HEPES 
buffer (50 mM, pH 7.0) in UV-transparent 96-well plates (BD Biosciences) at 
appropriate wavelengths (LARAKI et al., 1999), using a SpectraMax 190 plate-reader 
(Molecular Devices) as described previously (SAMUELSEN et al., 2008). Stock 
substrate concentrations were determined from measurements of complete 
hydrolysis using previously reported extinction coefficients (LARAKI et al., 1999).  
Typically, experiments were conducted in which data points were recorded 
every 3-4 seconds for 20 - 30 minutes. Substrate and enzyme concentrations 
employed were adjusted to ensure that the evolution of product remained linear over 
a substantial fraction of the total time recorded across the whole range of substrate 
concentrations under investigation, i.e. that the reaction was taking place under 
steady-state conditions and that initial rates were indeed being recorded. Results 
obtained from experiments conducted in an independent laboratory with a 
conventional spectrophotometer using a subset of substrates (M.N. Lisa and A.J. 
Vila, personal communication) were in good agreement with those reported here, 
giving us further confidence in the accuracy of plate reader data. Kinetic parameters 
(kcat (s-1) and KM (µM)) were determined by non-linear least squares fitting of the 
initial velocity of hydrolysis versus substrate concentration plots using GraphPad 
Prism (version 5.01, GraphPad Software Inc., La Jolla, USA). For cephalothin, the Km 
was determined as the inhibition constant, Ki, calculated by nonlinear global fitting 
of initial velocity versus [nitrocefin] curves obtained at multiple cephalothin 
concentrations using the competitive inhibition model contained within GraphPad 
Prism. Reactions were initiated by addition of Sfh-I (final concentration 1.5 µM) to 
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pre-mixed nitrocefin and cephalothin and data recorded immediately (i.e. there was 
no pre-incubation of Sfh-I with cephalothin).  
 
5.2.5 Time- and concentration-dependence of Sfh-I inhibition by cephalothin 
 
In assays of the time-dependence of inhibition, 1.5 µM Sfh-I was incubated 
with a 1:5 molar ratio of cephalothin for 0.5−1200 minutes in 50 mM HEPES buffer 
pH 7.0 at room temperature. 100 µl samples were withdrawn at appropriate time 
intervals and residual activity was assayed by introducing these into a 1 ml cuvette 
containing nitrocefin as reporter substrate at a final concentration of 200 µM. Initial 
hydrolysis rates for the reporter substrate were measured using a Lambda 35 
spectrophotometer (Perkin-Elmer). Extinction coefficients and wavelengths used were 
as described (LARAKI et al., 1999). Hydrolysis of cephalothin under these conditions 
was monitored in parallel in a 1 ml sample by continuously recording absorbance at 
265 nm in another spectrophotometer. 
In order to determine the reversibility of inhibition, Sfh-I was incubated with 
cephalothin as above for a time sufficient to inhibit the enzyme, and the mixture was 
then dialyzed overnight at 4ºC against 50 mM HEPES buffer pH 7.0. A control 
sample of protein incubated in the absence of inhibitor was treated identically and 
used for comparison. The recovery of enzymatic activity was determined by 
measuring the residual activity as described above. 
 
5.2.6 Inactivation of Sfh-I by hydrolysed antibiotics 
 
The antibiotics here studied as putative Sfh-I inactivators (cephalothin, 
cefoxitin and moxalactam) (2 mM) were hydrolysed by IMP-1 (LARAKI et al., 1999) in 
50 mM HEPES pH 7.0, as monitored spectrophotometrically. After complete 
hydrolysis, the products were separated from the enzyme by centrifugal filtration 
(Amicon Ultra-4 – 10,000 NMWL; Millipore) and stored on ice until use. Hydrolysed 
antibiotics at a concentration of 1 mM were used to inactivate 3.6 mM Sfh-I at 4ºC. 
Inactivation was followed by measuring the residual activity as described above. 
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5.2.7 Mass spectrometry 
 
The molecular mass and metal content of Sfh-I were determined by 
electrospray mass spectrometry. Sfh-I (200 µM) was dialysed into ammonium acetate 
buffer (25 mM, pH 7.0) and mass spectra were recorded under both native and 
denaturing conditions. Samples were delivered at nanolitre per minute flow rates 
using a Nanomate source (0.3psi, 1.4kV) and mass spectra were recorded on a QStar 
XL qTOF instrument in positive ion mode. 
Inhibition of Sfh-I by cephalothin was studied by liquid chromatography mass 
spectrometry (LC-MS). A sample of 500 pmols of a mixture (5:1 or 15:1) of 
cephalothin and Sfh-I (200 µM) incubated for 30 minutes was run on a Zorbax C3 
column with a linear gradient of 1:1 (v/v) water-acetonitrile containing 0.06% formic 
acid. Eluent was fed directly into a Q-TOF I (Micromass) mass spectrometer and 
mass spectra were acquired.  
The sample containing a 5:1 ratio of cephalothin-SfhI was incubated with 
trypsin (1:50 substrate ratio) for 3h at 37ºC and analysed by MALDI mass 
spectrometry. 
 
5.2.8 Zinc binding 
 
Fluorescence emission spectra of the enzyme (1 µM) in the presence of 
increasing amounts of Zn2+ were recorded on a FluoroLog® spectrofluorometer 
(Horiba Jobin Yvon) using excitation and emission wavelengths of 280 and 341 nm, 
respectively. Slits were set to a band pass width of 5 nm. Assays were conducted at 
25ºC in 50 mM HEPES buffer, pH 7.0, in a 1 ml cuvette with continuous mixing 
provided by a magnetic stirrer. The dissociation constants (Kd) for zinc binding to 
Sfh-I were estimated by plotting the measured change in fluorescence (Y) against zinc 
concentration ([Zn2+]) and nonlinear fitting to a two-site hyperbola model: 
 
Y=Y1*[Zn2+]/(Kd1+[Zn2+]) + Y2*[Zn2+]/(Kd2+[Zn2+]) 
 
where Y1 and Y2 are the maximal fluorescence changes associated with the binding 
events described by Kd1 and Kd2, respectively. 
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5.2.9 Zinc concentration dependence of Sfh-I activity 
 
Zinc dependence assays of Sfh-I activity were conducted in 96-well plate 
format under the conditions described above using nitrocefin and imipenem as 
reporter substrates and a range of ZnCl2 concentrations (0-500 µM). Reactions were 
initiated by addition of Sfh-I (1.5 µM with nitrocefin and 1.0 nM with imipenem) to 
pre-mixed nitrocefin and zinc and data recorded immediately. Apparent kcat and KM 
values were determined as described above in the presence of increasing 
concentrations of zinc. The ratio kcat/kcat0 (where kcat0 is the value of kcat measured 
in the absence of added zinc) was plotted against zinc concentration and the 
resulting hyperbola was fitted to Equation 5.1: 
 
kcat/kcat0 = (Kd2 + α*[Zn2+]) /([Zn2+] + Kd2)   Equation 5.1 
 
by non-linear regression analysis using GraphPad Prism where α is the value of the 
kcat/kcat0 ratio when zinc concentration is saturating. Kd 2 represents the dissociation 
constant for the second zinc ion.  
Circular dichroism (CD) spectroscopy was used to give information about the 
effect of zinc on the secondary structure of Sfh-I. For these studies, the buffer of the 
Sfh-I solution was exchanged to 20 mM sodium phosphate pH 7.0, by dialysis 
overnight at 4ºC, using Slide-A-Lyzer® Dialysis Cassettes (10K MWCO, Pierce). CD 
spectra were recorded on a Jasco J-815 spectropolarimeter in the range 260-190 nm 
using 8.5 μM Sfh-I in a 1 mm cuvette. Temperature was set to 20ºC. For each 
sample four spectra were collected and averaged. Baselines of phosphate buffer 
without protein were subtracted from the samples to yield the contribution of the 
protein component. Thermal stability spectra were measured at 220 nm with 
temperature stepwise increased from 20ºC to 90ºC at an interval of 5ºC. Four scans 
were obtained for each sample and averaged. 
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5.3 Results and Discussion 
 
5.3.1 Over-expression and purification of Sfh-I 
 
The production of S. fonticola Sfh-I in E. coli BL21 (DE3), from the T7 
promoter-based expression vector pET-26b, was tested with 3 different constructs. 
The first construct of Sfh-I was prepared as previously described for 
production of recombinant SFC-1 (Chapter 3), i.e. the open reading frame encoding 
the mature Sfh-I polypeptide without the leader sequence was expressed as a fusion 
with the pelB leader sequence from the pET-26b vector. Although high-level 
expression was attained in E. coli (Figure 5.1A), the majority of the recombinant 
protein aggregated inside the cells in insoluble inclusion bodies (BANEYX and 
MUJACIC, 2004; VILLAVERDE and MAR CARRIÓ, 2003) (Figure 5.1B).  
 
 
Figure 5.1 Analysis of recombinant Sfh-Iv2 expression in E. coli BL21 (DE3) by SDS-PAGE 
(12%), stained with Coomassie Blue. A) Lane 1, marker proteins (Precision Plus Protein™ all blue 
standards – Bio-Rad;); lanes 2-3, total protein from uninduced cultures grown in Glucose M9Y and 
LB broth, respectively; lanes 4-9, total protein from induced cultures (1 mM IPTG) grown at 37ºC in 
different culture media including Glucose M9Y, Turbo, Hyper, Super, Power and LB broth (lanes 4-
9, respectively) 3h post-induction. B) marker proteins (lane 1), soluble (lane 2) and insoluble (lane 
3) fractions of E. coli BL21 (DE3) host cells containing the pSfh-Iv2 plasmid induced with 1 mM 
IPTG (37ºC for 3h). Protein was extracted using the BugBuster® Protein Extraction Reagent.  
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An extensive expression optimization was carried out to improve solubility by 
testing a number of parameters. These included growth temperature, culture media 
composition (Figure 5.1A), time-course of induction and the concentration of the 
inducing agent. However, the improvement in the solubility of the recombinant 
enzyme was not significant as only a small quantity of soluble protein was achieved. 
In an effort to obtain soluble protein from this construct, the solubilisation and 
refolding of the insoluble material was attempted. Nonetheless, the efficiency of the 
procedures used to solubilise/refold the insoluble protein proved to be very low, as 
revealed by the activity assays (data not shown).  
Two other constructs were designed and cloned into pET-26b using the NdeI 
(and XhoI) restriction site(s) such that the pelB leader sequence was no longer 
present. Both the constructs pSfh-Iv3, which encodes a version from which the 
signal peptide is deleted, and pSfh-Iv4, which encodes a form that contains the 
original signal peptide, produced soluble recombinant protein.  
 
When evaluated the expression of the two constructs without the pelB leader 
sequence by SDS-PAGE (Figure 5.2), mature Sfh-I (Sfh-Iv3) was generated in higher 
yields and was accordingly purified and used for kinetic experiments.  
 
 
Figure 5.2 Analysis of recombinant Sfh-Iv3 (v3) and Sfh-Iv4 (v4) expression in E. coli BL21 
(DE3) by SDS-PAGE (12%), stained with Coomassie Blue. A) Lane 1, protein ladder; lanes 2-9, 
soluble fraction from induced (1 mM IPTG, I) and uninduced (NI) cultures grown in LB media at 
25ºC. Cells were collected at 3h (T3) and 5h (T5) post-induction. B) As described in A) except cells 
were grown up to 21h after induction. The blue arrow shows the position of a protein band with the 
expected size of Sfh-I. Protein was extracted using the BugBuster® Protein Extraction Reagent.  
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Recombinant Sfh-I was readily purified from induced (1 mM IPTG) cultures of 
E. coli BL21 (DE3) cells containing the pSfh-Iv3 plasmid grown overnight at 25ºC. 
The optimised purification protocol consists of two chromatographic steps: an 
anionic exchange (Q-Sepharose) run with 50 mM Tris buffer pH 8.5 containing 100 
µM ZnCl2 and eluted with a linear gradient (0-25 %) of 1 M NaCl (Figure 5.3A), 
followed by a gel filtration (Superdex 75).  
 
 
Figure 5.3 Optimised purification of recombinant Sfh-Iv3. A) and C) Chromatograms 
obtained from an extract of culture of E. coli BL21 (DE3) cells containing the pSfh-Iv3 plasmid 
applied to a Q-SepharoseTM anionic exchange column with β-lactamase active peak indicated by an 
arrow, and from the fraction pointed in A) applied to a SuperdexTM 75 gel filtration column, 
respectively. B) and D) Analysis of the purification by SDS-PAGE (12%) stained with Coomassie 
Blue. B) Soluble extract of E. coli culture (lane 2) and fractions from anionic exchange (lanes 3-9). 
D) Protein fractions from gel filtration chromatography. M is the protein ladder.  
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The active fractions recovered from the anionic exchange were applied to the 
gel filtration column and elution was performed with 50 mM Hepes buffer pH 7.0 
(Figure 5.3C). This step allows excess zinc and salt to be washed from the purified 
protein (peak in the conductivity scale; silver line in Figure 5.3C) as well as a change 
in the pH promoting a higher stability of the protein during storage. The analysis of 
purified protein by SDS-PAGE confirmed the purification of recombinant Sfh-I to 
homogeneity (Figure 5.3D). The purification procedure used enabled to yield 50 
mg/liter of purified protein at a purity of >95% as adjudged by SDS-PAGE (Figure 
5.3).  
 
The interpretation of electrospray mass spectrometry experiments (in 
particular the native spectrum) is complicated by multiple peaks that may arise from 
bound salt and/or water molecules. However, the mass of 26 136 Da obtained under 
denaturing conditions (Figure 5.4A) is consistent with removal of the N-terminal 
methionine from Sfh-Iv3 and in agreement with the value predicted from sequence 
(26 134 Da). A similar result for the Sfh-Iv4 construct confirms previous predictions 
that Sfh-I is expressed with a 21-amino-acid signal peptide that is cleaved between 
Ala and Ser to generate the mature form of the enzyme (SAAVEDRA et al., 2003). 
 
5.3.2 Sfh-I is isolated as a monozinc enzyme 
 
In the native spectrum (Figure 5.4B) peaks at 26 201 Da (26 136 + 65 Da); 26 
218 Da (26 152 + 66 Da) and 26 239 Da (26 170 + 69 Da) all indicate addition of one 
equivalent of zinc (65 Da) to species found under denaturing conditions. These 
results, together with the size exclusion analysis, confirm that as isolated Sfh-I exists 
primarily in the mononuclear form, consistent with the assignment, from sequence, 
of Sfh-I as a B2 MBL (SAAVEDRA et al., 2003). The same zinc content was reported 
from previous investigations of the CphA and ImiS enzymes (CRAWFORD et al., 
2004; VALLADARES et al., 1997).  
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Figure 5.4 Electrospray mass spectra of purified Sfh-I showing molecular mass of 26 136 
Da (A) and binding of one zinc equivalent (Mr = 65) per protein molecule under non-denaturing 
conditions (B).  
 
5.3.3 Kinetic parameters of Sfh-I  
 
Hydrolysis of a representative set of β-lactam antibiotics by Sfh-I was 
investigated under steady-state conditions (Table 5.2). Sfh-I efficiently hydrolyses 
carbapenems (imipenem, meropenem) but exhibits low affinity (KM > 300µM) for 
many penicillins (ampicillin, carbenicillin and benzylpenicillin) and some 
cephalosporins (cefotaxime, ceftazidime). This behaviour is broadly similar to that 
previously reported for other Aeromonas B2 enzymes (FELICI and AMICOSANTE, 
1995; FELICI et al., 1993; SEGATORE et al., 1993; VANHOVE et al., 2003; WALSH et 
al., 1996; YANG and BUSH, 1996). However, compared to A. hydrophila CphA, Sfh-I 
shows higher KM values (indicative of lower affinity) for penicillins (with the exception 
of ampicillin) and significantly increased turnover rates (kcat) for ampicillin. For 
cephalosporins such as cefoxitin, nitrocefin and cephaloridine, KM values are 
reduced (indicative of higher affinity) compared to those reported for CphA (Table 
5.2). With respect to CphA, catalytic efficiency (kcat/KM) is thus increased for all non-
carbapenem substrates except carbenicillin and cephaloridine. In the case of 
ampicillin this increase is almost four orders of magnitude. Sfh-I hydrolysed the 
cephalosporins cefotaxime and ceftazidime, as well as the serine-β-lactamase 
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inhibitor sulbactam, but plots of hydrolysis rate against substrate concentration 
were linear and we were consequently unable to derive kinetic parameters for these 
substrates.  
Unexpectedly, and in contrast to the poor hydrolysis of many other 
cephalosporins, Sfh-I (0.01 µM) hydrolysed cefepime with relatively high efficiency 
(3.02 x 103 M-1s-1) when compared to that of CphA for other cephalosporin 
substrates. Felici and Amicosante have previously reported that 0.5 µM CphA shows 
no detectable activity towards cefepime (FELICI and AMICOSANTE, 1995). Compared 
to the other less well characterised subclass B2 MBLs from other Aeromonas species, 
Sfh-I is distinguished by its faster hydrolysis of penicillins and differs from AsbM1, 
but resembles ImiS, in its relatively low affinity towards penicillins. Faster hydrolysis 
(higher kcat) but weaker KM values for meropenem compared to imipenem appears to 
be a shared property of all of these enzymes. 
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Table 5.2 Kinetic parameters of purified Sfh-I β-lactamase and comparison with other B2 metallo-β-lactamases.a 
Substrate or 
inhibitor 
kcat (s-1) KM (µM) kcat/KM (M-1s-1) 
Sfh-I  CphA AsbM1 ImiS Sfh-I CphA AsbM1 ImiS Sfh-I CphA AsbM1 ImiS 
Ampicillin 9.53 <0.01b 0.13 1.1 676  2500b 65 510 1.41 x 104 <4b 7.5 x 103 2.2 x 104 
Benzylpenicillin ND 0.03 1.2 0.53 >1500 870 160 250 ND 35 2.0 x 103 2.1 x 103 
Carbenicillin 9.15 10d 0.44 0.5 1280 500d 28 260 7.18 x 103 2.0 x 104d 1.6 x 104 2.1 x 103 
             
Nitrocefin 0.06 0.0028 ≤0.02 0.024g 106 1200 ND 51g 5.67 x 102 2.5 ND 4.0 x 103g 
Cephaloridine 8.21 x 10-5 <0.006 ≤0.06 NH 334 ~6000 ND NH 2.46 x 10-1 <1 ND NH 
Cephalothin ND NR NR NR  NR NR NR ND NR NR NR 
Cefotaxime ND 0.009b NR NH >1000 1000b NR NH ND 9b NR NH 
Ceftazidime ND NR NR NR >500 NR NR NR ND NR NR NR 
Cefoxitin 0.032 0.02e ≤0.06 NH 99 615e ND NH 3.23 x 102 33e ND NH 
Cefepime 0.61 NHc NR NR 202 NHc NR NR 3.16 x 103 NHc NR NR 
Moxalactam 0.017 NR NR NH 91 NR NR NH 1.87 x 102 5.6e NR NH 
             
Imipenem 51  1200 71 350f 79 340 230 100f 6.42 x 105 3.5 x 106 3.1 x 105 9.1 x 105f 
Meropenem 109  3100 220 296g 215 1340 630 308g 5.05 x 105 2.3 x 106 3.5 x 105 3.3 x 106g 
a Kinetic data displayed for CphA, AsbM1 and ImiS as reported by Vanhove et al. (2003), Yang et al. (1996) and Walsh et al. (1996), respectively, except 
where indicated. 
b Bebrone et al. (2005), c Felici and Amicosante (1995), d Segatore et al., (1993), e Zervosen et al. (2001), f Sharma et al. (2006) g Crawford et al. (2004). 
ND, values could not be determined; NH, no hydrolysis detected; NR, not reported.  
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5.3.4 Inhibition of Sfh-I by cephalothin 
 
Previous workers (ZERVOSEN et al., 2001) have reported that A. hydrophila 
CphA may be inactivated by the cephamycin cefoxitin and the oxacephem 
moxalactam, as well as by other cephalosporin antibiotics with good 3’ leaving 
groups. Similarly, the degradation products of various cephalosporins have been 
shown to inhibit the subclass B1 MBL BcII from Bacillus cereus (BADARAU et al., 
2005). Accordingly, we investigated the interactions of Sfh-I with the hydrolysis 
products of cefoxitin, cephalothin and moxalactam.  
Incubation (18 h; 25ºC) of Sfh-I (3.6 µM) with each of these hydrolysis 
products (1 mM) resulted in reductions in hydrolytic activity against imipenem (200 
µM) of 13% (cefoxitin), 36% (cephalothin) and 94% (moxalactam). These results 
suggest that, similarly to CphA, Sfh-I is inhibited by the degradation products of 
certain cephalosporins and related compounds, although in no case were we able to 
obtain complete inactivation.  
As the reactions of CphA with hydrolysed cefoxitin and moxalactam have been 
extensively described (ZERVOSEN et al., 2001), but those with cephalothin have not, 
we investigated the Sfh-I:cephalothin interaction in more detail. Experiments in 
which Sfh-I was preincubated with cephalothin, or its hydrolysis product, and 
aliquots removed and assayed for nitrocefin hydrolysis at a range of time points, 
confirmed that both of these compounds inactivate the enzyme in a time-dependent 
fashion. Experiments in which absorbance at 265 nm (reporting breakdown of 
cephalothin during incubation with Sfh-I) was monitored in parallel with 
measurements of enzyme activity suggested that loss of Sfh-I activity correlates with 
cephalothin hydrolysis (Figure 5.5), indicating that the hydrolysis product is the 
likely inhibitory species. Activity of cephalothin-treated samples remained 54% that 
of control samples, even after overnight dialysis was performed to remove unbound 
cephalothin and/or its degradation products, suggesting that inactivation results 
from a modification of the enzyme. 
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Figure 5.5 Effect of cephalothin on Sfh-I activity. A) Activity of Sfh-I (1.5 μM) after 
incubation with cephalothin (7.5 μM) assayed in the presence of 200 μM nitrocefin; the control 
sample was submitted to the same treatment but without cephalothin added in the incubation 
mixture. B) Hydrolysis of cephalothin measured as a decrease in absorbance monitored at 265 nm.  
 
Zervosen and co-workers have suggested that the moxalactam, and probably 
cefoxitin, hydrolysis products form covalent bonds to the free thiol of the conserved 
cysteine, Cys221, in the B2 MBL active site (ZERVOSEN et al., 2001). Similar 
inactivation mechanisms, in which Cys221 could interact either with the thiol 
generated by opening the dihydrothiazine ring of the hydrolysed cephalosporin 
(BADARAU et al., 2005), or by addition to the exo-methylene formed after elimination 
of the 3’ leaving group, could also explain inactivation of Sfh-I by cephalothin. 
Accordingly we incubated Sfh-I with cephalothin, used trypsin to degrade the sample 
and analysed the resulting peptide mixture by MS/MS. Unfortunately, while all 
expected Sfh-I-derived peptides were detected, we were unable to observe any 
modified fragments, suggesting that the inhibitory complex is labile under the 
conditions employed.  
 
5.3.5 The effect of excess Zn2+  
 
Previous studies have revealed that CphA binds a single zinc ion tightly (Kd1 < 
20 nM) and is most active as a mono-zinc enzyme, but can bind a second, inhibitory 
zinc ion more weakly (Kd2= 46 µM) (VALLADARES et al., 1997). As shown by mass 
spectrometry (Figure 5.4), in the absence of added zinc Sfh-I is already in a monozinc 
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form, as is the case for ImiS and CphA (CRAWFORD et al., 2004; VALLADARES et al., 
1997).  
 
Monitoring fluorescence emission during a titration of Sfh-I with excess zinc 
(Figure 5.6) shows two distinct transitions, demonstrating that the enzyme is able to 
bind 2 further zinc ions with dissociation constants for the second (Kd2) and third 
(Kd3) zinc equivalents calculated as 95 ± 14 µM and 2300 ± 870 µM, respectively. The 
value that we obtained for Kd2 is broadly comparable to that reported for binding of a 
second zinc ion to CphA. The crystal structure of CphA determined in the presence of 
excess zinc (BEBRONE et al., 2009) shows that CphA can bind a third zinc ion on the 
protein surface at a site distinct from the active site. Similarly, our results indicate 
that binding of a third zinc equivalent by Sfh-I is weak (very high Kd3) and 
accordingly is unlikely to be of physiological relevance. 
 
 
Figure 5.6 Variation in fluorescence emission intensity of Sfh-I (1 μM) as a function of the 
concentration of added zinc monitored at 341 nm. The data were background subtracted and 
analysed by nonlinear fitting using two site binding analysis in GraphPad Prism. 
 
Other members of subclass B2 are known to be active as monozinc enzymes, 
whereas the binding of a second zinc ion results in non-competitive inhibition 
(CRAWFORD et al., 2004; VALLADARES et al., 1997; YANG and BUSH, 1996).  
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To investigate the effect of added zinc on Sfh-I activity, hydrolysis of the 
substrates nitrocefin and imipenem was measured in the presence of increasing 
concentrations of zinc (Figure 5.7). The activity of Sfh-I against imipenem was 
essentially unaffected in the presence of zinc up to 400 µM, in clear contrast to 
reports for related enzymes. Previous studies revealed that the highest imipenem 
hydrolysis activity was observed when ImiS, CphA, or AsbM1 bind one equivalent of 
zinc and the activity of the enzyme decreases as the more zinc is added (CRAWFORD 
et al., 2004; VALLADARES et al., 1997; YANG and BUSH, 1996). Surprisingly, 
nitrocefinase activity increased (3.7 fold) with the increase in zinc concentration 
(Figure 5.7), due to increases in kcat with little effect on KM (Table 5.3). It was shown 
for CphA that added zinc did not influence the activity of the enzyme with nitrocefin 
as substrate (BEBRONE et al., 2005) but an increase in activity was observed for 
some CphA mutants. These results, together with the substrate-dependent activity of 
Sfh-I in the presence of added zinc, reinforce the idea of a different mechanism for 
hydrolysis of imipenem and nitrocefin, as already suggested for CphA mutants 
(BEBRONE et al., 2005; VANHOVE et al., 2003). Although Sfh-I and CphA have the 
functional (active site) residues conserved, the two enzymes overall share just 50% 
identity, so the differences in activity described here can most likely be attributed to 
a combination of substitutions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7 Effect of added zinc on kcat/kcat0 (ratio of kcat at a given zinc concentration to 
kcat0 determined in the absence of excess zinc) for hydrolysis of nitrocefin (filled circles) and 
imipenem (open circles). Solid line is a fit of nitrocefin data to Equation 5.1. 
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Table 5.3 Influence of added zinc on kcat and KM values of nitrocefin hydrolysis by Sfh-I. 
Antibiotic 
Added zinc 
(µM) 
kcat (s
-1) KM (µM) Kd2 (µM) 
Nitrocefin 0 0.13 250 90 
 50 0.22 160  
 100 0.27 190  
 200 0.31 200  
 500 0.35 190  
 
 
To study the effect of added zinc on Sfh-I secondary structure and stability, 
circular dichroism (CD) wavelength scans and temperature melts were acquired 
(Figure 5.8).  
 
 
Figure 5.8 Effect of additional zinc on Sfh-I. A) Far-UV circular dichroism spectra of Sfh-I 
measured in the absence (green line) and presence (red line) of 1 mM Zn2+. B) Second derivatives of 
plots of ellipticity at 220nm against temperature for thermal unfolding of Sfh-I in the absence 
(green line) and presence (red line) of 1 mM Zn2+. 
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The CD spectra obtained for Sfh-I in the presence and absence of 1 mM Zn2+ 
reveals that the addition of zinc does not cause major structural rearrangements, 
inducing a small increase in Sfh-I secondary structure (Figure 5.8A). The thermal 
stability monitored by CD spectroscopy showed no significant difference between the 
midpoint for thermal unfolding of Sfh-I in the absence (60ºC) and in the presence of 
additional Zn2+ (58ºC) (Figure 5.8B), indicating that the addition of Zn2+ to the Sfh-I 
enzyme does not significantly affects its thermal stability. 
 
5.3.6 Concluding remarks 
 
We show here that Sfh-I is readily produced from recombinant E. coli and that 
the purified protein is a monozinc enzyme with a strong preference for carbapenem 
substrates. These properties confirm Sfh-I to be a member of the B2 MBL subgroup, 
previously known to contain only enzymes from Aeromonas spp. 
Our kinetic characterisation, however, shows that Sfh-I differs significantly 
from CphA, the best characterised B2 MBL, in its activity towards a range of 
substrates including cephalosporins (cefepime) and sulbactam.  
Fluorescence and activity measurements suggest that, while isolated as a 
predominantly monozinc enzyme, Sfh-I is able to bind up to three zinc ions with 
varying affinities, and that the effect of added zinc on enzyme activity is substrate-
dependent. Further investigation of the recombinant enzyme is needed to establish 
the basis for these differences. 
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6.1 Introduction 
 
Class B β-lactamases are zinc-dependent enzymes that are also known as 
metallo-β-lactamases (MBLs) (CROWDER et al., 2006)). These enzymes are able to 
inactivate almost all β-lactams, including the carbapenems, drugs of increasing 
importance in treatment of infections by multidrug resistant Gram-negative bacteria 
(MASTERTON, 2009), and are resistant to the clinical β-lactamase inhibitors (e.g. 
clavulanic acid, sulbactam) currently available. Despite the increasing importance of 
the MBLs, clinically useful inhibitors are not yet available. 
MBLs are divided into subclasses B1, B2 and B3, based on their primary 
sequences, substrate specificity, and metal-ion requirement (GALLENI et al., 2001). 
Subclasses B1 and B3 include the most extensively studied enzymes, display activity 
against a wide range of β-lactam substrates and generally bind two zinc ions (FELICI 
et al., 1993), (SPENCER et al., 2001). In these enzymes the binuclear zinc centre 
comprises a tetrahedral site (Zn1) with three histidine ligands (His116, His118, 
His196), and a five-coordinate site (Zn2) with cysteine (Cys221) – histidine (His263) - 
aspartate (Asp120; subclass B1) or histidine (His121) – histidine (His263) - aspartate 
(Asp120; B3) ligands. Coordination is completed by two water molecules, one 
bridging the two metal ions and the other situated in the Zn2 site (CROWDER et al., 
2006; WALSH et al., 2005).  
A number of crystal structures for representatives of subclasses B1 and B3 
are currently available (CARFI et al., 1995; CONCHA et al., 2000; CONCHA et al., 
1996; MURPHY et al., 2006; ULLAH et al., 1998). In contrast, the best characterised 
representatives of subclass B2, CphA and ImiS from Aeromonas sp., efficiently 
hydrolyse carbapenems but have poor activity against penicillins and cephalosporins 
(FELICI et al., 1993; WALSH et al., 1996). These enzymes lack the Zn1 ligand His116 
and are fully active with one bound zinc ion, located in the Zn2 (Cys – His – Asp) site, 
but are noncompetitively inhibited upon binding of a second zinc equivalent 
(CRAWFORD et al., 2004; VALLADARES et al., 1997).  
Despite efforts to characterise B2 MBLs with regard to substrate specificity, 
zinc binding and catalytic mechanism, (WALSH et al., 1996), (COSTELLO et al., 
2006), (BEBRONE et al., 2008), (SHARMA et al., 2006; SIMONA et al., 2009; XU et 
al., 2006), these remain the least studied MBLs. To date the only structures available 
for B2 MBLs are of CphA from A. hydrophila, including a CphA mutant in complex 
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with the hydrolysis product of the carbapenem biapenem (BEBRONE et al., 2009; 
GARAU et al., 2005). The mechanism of action of B2 MBLs is also incompletely 
understood (GARAU et al., 2005; SHARMA et al., 2006; SIMONA et al., 2009; XU et 
al., 2006).  
Previously determined crystal structures (BEBRONE et al., 2009; GARAU et 
al., 2005) all contain small molecule ligands such as bicarbonate or sulphate and the 
origin and mechanism of activation of the water nucleophile essential to the 
hydrolytic reaction, and the identity of the proton donor to the β-lactam amide 
nitrogen, thus remain to be unambiguously established. Computational studies have 
proposed two possible candidates: His118 (SIMONA et al., 2009) or Asp120 (XU et al., 
2006) for the general base that activates the nucleophilic water molecule in subclass 
B2 MBLs. 
Sfh-I, a member of the B2 MBL subclass, was previously described. Sfh-I 
possesses 60% sequence identity to A. hydrophila CphA (mature polypeptides) and is 
specific to Serratia fonticola strain UTAD54 (SAAVEDRA et al., 2003). Like previously 
characterised B2 MBLs, Sfh-I efficiently hydrolyses carbapenems but displays 
reduced activity against penicillins and cephalosporins (Chapter 5). However, Sfh-I 
also displays some distinctive properties when compared to other B2 enzymes, 
showing some hydrolytic activity against the cephalosporin cefepime and being only 
weakly inhibited by excess zinc in a substrate-dependent fashion (Chapter 5). Sfh-I is 
thus the most divergent member of the B2 MBL subgroup that has been identified to 
date. 
This Chapter presents crystal structures of Sfh-I determined at two different 
resolutions in the presence and absence of a bound glycerol ligand. The glycerol 
complex structure results from attempts at ligand soaking. These data reveal, for the 
first time, the architecture of water molecules in the B2 MBL active site and strongly 
suggest that the catalytic water nucleophile is associated with His118, rather than 
the active site zinc ion or Asp120. Based on these results, a catalytic mechanism for 
B2 MBLs is offered. 
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6.2 Materials and methods 
 
6.2.1 Purification and crystallisation 
 
Wild-type Sfh-I was produced in Escherichia coli BL21 (DE3) cells harbouring 
the pSfh-Iv3 recombinant plasmid and purified by liquid chromatography as 
described in Chapter 5. Following purification protein fractions showing >99% purity 
by SDS–PAGE were concentrated by Amicon Ultra-15 spin concentrators with a 
molecular weight cut off (MWCO) of 10 kD, stored at 4ºC, and used in crystallisation 
trials. Purified Sfh-I was quantified spectroscopically by absorbance at 280 nm using 
a molar extinction coefficient of 35995 M-1cm-1 calculated from the amino acid 
composition using the method of Gill and von Hippel (1989) as implemented in the 
software Protean (Lasergene Software, DNAStar Inc.).  
Initial crystallisation trials of native Sfh-I were performed by the sitting drop 
vapour diffusion method using Molecular Dimensions Structure screen I & II HT-96 
(JANCARIK and KIM, 1991), JCSG-plus HT-96 and PACT premier screens (NEWMAN 
et al., 2005). Drops were set up using a Phoenix liquid-handling system (Art Robbins 
Instruments) and 96-well MRC two well crystallisation plates (Hampton Research). 
Crystallisation drops consisted of 1 μL of both the protein, concentrated to 11 and 22 
mg/mL, and reservoir solutions. Plates were sealed with ClearSeal FilmTM (Hampton 
Research) and placed at 20ºC.  
The initial crystallisation conditions were optimised in 24-well XRL 
crystallisation plates (Molecular Dimensions) using a gradient of PEG and salt 
concentration, by the hanging drop vapour diffusion method. The drops resulted 
from a 1:1 mixture of protein solution at 15 mg/mL and reservoir solution (1 µl each 
component). Samples were equilibrated against 500 μL of reservoir solution. 
Conditions derived from C3 (0.2 M ammonium nitrate, 20% polyethylene glycol (PEG) 
3350) and H6 (0.1 M ammonium acetate, 0.1 M Bis Tris pH 5.5, 17% PEG 10000) 
were further refined using an Additive Screen (Molecular Dimensions) with protein 
concentrated to 15 mg/mL. The most promising crystals of Sfh-I were observed in 
drops consisting of 0.1 M ammonium nitrate and 25% PEG 3350 with several 
additives (calcium chloride, strontium chloride, dioxane, isopropanol) at a final 
concentration of 10%. Using these crystals higher quality crystals were obtained by 
streak seeding (Figure 6.1A). 
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The best crystals of native Sfh-I grew in 0.1 M ammonium nitrate, 3% v/v 
isopropanol, 25% w/v PEG 3350. Crystals appeared after 2-3 days at 20°C, in a 
variety of morphologies from flattened hexagonal rods to rhombohedral crystals. 
Prior to data collection crystals were briefly soaked in reservoir solution 
supplemented with 30% v/v ethylene glycol as cryoprotectant and flash-cooled in 
liquid nitrogen.  
Further screening was carried out with the aim of obtaining diffraction-quality 
crystals of Sfh-I in complex with excess zinc (1 mM), cefepime or cephalothin at 
different concentrations. This included co-crystallisation using commercial screens 
as above with substrate/zinc as additives, seeding to new drops containing the 
additive with additional refinement of some of the conditions and adding β-lactam 
powder to drops containing crystals. Although data sets from several crystals were 
collected, no complex was obtained. However, this screening established that 
superior crystals could be generated by mixing 2.5 µl of protein (15 mg/mL), 2 μL of 
reservoir solution (0.2 M sodium acetate, 27% w/v PEG 3350) and 0.5 µl 30% 
glycerol (Figure 6.1B) and equilibrating against a 500 µl reservoir in hanging-drop 
format in XRL crystallisation plates (Molecular Dimensions). 20% v/v PEG 400 was 
used as a cryoprotectant. 
 
6.2.2 Data collection and crystallographic refinement 
 
Diffraction data were collected at Diamond Light Source beamline IO4 and 
processed with HKL2000 (OTWINOWSKI and MINOR, 1997) (apo Sfh-I) or MOSFLM 
(LESLIE, 2006) and SCALA (EVANS, 2006) (glycerol complex) (Table 6.1) from the 
CCP4 program suite (COLLABORATIVE COMPUTATIONAL PROJECT, 1994). 
Structures were solved by molecular replacement using the programs AMoRe 
(NAVAZA, 2001) (apo Sfh-I) or PHASER (MCCOY et al., 2007) (glycerol complex) and 
the three-dimensional structure of A. hydrophila CphA (GARAU et al., 2005) (PDB ID 
1X8G) as a search model.  
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Table 6.1 Data Collection Statisticsa 
 Native Glycerol complex 
X-ray Source DIAMOND IO4 DIAMOND IO4 
Wavelength (Å) 0.9529 0.9795 
Data processing HKL2000 MOSFLM/SCALA 
Space group P21 P21 
Asymmetric unit 2 molecules 2 molecules 
Cell dimensions     
    a, b, c (Å) a = 32.92 b = 72.17 c = 86.46 a = 32.83 b = 87.28 c = 72.57 
    α, β, γ  (°) β = 90.12º β = 90.85º 
Resolution (Å) 50 – 1.8 (1.86 – 1.8) 33.5 – 1.37 (1.45 – 1.37) 
Rmerge 0.076 (0.500) 0.056 (0.55) 
No. reflections (total) 109 572 (9 549) 603 317 (84 447) 
No. reflections (unique) 36 421 (3 537) 84 788 (12 336) 
I / σI 13.2 (1.9) 18.0 (3.3) 
Completeness (%) 97.3 (95.3) 99.8 (100) 
Redundancy 3.0 (2.7) 7.1 (6.8) 
 
*Values in parentheses are for the highest resolution shell. 
 
Models were refined iteratively using positional refinement in REFMAC5 
(MURSHUDOV et al., 1997) followed by manual rebuilding into 2mFo−dFc electron 
density maps using the program COOT (EMSLEY et al., 2010). Water molecules were 
added to the models at positions showing large positive peaks in Fo-Fc electron 
density. During iterative rebuilding residue geometries, van der Waals contacts and 
hydrogen bonds were monitored using the MOLPROBITY server (CHEN et al., 2010). 
Statistics from structure refinement are shown in Table 6.2. 
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Table 6.2 Refinement Statisticsa 
 Native Glycerol complex 
Resolution (Å) 27.70 – 1.80 (1.847 – 1.800) 26.23 – 1.37 (1.41 – 1.37) 
No. reflections 34 573 (2 482) 80 514 (5 932) 
Rwork / R free 18.7/23.6 (23.5/33.8)) 16.3/19.6 (26.5/30.2) 
No. atoms   
    Protein 3 662 3 878 
    Ligand/ion 2 14 
    Water 266 436 
B-factors   
    Protein 13.42 15.40 
    Ligand/ion 28.91 22.95 
    Water 19.50 27.02 
R.m.s deviations   
    Bond lengths (Å) 0.0128 0.0101 
    Bond angles (°) 1.338 1.322 
 
aValues in parentheses are for the highest resolution shell. 
 
 6.2.3 Circular Dichroism (CD) 
 
Circular dichroism (CD) spectroscopy was employed to compare the secondary 
structure, and the conformational stability of both Sfh-I and ImiS by increasing the 
temperature. ImiS is the Aeromonas veronii subclass B2 MBL, with a sequence 98% 
identical to that of CphA (differing at only seven amino acids) (WALSH et al., 1998). 
ImiS was used as a comparator as an over-expressing construct was readily 
available. 
ImiS was over-expressed and purified as previously reported (CRAWFORD et 
al., 2004). Briefly, 4 x 1L flasks of LB containing 50 μg/mL kanamycin were 
inoculated with an overnight culture of E. coli BL21 DE3 containing the pET26bimiS 
plasmid and incubated at 37ºC until an optical density of 0.6 was reached. At this 
point cell cultures were induced with 1 mM IPTG and allowed to grow at 37ºC for 3 
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hours. Cells were collected by centrifugation (4000 rpm, 30 minutes at 4ºC), 
resuspended in 40 mL of cold, 50 mM Tris 100 µM ZnCl2, pH 7.0, and lysed by 
sonication followed by centrifugation (18000 rpm, 30 min at 4ºC). The supernatant 
with protein solution was dialyzed overnight at 4ºC versus 2 L of 50 mM Tris 100 µM 
ZnCl2, pH 7.0. The dialyzed crude extract was centrifuged (18000 rpm, 30 min at 
4ºC) and the cleared supernatant was loaded onto a pre-equilibrated SP-Sepharose 
column with 50 mM Tris 100 µM ZnCl2, pH 7.0. Elution was performed with a linear 
gradient of 0 to 50 mM NaCl in 50 mM Tris 100 µM ZnCl2, pH 7.0. Fractions 
containing ImiS were identified by SDS-PAGE (bands of approximately 25 kDa), 
concentrated by Amicon Ultra-15 spin concentrators (MWCO of 10 kDa) and loaded 
onto a Superdex 75 gel filtration column. ImiS was eluted in 50 mM Tris, pH 7.0 and 
protein fractions were analysed by SDS-PAGE. ImiS fractions with purity greater 
than 95% were pooled and concentrated. 
For CD studies, protein samples, both Sfh-I and ImiS, were dialyzed overnight 
at 4ºC versus 1 L of 20 mM sodium phosphate pH 7.0 using Slide-A-Lyzer® Dialysis 
Cassettes (10K MWCO, Pierce). The concentration of ImiS was determined from 
absorbance at 280 nm using the extinction coefficient, Δε = 37250 M−1cm−1, 
estimated previously by Crawford and co-workers (2004). 
CD spectra were recorded at 20ºC on a Jasco J-815 CD spectropolarimeter 
using 8.5 μM protein in 20 mM sodium phosphate, pH 7.0. The wavelength range 
scanned was 260-190 nm. For each sample four spectra were collected and averaged. 
Baselines of phosphate buffer without protein were subtracted from the samples to 
yield the contribution of the protein component. Thermal stability spectra were 
measured at 220 nm with temperature stepwise increased from 20ºC to 90ºC at an 
interval of 5ºC. Four scans were obtained for each sample and averaged. 
 
6.2.4 Accession numbers 
 
The coordinates and structure factors for the two Sfh-I structures have been 
deposited in the Protein Data Bank (PDB) with accession numbers 3Q42 (unliganded 
structure) and 3Q6V (glycerol complex). 
 
Chapter 6 ____________________________________________________________________________________________________________________________________________________ 
 
124 
6.3 Results and Discussion 
 
 6.3.1 Sfh-I overall structure 
 
From the initial crystallisation trials of native Sfh-I using commercial screens, 
the most promising conditions, containing plate-like crystals or small crystals, were 
identified as conditions C3 (0.2 M ammonium nitrate, 20% w/v PEG 3350), H6 (0.1 
M ammonium acetate, 0.1 M Bis Tris pH 5.5, 17% w/v PEG 10000), H7 (0.2 M 
ammonium sulphate, 0.1 M Bis Tris pH 5.5, 25% w/v PEG 3350) and H9 (0.2 M 
lithium sulphate, 0.1 M Bis Tris pH 5.5, 25% w/v PEG 3350) from JCSG-plus HT-96.  
Upon optimisation of initial conditions, crystals of apo Sfh-I grew by hanging 
drop vapour diffusion from 15 mg/ml protein and 0.1 M ammonium nitrate, 25% 
(w/v) PEG3350 with isopropanol as additive (3% v/v). Streak seeding was employed 
to improve crystal quality for X-ray diffraction experiments (Figure 6.1A). Crystals 
grown in conditions such as 0.2 M sodium acetate, 27% (w/v) PEG 3350, 3% glycerol 
and 0.2 M lithium chloride, 0.1 M Hepes pH 7.0, 28% (w/v) PEG 3350 (Figure 6.1B 
and 6.1C) were also used to collect diffraction data. However, crystals recovered from 
the lithium chloride solution proved to be highly mosaic and these data were not 
used for the determination of the Sfh-I structure. 
 
 
Figure 6.1 Crystals of native Sfh-I. A. Individual panels showing the effect of additives on 
Sfh-I crystallisation in 0.1 M ammonium nitrate, 25% (w/v) PEG3350. B. and C. Native crystals 
grown in 0.2 M sodium acetate, 27% (w/v) PEG 3350, 3% glycerol and in 0.2 M lithium chloride, 
0.1 M Hepes pH 7.0, 28% (w/v) PEG 3350 with additives (glycerol and ethylene glycol), respectively. 
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Two crystal structures of recombinant Sfh-I were determined by molecular 
replacement, using the structure of A. hydrophila CphA (GARAU et al., 2005) as a 
search model. An unliganded structure was obtained to a resolution of 1.8 Å, and a 
structure with glycerol bound in the active site to a resolution of 1.4 Å.  
Both structures contain 228 amino acids (residues 41-304 using the BBL 
numbering system (GALLENI et al., 2001)). The overall fold of Sfh-I (Figure 6.2) 
conforms to the αβ/βα sandwich structure characteristic of MBLs and related 
enzymes, with the active site located in a shallow cleft formed by the interface of the 
two β-sheets. The two Sfh-I structures are almost identical (root mean square 
deviation (r.m.s.d.) of 0.279 Å between Cα atoms for molecule A in the respective 
structures as determined using SSM (KRISSINEL and HENRICK, 2004)).  
 
 
Figure 6.2 Stereo ribbon diagram of the Sfh-I structure (glycerol complex). The polypeptide 
chain is colour-ramped from N- (blue) to C- (red) terminus. Zinc ion is rendered as a grey sphere 
and zinc ligands shown as sticks (atom colours as standard, carbons in green). Bound glycerol is 
shown as a stick model with carbon atoms in cyan. This figure and Figures 6.3, 6.5 and 6.6A were 
generated using PyMol (DELANO, 2008). 
 
Comparison with A. hydrophila CphA (Figure 6.3A) shows the two B2 MBL 
structures to be closely superimposable (Cα r.m.s.d. 0.646 Å) with the major 
difference between them the extended loop between helix α4 and strand β12 arising 
from the presence of a 4-amino acid insertion (BBL residues 254a-d) in the Sfh-I 
sequence relative to that of CphA.  
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The Sfh-I crystal structure, the second for a B2 MBL, thus confirms that the 
elongated and kinked α3 helix, and the absence of extended mobile loops between 
strands β2 and β3 (as in B1 MBLs) or between α3 and strand β7 (as in B3 MBLs) are 
likely to be general structural features that distinguish B2 MBLs from those of 
subclasses B1 and B3 (GARAU et al., 2005). 
 
Figure 6.3 A. Overlay of Sfh-I (blue) and A. hydrophila CphA (red; pdb accession 1X8G) 
(GARAU et al., 2005) structures. Positions of loops (β11–α4; α4–β12) whose conformations vary 
between the two structures are marked. B. Ribbon diagram of Sfh-I structure (blue) highlighting 
(green) positions of residues that differ between Sfh-I and CphA. Positions of alterations involving 
proline residues are numbered and coloured magenta (proline deletions in Sfh-I relative to CphA) or 
orange (proline insertions in Sfh-I relative to CphA). Proline substitutions in the vicinity of the Sfh-I 
active site (positions 162, 194 and 198) are labelled and depicted in stick form.  
 
In CphA the conformation of the loop connecting β11 and α4 varies between 
the uncomplexed and biapenem-bound structures, enabling Asn233 to make H-
bonding contacts with the C3 carboxylate of bound biapenem (GARAU et al., 2005). 
In both of our Sfh-I structures this loop adopts the “closed” conformation associated 
with the biapenem-bound CphA structure, rather than that observed in the 
uncomplexed enzyme. However, in the unliganded structure the Asn233 side chain 
adopts either a dual conformation (molecule A of the 2 molecules in the asymmetric 
unit), or points away from, rather than towards, the zinc centre, indicating that some 
mobility at this position is required to permit interactions with bound β-lactam 
substrates. 
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Sfh-I, like other subclass B2 MBLs and unlike the enzymes of subclasses B1 
and B3, displays a strong preference for carbapenem substrates and has only weak 
activity against β-lactams of other classes (e.g. penicillins and cephalosporins). 
However, Sfh-I has some limited activity against certain substrates, for example the 
cephalosporin cefepime, against which CphA is entirely inactive (Chapter 5). 
Accordingly, the positions where the Sfh-I and CphA sequences differ onto the Sfh-I 
structure were mapped in an effort to identify substitutions likely to affect the 
spectrum of activity of Sfh-I (Figure 6.3B). While the majority of the substitutions are 
in surface-exposed regions, such as α-helices 1, 2, 4 and 5 and at the ends of β-
strands, that are not expected to influence catalytic activity, it is noticeable that Sfh-I 
contains 4 fewer proline residues than does CphA. In particular, two of these 
substitutions, CphA Pro194Glu and CphA Pro198Lys, are at positions that define a 
loop (linking strands β12 and β13) that bears the conserved active site residue 
His196; and the CphA Pro168Glu substitution is located at the end of the extended 
α3 helix. 
 
 
Figure 6.4 Circular dichroism (CD) spectroscopy of Sfh-I (green) and ImiS (red) A. CD 
spectra from 8.5 µM protein in 20 mM phosphate buffer, pH 7.0 at 20ºC. B. Thermal unfolding of 
the metallo-β-lactamases by stepwise increasing the temperature, measured by CD at 222 nm. 
 
It is possible that these substitutions may increase the flexibility of the Sfh-I 
active site with respect to that of CphA (or ImiS), potentially enabling it to adjust to 
accommodate some additional substrates. In order to explore possible collective 
impact of these substitutions on protein secondary structure and stability, circular 
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dichroism (CD) wavelength scans and temperature melts were carried out for Sfh-I 
and ImiS (Figure 6.4). The CD spectra produced for each of the purified enzymes 
were nearly superimposable (Figure 6.4A), revealing a very similar secondary 
structure. Moreover, the thermal stability monitored by CD spectroscopy indicated 
no significant difference between the midpoint for thermal unfolding of Sfh-I (60ºC) 
compared to that of ImiS (58ºC) (Figure 6.4B) or that reported for CphA (58.7ºC; 
(BEBRONE et al., 2009)), demonstrating that these substitutions do not impose a 
stability cost on the Sfh-I enzyme. 
 
 6.3.2 Active site 
 
The active site of uncomplexed Sfh-I (Figure 6.5) contains a single zinc ion 
coordinated by the three conserved protein ligands: Asp120 (one oxygen; 1.98 Å, 
distances are for chain A), Cys221 (2.39 Å) and His263 (2.01 Å) that comprise the 
Zn2 site. Similar to CphA, but unlike the Zn2 sites of B1 or B3 MBLs, the Zn2 site 
adopts a tetrahedral, rather than trigonal bipyramidal, geometry. Coordination is 
completed by a single water molecule (Wat1; 2.24 Å) that occupies a similar position 
to the amide nitrogen (N1) of bound biapenem in the CphA complex structure; i.e. a 
location distinct from those of water molecules found in B1 or B3 MBL active sites.  
 
 
Figure 6.5 Stereo view of uncomplexed Sfh-I active site. Electron density shown is 2Fo-
Fc. φcalc, contoured at 1.2σ. Zinc ion is rendered as a grey and water molecules as red spheres. 
Protein is colour-ramped from N- (blue) to C- (red) terminus; side chain atom colouring is as 
standard excepting carbon atoms are rendered in green. Hydrogen and coordination bonds are 
depicted as dashed lines. Bound glycerol, positioned by overlaying the complex structure, is 
rendered semitransparent with carbon atoms in cyan. 
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In common with other B2 MBLs, Sfh-I lacks the Zn1 ligand His116 and 
consequently binds a second zinc equivalent with greatly reduced affinity (Chapter 
5). In Sfh-I structure the Zn1 site is instead occupied by a second water molecule 
(Wat2) that is tightly bound (2.00 Å) by His118 and makes weaker interactions with 
both His196 (2.50 Å) and Wat1 (2.52 Å). Importantly, Wat2 is comparatively far (3.82 
Å) from the unbound oxygen of Asp120. In the complex structure, the positions of 
glycerol oxygen atoms superimpose upon those of Wat1 and Wat2 (Figure 6.5). Taken 
together, these two structures thus define two favoured positions for protein:ligand 
interactions in the Sfh-I active site. 
 
 6.3.3 Implications for catalytic mechanism 
 
The catalytic mechanism of B2 MBLs has been the subject of considerable 
debate (GARAU et al., 2005; SHARMA et al., 2006; SIMONA et al., 2009; XU et al., 
2006). Available CphA crystal structures (BEBRONE et al., 2009; GARAU et al., 2005) 
all contain small molecule ligands (biapenem, sulphate or bicarbonate), and the 
disposition of water molecules in the B2 active site, and thus the likely means by 
which the water nucleophile is activated, have consequently remained uncertain. The 
identification of bound water molecules in the Sfh-I active site therefore provides new 
insights into B2 MBL mechanism.  
Previous crystal structures, including that of the CphA biapenem complex 
(GARAU et al., 2005), and spectroscopic studies (SHARMA et al., 2006) suggest 
interaction between Zn2 and the β-lactam amide nitrogen during the catalytic cycles 
of all MBL subclasses (GARRITY et al., 2004; SPENCER et al., 2005; TIONI et al., 
2008). These data indicate that Wat1 is displaced by substrate during the catalytic 
cycle and we thus consider Wat2 to be the most likely nucleophile. Computational 
studies have suggested that either Asp120 (XU et al., 2006) or His118 (SIMONA et 
al., 2009) may activate a water nucleophile (Wat2) located in the B2 Zn1 site. The 
location of Wat2 in the structure of metallo-β-lactamase Sfh-I strongly supports the 
proposal that His118 fulfils this function: Wat2 makes a tight interaction with 
His118 but a much weaker contact with Asp120. 
Inspection of both the Sfh-I and CphA crystal structures further supports the 
idea that His118, while completely conserved across all three MBL subclasses, fulfils 
a different function in B2 MBLs (activating the hydrolytic water molecule) compared 
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to subclasses B1 and B3, where it is a Zn1 ligand. In B1 MBLs His118 is H-bonded 
to a conserved acidic residue (Asp or Glu) at position 236 (Figure 6.6A). In available 
crystal structures of B3 enzymes this interaction is maintained, although the 
sequence position of the interacting carboxylic acid varies. Such second shell 
interactions between histidine zinc ligands and aspartate or glutamate side chains 
have been proposed to promote catalysis by enzyme zinc centres through a range of 
effects that include enhancing the reactivity of the metal-bound hydroxide 
nucleophile (LIN et al., 2005). By way of contrast, in the Sfh-I and CphA structures, 
the residue at position 236 is a phenylalanine, and the His118 side chain is not 
strongly H-bonded, but instead occupies a hydrophobic pocket formed by the side 
chains of Tyr117, Ile153 and Phe236 (Figure 6.6A).  
By virtue of its tight association with His118, Wat2 is therefore part of an 
electron-rich environment that, we believe, will enhance its nucleophilicity. 
Additional interactions with Wat1 and with the His196 side chain will then serve to 
appropriately orient Wat2 for nucleophilic attack upon the carbonyl carbon of 
incoming β-lactam substrate. 
 
 
 Figure 6.6 A. Active site of VIM-2 (GARCIA-SAEZ et al., 2008) (PDB accession 1KO3) 
showing altered second shell ligands of His118. Protein is colour-ramped from N- (blue) to C- (red) 
terminus; side chain atom colouring is as standard excepting carbon atoms that are rendered in 
magenta. Hydrogen and coordination bonds are depicted as dashed lines. B. Molecular surfaces of 
uncomplexed Sfh-I (left) and VIM-2 (right) coloured by electrostatic potential. A molecule of 
meropenem (atom colours as standard; carbons in green) is manually placed in the Sfh-I structure 
to highlight the occluded Sfh-I active site. Figure 6.6B was generated using CCP4MG (POTTERTON 
et al., 2004). 
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 6.3.4 Proposed catalytic mechanism 
 
Based upon these and previously published observations, a catalytic 
mechanism for Sfh-I and, by inference, for other B2 MBLs is therefore proposed 
(Scheme 6.1). 
 
Scheme 6.1. Hydrolysis of the carbapenem meropenem by subclass B2 metallo-β-
lactamases. Zinc: ligand interactions (omitted for clarity in lower panels) are shown as dotted lines. 
 
Incoming carbapenem 
substrate 1 displaces Wat1 from 
the Sfh-I active site to interact 
directly with the zinc ion 
through the C2 carboxylate 
group. The second carboxylate 
oxygen contacts the side chain of 
Lys224, as observed in the 
CphA:biapenem complex 
(GARAU et al., 2005). 
Replacement of Lys224 by Thr 
decreases carbapenemase 
activity of the related ImiS 
enzyme (SHARMA et al., 2006). 
This mode of binding positions 
Wat2, activated as described by 
contact with His118, to make a 
nucleophilic attack upon the 
carbonyl carbon of the β-lactam 
amide.  
The consequent electronic 
rearrangement results in opening of the β-lactam ring and accumulation of negative 
charge in a delocalized system, comprising N1, C2 and C3, that is partially stabilized 
by proximity to the Sfh-I zinc centre. Stabilisation of anionic species 2, generated 
upon fission of the β-lactam amide bond, by interaction with the metal ion in the 
MBL Zn2 site has been proposed to be important to MBL-catalysed hydrolysis of a 
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range of cephalosporin and carbapenem substrates (MCMANUS-MUNOZ and 
CROWDER, 1999; SPENCER et al., 2005; TIONI et al., 2008; WANG, Z. et al., 1999). 
Freeze-quench EPR studies of meropenem hydrolysis by Co++-substituted ImiS 
identified populated species with a 5 – co-ordinate metal centre, as proposed for this 
species, rather than the resting 4 – co-ordinate state (SHARMA et al., 2006). This 
anionic species may then decay by up to three possible routes. Proton transfer to N1 
from an incoming water molecule, most likely in the Wat2 position, will generate the 
expected hydrolysis product (Δ2 tautomer, 3). An appropriately positioned water 
molecule, located very close to the Sfh-I Wat2 site, is observed in the CphA:biapenem 
complex (GARAU et al., 2005). However, this structure also reveals hydrolysed 
biapenem to be present in an unanticipated cyclised form, suggesting that, for B2 
MBLs, carbapenem hydrolysis may also involve an intramolecular rearrangement 
that requires abstraction of a proton from the C8 hydroxyl, its addition to C3, and 
subsequent attack of the nucleophile so generated upon C2 (4). Protonation at C3 
could then also occur from an incoming water molecule, generating the hydrolysis 
product in the imine (Δ1) tautomer 5. The role of zinc in B2 MBLs is then twofold: 
firstly binding substrate via interaction with the C2 carboxylate, and second in 
providing a means of stabilizing the negative charge that accumulates on N1 during 
and after cleavage of the β-lactam amide bond. In contrast to the binuclear enzymes 
of subclasses B1 and B3, the metal ion is not involved in activation of the water 
nucleophile. 
Such a mechanism implies comparatively inefficient proton transfer to N1, a 
possible consequence of the occluded active site observed in the Sfh-I and CphA 
structures (Figure 6.6B), in which access of water molecules to the carbapenem-
bound active site may be difficult. It would also predict that the anionic intermediate 
2 can accumulate during carbapenem hydrolysis. Preliminary investigations of 
imipenem hydrolysis by Sfh-I under pre-steady-state conditions indeed indicate the 
existence of transiently populated intermediates during the catalytic cycle (Lisa, M.N. 
and Vila, A.J., personal communication).  
The preference of Sfh-I, and other B2 MBLs, for carbapenem substrates then 
arises from a combination of factors- restricted access to the active site, likely to be 
particularly deleterious to binding of substrates with bulky substituents at the C6 
(penicillin) or C7 (cephalosporin) positions; presence of the C2 = C3 double bond in 
carbapenems, enabling anionic species to be stabilized by conjugation as well as 
interaction with zinc; and the availability of the C8 hydroxyl group, permitting 
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resolution of the anionic intermediate 2 by intramolecular rearrangement, as in 4. 
Limited activity, as is observed against some penicillin substrates, may be possible 
when some of these factors are absent, but only carbapenems satisfy all of these 
criteria. These are thus the preferred substrates for B2 MBLs. 
 
 6.3.4 Concluding remarks 
 
The data presented here, from a divergent member of the B2 metallo-β-
lactamase subclass, confirms that structural features such as the extended 3 helix 
and occluded active site cavity are likely to be common to this group of enzymes and 
distinguish them from other MBLs.  
Most importantly, clear evidence is provided for an active site water molecule 
bound to His118, rather than Asp120, clarifying the means by which the nucleophile 
is activated for β-lactam hydrolysis in these enzymes.  
In support of this contention it is shown that His118 occupies a distinct 
environment in B2 MBLs, consistent with a mechanistic function rather than a role 
as a zinc ligand. These results provide further evidence that B2 MBLs operate via a 
distinct catalytic mechanism and thus highlight the challenges associated with 
development of MBL inhibitors with activity against the full range of these enzymes. 
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7.1 Antibiotic resistance – the problem 
 
Antibiotics have been successfully used since the 1940s and are essential 
drugs with which to treat patients who have infectious diseases. For the last 70 years 
antibiotic use has significantly reduced morbidity and mortality caused by infectious 
diseases. However, the wide and prolonged use of these drugs, initially seen as 
“magic bullets”, promoted the evolution of the target infectious bacteria in order to 
overcome their action and make them ineffective (KUMARASAMY et al., 2010; 
LIVERMORE, D., 2009). While some microorganisms are resistant to a single 
antibiotic or related class, others can develop resistance to several antibiotics. The 
later are known as multidrug resistant (MDR) strains (LIVERMORE, 2007). The 
continuing emergence, development and spread of drug-resistant pathogenic strains 
are a cause of increasing concern.  
Antibiotic resistance is now one of the leading unresolved problems in public 
health whose consequences include high human and economic costs associated with 
the treatment of infectious diseases. Indeed, infections caused by drug-resistant 
strains require longer, resulting in potential spread of resistant microorganisms to 
others, and more expensive therapies, being associated with an increased risk of 
death (DE KRAKER et al., 2011; NOSKIN et al., 2005). Recently a study based on a 
sample of high-risk hospitalised adult patients, 13.5% of which had antibiotic 
resistant infections (ARIs), revealed that the medical cost attributable to ARIs ranged 
from $18,588 to $29,069 per patient, while the duration of hospital stay was 
extended by 6.4 to 12.7 days for affected patients (ROBERTS et al., 2009). This study 
found that ARIs alone contribute to an excess mortality of 6.5 %, a death rate two 
times higher than in patients without ARIs. All together, these reports aim to be an 
alert for a better management of infections caused by antibiotic resistant strains and 
for an effective control and prevention of these infections. 
However, bacteria resistant to several antibacterial agents now occur 
worldwide and are no longer limited to the nosocomial environment. Originally, most 
multidrug resistant pathogens emerged in hospitals, in which antibiotic use was 
prevalent, though antibiotic resistant strains are spreading and becoming more 
common in the community (DELEO et al., 2010; ROONEY et al., 2009). The 
widespread development of antibiotic resistance has weakened their value as 
treatments for bacterial infections. Moreover, there is paucity in the development of 
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new effective drugs, in particular against Gram-negative bacterial pathogens such as  
A. baumannii and P. aeruginosa (ABBANAT et al., 2008). Since the 1990s, the 
number and effort of pharmaceutical companies conducting research to discover 
novel antimicrobials has decreased (PROJAN, 2003). This is possibly explained by 
the fact that antibacterial agents have a low rate of return on investment. Indeed, 
antibiotics are taken just for a few days/weeks, in comparison with other drugs that 
are used for life, they become useless after a while due to resistance, and also 
because it takes a long time and funds for a new drug to reach the market (PROJAN, 
2003; SPELLBERG et al., 2008). 
 
7.2 Antibiotic resistance as a whole 
 
As previously referred, bacteria resistant to multiple antibiotics represent a 
huge threat in the hospital setting and, consequently, the majority of the studies 
address the antibiotic resistance mechanisms of clinically important bacteria 
(PATERSON and BONOMO, 2005; RICE, 2009). Nonetheless these reports do not 
address the origin and sources of the resistance determinants that are of clinical 
significance at present. Moreover, it is clear that currently disseminated resistance 
mechanisms represent just a fraction of the total antibiotic resistance scenario. 
A broader view of antibiotic resistance would involve all of the antibiotic 
resistance genes found in microorganisms, known as the resistome (WRIGHT, 2007). 
The resistome, a concept introduced by D’Costa et al. (2006), comprises not only 
resistance elements from pathogens but also those found in environmental 
organisms that are not usually associated with disease. It includes resistance genes 
from antibiotic-producing bacteria, and genes that are embedded in the bacterial 
chromosome and have some potential to have a role in resistance, termed cryptic 
genes. The resistome also comprises precursor genes encoding proteins with modest 
antibiotic resistance activity but that are able to evolve into effective resistance genes 
if the right selective pressure is applied (WRIGHT, 2007). 
In recent years, several studies have drawn the attention of the scientific 
community to the fact that important resistance determinants that have emerged 
clinically are closely associated with mechanisms found in environmental organisms, 
whether antibiotic producers or not (ALLEN et al., 2010; D'COSTA et al., 2006; 
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DANTAS et al., 2008). For example, β-lactam resistance by production of CTX-M β-
lactamases is likely to have originated from environmental isolates of Kluyvera spp. 
(HUMENIUK et al., 2002; POIREL et al., 2002), while water-borne Shewanella algae 
and Vibrionacea species are the potential progenitors of the qnr quinolone resistance 
determinants, encoding proteins that protect DNA gyrase and topoisomerase IV from 
the inhibitory activity of quinolones (CATTOIR et al., 2007; POIREL et al., 2005). 
These reports show that it is essential to expand research into antibiotic resistance 
to include nonpathogenic organisms. Thus, an integrated view of resistance 
determinants may help researchers to better understand the evolution of antibiotic 
resistance and predict new resistance mechanisms prior to their emergence clinically 
(MARTINEZ, 2009; WRIGHT, 2010). The knowledge obtained can therefore be used to 
develop new therapeutic strategies to fight resistance before it reaches pathogenic 
bacteria (MARTINEZ, 2009; WRIGHT, 2010).  
 
7.3 Study of carbapenemases from S. fonticola UTAD54 
 
The overall purpose of this dissertation was to study the biochemical 
properties, and determine the structures of carbapenemases expressed by Serratia 
fonticola UTAD54, a naturally-occurring strain isolated from untreated drinking 
waters in the Northeastern Portugal. Previous studies have shown that carbapenem-
resistant S. fonticola UTAD54 possesses chromosomal genes encoding two 
carbapenem-hydrolyzing β-lactamases, a class A enzyme and a subclass B2 metallo-
protein (HENRIQUES et al., 2004; SAAVEDRA et al., 2003). These genes are absent 
from other S. fonticola strains and are phylogenetically distant from previously 
characterised related β-lactamases (HENRIQUES et al., 2004; SAAVEDRA et al., 
2003). Carbapenems are the most powerful class of β-lactams and have a broad 
spectrum of activity against Gram-negative opportunist pathogens including both the 
Enterobacteriaceae and non-fermenting species such as P. aeruginosa and A. 
baumannii (BAUGHMAN, 2009). The spread of resistance to other antibiotics, 
including penicillins and cephalosporins, in these species, has severally reduced 
treatment options for these patients (LIVERMORE, D., 2009; MASTERTON, 2009). 
Therefore, S. fonticola UTAD54 is a potential source of new resistance mechanisms to 
antibiotics that are clinically used as last resort treatments for serious infections by 
Gram-negative organisms. Moreover, there is evidence that the carbapenem 
Chapter 7 ____________________________________________________________________________________________________________________________________________________ 
 
140 
resistance gene blaSfh-I encoded on the chromosome of S. fonticola UTAD54 is 
embedded in mobile genetic elements (I Henriques and A. Correia, unpublished 
results), potentially enabling its dissemination into other bacteria. 
 
In order to overcome resistance to β-lactam antibiotics it is fundamental to 
understand in detail the mechanisms of resistance and the mechanism of action of 
β-lactamases, so that new effective drugs and/or inhibitors can be developed. The 
results here presented can be seen as part of this global approach. This work is 
divided in two independent parts, each concerning the study of a carbapenemase 
from S. fonticola UTAD54. Thus, in the discussion I will consider each of these 
enzymes in turn. 
 
7.3.1 SFC-1, an Ambler class A carbapenemase 
 
SFC-1 is a Bush subgroup 2f β-lactamase that has been shown to be active 
against penicillins, cephalothin, and aztreonam with reduced susceptibility to the 
carbapenems meropenem and imipenem, and to be inhibited by clinically used 
inhibitors (HENRIQUES et al., 2004). Although this resistance profile is typical for 
class A carbapenem-hydrolysing β-lactamases, the kinetic characterisation of SFC-1 
revealed that this enzyme exhibits unique properties.  
In this work it was shown that for SFC-1 the turnover rates for ceftazidime 
and cefoxitin are higher than those reported for IMI-1 and KPC-2. Previous studies 
have shown that a threonine at position 237, as displayed by SFC-1 and KPC, is 
involved in broadening the activity of class A carbapenemases to include extended-
spectrum cephalosporins (MAJIDUDDIN and PALZKILL, 2005; SOUGAKOFF et al., 
1999). Additionally, a second substitution present in SFC-1 and KPC amino acid 
sequences but absent in the remaining enzymes of subgroup 2f, an Ala240Val 
mutation can also explain the increased activity against the extended-spectrum 
cephalosporins, as suggested for the ESBL TEM-149 (PERILLI et al., 2008). 
Nonetheless, more studies are required to validate these hypotheses in SFC-1. 
This study of SFC-1 also demonstrated that although this enzyme is inhibited 
by the typical class A β-lactamase inhibitors, the inhibition is weak (IC50 higher than 
1 µM) when compared to carbapenemases IMI-1 and KPC (RASMUSSEN et al., 1996; 
YIGIT et al., 2001). These results show that SFC-1 is a class A β-lactamase with a 
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very broad substrate profile, able to hydrolyse carbapenems and extended-spectrum 
cephalosporins with reduced susceptibility to available β-lactamase inhibitors. 
Although the genetic context of blaSFC-1 does not include mobile genetic elements, 
unpublished results reveal a close proximity (within 10 Kb) of the blaSFC-1 and blaSfh-I 
genes on the chromosome of S. fonticola UTAD54. Therefore we cannot rule out the 
possibility that both genes are associated to mobile genetic elements. Moreover, these 
genes were found in S. fonticola UTAD54 (HENRIQUES et al., 2004) but not in related 
strains, further supporting an exogenous origin. 
 
Despite the availability of crystal structures for several class A 
carbapenemases (KE et al., 2007; SOUGAKOFF et al., 2002; SWARÉN et al., 1998), 
the structural basis for β-lactam resistance mediated by these enzymes remains 
elusive. In an attempt to attain more information on the interaction between β-
lactamases and β-lactams, especially carbapenems, crystal structures of the 
carbapenemase SFC-1, the acylation-deficient S70A mutant and the deacylation-
deficient E166A mutant in complex with the carbapenem meropenem, were solved 
during this work. As reported for other class A carbapenemases, the structure of 
native SFC-1 is very similar to those of class A β-lactamases, such as TEM-1 (STEC 
et al., 2005) and SHV-1 (KUZIN et al., 1999), but with the disulphide bridge between 
Cys69 and Cys238 that distinguishes class A carbapenemases (WALTHER-
RASMUSSEN and HOIBY, 2007). The structure of wild-type SFC-1 alone does not 
offer a clear explanation for its broad spectrum of activity. However, the presence of a 
proline residue at position 104 and the orientation of His105 may contribute to the 
expansion of the catalytic cavity. The opened cavity can then accommodate the bulky 
side chains of extended-spectrum cephalosporins, avoiding steric constraints that 
could arise from bulkier or more flexible residues at positions 104 and 105 (BETHEL 
et al., 2006; DOUCET et al., 2004). A study concerning the role of the residue at 
position 104 in SHV supports these results, providing indication that the Asp104Pro 
substitution increases β-lactam resistance, according to reported MIC values 
(BETHEL et al., 2006). However, in a similar investigation using β-lactamase SME-1, 
the Tyr104Pro mutant only maintained high levels of resistance to imipenem, 
exhibiting a decrease in resistance to ampicillin and, to a lesser extent, cefotaxime 
(MAJIDUDDIN and PALZKILL, 2005). These studies demonstrate that is difficult to 
assign substrate specificity in many β-lactamases to a single position, and most 
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likely this property results from the interaction of several residues and its influence 
in the active site of these enzymes. 
The X-ray crystal structure of the SFC-1 S70A mutant in complex with 
meropenem has shown that the β-lactam carbonyl oxygen of the substrate is 
completely bound in the oxyanion hole, a result that clearly differs from earlier 
observations of other class A β-lactamases (MAVEYRAUD et al., 1998; NUKAGA et 
al., 2008). It was also observed that bound meropenem establishes contacts with the 
amide nitrogens of Thr237 and Ala70, and Ser130 is close to the meropenem amide 
nitrogen, consistent with a role in the protonation of the β-lactam nitrogen. 
The structure of the E166A acylenzyme shows that a number of modifications 
occur upon acylation of the SFC-1 β-lactamase. Among these are: the positioning of 
the β-lactam ring carbonyl oxygen in close proximity to the amide nitrogens of both 
Ser70 and Thr237, the substrate carboxylate is nearer to the side chain hydroxyls of 
Thr237 and Thr235 than in the substrate complex, while the hydrogen bond between 
the meropenem carboxylate and Ser130 is missing. Also, the 6-hydroxyethyl 
substituent of meropenem is rotated and no longer interacts with the catalytic water 
molecule, a result that distinguishes the acylenzyme of SFC-1 from carbapenem 
acylenzymes of TEM-1 and SHV-1 (MAVEYRAUD et al., 1998; NUKAGA et al., 2008). 
In the later enzymes, the 6-hydroxyethyl carbapenem substituent is hydrogen 
bonded to the hydrolytic water, possibly explaining the longevity of carbapenem 
acylenzymes in the active sites of these β-lactamases. 
Another important observation, arising from the structures of SFC-1, refers to 
the position adopted by Ser130 in class A carbapenemases. In TEM-1 and SHV-1, 
both non-carbapenemases, Ser130 is reoriented in the presence of the substrate, 
pointing its hydroxyl group towards the amino group of Lys234 instead of Lys73, as 
seen in the apo structure (MAVEYRAUD et al., 1998; NUKAGA et al., 2008). By 
contrast, in SFC-1 the Ser130 hydroxyl assumes the same position as in the apo 
structures of other class A β-lactamases. This arrangement allows interaction with 
Lys73 and Lys234, as well as the amide nitrogen (N4) of meropenem in the SFC-1 
acylenzyme, suggesting that Ser130 also helps to position meropenem in a favorable 
orientation for deacylation. A close interaction of the acylenzyme amide nitrogen with 
Ser130 may also prevent tautomerisation to the less reactive imine (delta-1 tautomer) 
form.  
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7.3.2 Sfh-I, a subclass B2 metallo-β-lactamase 
 
Sfh-I is the first subgroup B2 metallo-β-lactamase to be identified in a genus 
other than Aeromonas. The gene coding for Sfh-I is present on the chromosome of S. 
fonticola UTAD54 (SAAVEDRA et al., 2003). However unpublished results from our 
group (I. Henriques and A. Correia, personal communication) provide evidence that 
blaSfh-I is flanked by transposable elements, suggesting a potential horizontal transfer 
of this genetic determinant from/into other isolates in the environment. 
In this work it was demonstrated that Sfh-I, like CphA and ImiS, has a 
preference for carbapenem substrates and displays high activity when coordinating 
one equivalent of Zn(II) (Chapter 5). Other groups of metallo-β-lactamases have a 
broad substrate profile but require two Zn(II) ions for optimal activity (CROWDER et 
al., 2006).  
Previous studies have shown that B2 MBLs are able to bind a second zinc ion, 
but their enzymatic activity is noncompetitively inhibited in this situation 
(CRAWFORD et al., 2004; VALLADARES et al., 1997). Sfh-I, however, is revealed to 
be a singular B2 MBL that exhibits a substrate-dependent behaviour upon binding of 
a second zinc ion (Chapter 5). No inhibition was detected when a good substrate 
(imipenem) was assayed, but nitrocefinase activity increased in the presence of a 
second zinc ion. Bebrone et al., (2005) reported no influence of added zinc on CphA 
activity when nitrocefin was used as substrate. In this investigation a CphA mutant, 
N116H/N220G, was engineered, whose di-zinc form is more active against nitrocefin 
(among other β-lactam antibiotics) than the mono-zinc form. With imipenem the 
activity decreases by binding of a second zinc ion (BEBRONE et al., 2005). A similar 
result has been observed for the CphA mutant N116H (VANHOVE et al., 2003). 
Based on these results the authors proposed that a slightly different mechanism 
would be used by these mutants to hydrolyse carbapenem, and some cephalosporin, 
substrates (BEBRONE et al., 2005). Our results on the effect of added zinc on Sfh-I 
activity thus emphasize the divergence between this enzyme and previously 
characterised B2 MBLs. Another distinctive property of Sfh-I is its ability to 
hydrolyse cefepime (Chapter 5), a fourth generation cephalosporin displaying 
enhanced in vitro activity against Gram-positive pathogens, along with Gram-
negative bacteria producing ESBLs (SADER et al., 2005). To our knowledge, this is 
the first description of cefepime hydrolysis by a subgroup B2 MBL; this 
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cephalosporin was not recognised as a substrate by CphA (FELICI and 
AMICOSANTE, 1995). 
The studies conducted along this dissertation provided evidence that Sfh-I 
binds up to three zinc ions if enough zinc is added to the enzyme’s milieu (Chapter 
5), although the binding affinities for the different zinc ions vary hugely. We were 
unable to determine the binding affinity for the first zinc ion but we believe it to be 
high, as reported for related enzymes (VALLADARES et al., 1997) and evidenced by 
its high occupancy in our crystal structures. However, the second zinc binds with an 
affinity (Kd2) similar to that reported for CphA (VALLADARES et al., 1997). Sfh-I 
binds a third zinc equivalent but very loosely (Kd3 > 1 mM), and we consider this 
metal ion unlikely to play a role in the enzyme’s activity. This result is in agreement 
with the crystal structure of CphA determined in the presence of excess zinc, where a 
third zinc ion was observed on the surface of the protein, away from the catalytic 
cavity (BEBRONE et al., 2009).  
To understand how β-lactams are hydrolysed by metallo-β-lactamases and 
hence make possible the design of new β-lactams, and/or inhibitors with decreased 
susceptibility to these enzymes, it is essential to determine the exact molecular 
mechanism that underlies the turnover of most β-lactams.  
Mechanistic and structural data is particularly scarce for subclass B2 
metallo-β-lactamases. Until now, the only crystal structures available for a B2 MBL 
are of CphA from A. hydrophila containing small molecules in the active site 
(BEBRONE et al., 2009; GARAU et al., 2005). No unliganded structure is accessible 
for subclass B2 MBLs. Moreover, there is no consensus about the catalytic 
mechanism employed by these enzymes, although crystallographic (GARAU et al., 
2005), spectroscopic (SHARMA et al., 2006) and molecular modelling (SIMONA et al., 
2009; XU et al., 2006) studies addressed this subject. The most important issue to be 
unambiguously clarified refers to the identity of the general base responsible for the 
activation of nucleophilic water, proposed to be either Asp120 (XU et al., 2006) or 
His118 (SIMONA et al., 2009).  
In this work, the crystal structure of Sfh-I from S. fonticola UTAD54 was 
solved. The overall fold was shown to be very similar to the previously determined 
structure of CphA from A. hydrophila (Chapter 6). The structure of Sfh-I is the first 
for an unliganded subclass B2 MBL, explicitly revealing the position of two water 
molecules in the active site. In the Sfh-I structure, the fourth zinc ligand is a water 
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molecule (Wat1) in contrast with the CphA structure where a carbonate ion occupies 
this position (GARAU et al., 2005). The involvement of a second water molecule 
(Wat2) in the catalytic mechanism of CphA was previously predicted by 
computational methods (SIMONA et al., 2009). However, no structural data to 
support this calculation was available. The observed bound water molecules in the 
Sfh-I active site-pocket thus provide new insights into the catalytic mechanism of 
subclass B2 MBLs. In fact, the structural data obtained on Sfh-I, suggest Wat2 to be 
the most likely nucleophile. Wat2 is positioned closer to His118 when compared to 
Asp120, the strongest candidates to act as the general base, and therefore, it is 
proposed that Wat2 is activated by His118, rather than by Asp120 as has been 
suggested for CphA (XU et al., 2006). 
 
7.4 Conclusions 
 
The work developed and described along this dissertation, through 
characterisation of the unique β-lactamases SFC-1 and Sfh-I found in S. fonticola 
UTAD54, provides new information on the interaction and hydrolysis of β-lactam 
antibiotics by Ambler class A carbapenemases and subclass B2 metallo-β-
lactamases. The main conclusions that can be extracted from the study here 
presented are as follows:  
 
1. As expressed in E. coli, SFC-1 is an enzyme with a very broad substrate 
profile, including penicillins, oxyimino-cephalosporins (ceftazidime and 
cefotaxime), cephamycins (cefoxitin), carbapenems (imipenem, meropenem) 
and the β-lactamase inhibitors (clavulanic acid, sulbactam and tazobactam); 
2. When compared to other class A carbapenemases, SFC-1 is more 
resistant to extended-spectrum cephalosporins and β-lactamase inhibitors; 
3. The crystal structure of SFC-1 reveals an overall fold that is essentially 
identical to those of other class A β-lactamases; 
4. The determination of atomic resolution structures of SFC-1 point 
mutants in complex with bound meropenem provided, for the first time, 
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information on the recognition and hydrolysis of carbapenems by class A 
carbapenemases; 
5. Recombinant Sfh-I produced from E. coli is a mono-zinc subclass B2 
MBL with a strong preference for carbapenem substrates, that is typical of 
such enzymes. Nonetheless, Sfh-I is able to hydrolyse cefepime and 
sulbactam, substrates not recognised by related enzymes; 
6. In the presence of added zinc Sfh-I was shown to behave differently 
from previously characterised B2 MBLs, since Sfh-I carbapenemase activity 
was not inhibited by elevated zinc concentrations; 
7. Despite the unique properties revealed by the kinetic characterisation 
of Sfh-I, the structure of this enzyme closely resembles that of CphA from A. 
hydrophila. Thus the differences in specificity exhibited by Sfh-I cannot be 
inferred from the structure alone; 
8. Of most importance, the structure of Sfh-I, the first for an unliganded 
B2 MBL, provides important information on the catalytic mechanism of 
these enzymes, for example the identity of the nucleophile species (Wat2) 
and the way it is activated (His118). 
 
7.5 Future studies  
 
The overall goal of this project was to characterise the carbapenem-
hydrolysing β-lactamases SFC-1 and Sfh-I from S. fonticola UTAD54. To continue 
pursuit of these objectives, further studies are suggested.  
In the work presented here, it was not possible to offer a clear explanation for 
the increased activity against oxyimino-cephalosporins, and the inhibitor resistance, 
displayed by SFC-1, when compared to other class A carbapenemases. To address 
this question it would be interesting to use site-directed mutagenesis, targeting 
residues at positions 237 and 240. Positions 237 and 240 are suggested to be 
involved in the activity of KPCs and TEM-149 against oxyimino-cephalosporins 
(PAPP-WALLACE et al., 2010b; PERILLI et al., 2008), respectively, while Thr at 
position 237 is also thought to play a role in inhibitor resistance in KPC (PAPP-
WALLACE et al., 2010b). Protein crystallography can also be used to unravel how 
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SFC-1 and related β-lactamases (e.g. KPCs) hydrolyse extended-spectrum 
cephalosporins.  
This project also raises a number of questions regarding the activity of Sfh-I. 
For example, the mechanism of inactivation of Sfh-I by cephalothin remains to be 
fully elucidated. Despite several attempts to co-crystallise Sfh-I with cephalothin, 
and the use of mass spectrometry in attempts to identify the modified peptide, no 
conclusive answer was obtained. The interaction between Sfh-I and cephalothin can 
also be examined by molecular modelling methods using the structure of Sfh-I. The 
same techniques can be used to describe the hydrolysis of cefepime by Sfh-I MBL. 
Further investigations to understand the effect of added zinc on the 
carbapenemase activity of Sfh-I are required. As crystals of Sfh-I in the presence of a 
high concentration of zinc proved to be difficult to obtain, the information about the 
metal binding sites can be achieved using spectroscopic techniques such as EXAFS 
(COSTELLO et al., 2006; CRAWFORD et al., 2005). 
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